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Chapter 1 
 
Introduction and Objectives of the Thesis 
 
 
Abstract  
In the general introduction the formulation development for hydrophobic proteins is 
discussed. The low solubility of these proteins often combined with a strong tendency to 
adsorb on different materials during processing or storage are the major challenges 
during formulation development. Human Serum Albumin (HSA) is frequently used as 
excipient to overcome the mentioned problems. As HSA is gained from human plasma, 
its use is always related to the risk of blood born pathogens, as well as batch to batch 
variations. Furthermore, specific analytics for the active protein are difficult in presence 
of an excess of HSA. Therefore, ways need to be found to circumvent the use of HSA in 
protein formulations. Possible approaches for the development of HSA-free formulations 
for hydrophobic proteins are described in Chapter 1.  
 
 
Keywords: hydrophobic proteins, solubility, adsorption, HSA 
 
 
 
 
 
 
 
 
 
 
 
 
 
Chapter 1 
   
 
2 
1. Introduction 
With the first successful production of recombinant somatostatin, a peptide hormone 
consisting of 14 amino acids in 1977 [1] and shortly later the production of recombinant 
insulin [2] the starting point for the tremendous increase of biotechnological products on 
the pharmaceutical market was set. At about the same time it was accomplished to 
produce murine monoclonal [3] and later chimeric and humanized antibodies [4,5]. 
Approved by the FDA in 1982, human insulin was the first genetically engineered 
consumer health product on the market. Since then, numerous products including 
recombinantly produced antibodies, proteins and peptides have entered the market and 
currently about 225 are under development [6]. 
One critical step for the production of a protein as pharmaceutical product is the 
development of a stable formulation, as proteins are complex molecules which are 
susceptible for various degradation mechanisms and instability reactions [7,8]. It is a 
great challenge to maintain the native and functional structure of a protein during 
pharmaceutical processing, production, storage and the final application at the patient. 
The first step is getting insight into the characteristics of the particular protein and 
identifying possible instability reactions. To achieve this goal the development of 
analytical techniques which are capable to detect and quantify structural and activity 
relating changes in the protein is inevitable. In pre-formulation studies the basic 
knowledge on the protein is gained and the optimum conditions, concerning pH, buffer 
system, ionic strength and protein concentration have to be determined [9]. Based on 
this information the further development of a liquid or lyophilized formulation can 
proceed. Depending on the protein and the type of formulation the addition of excipients 
and stabilizers has to be evaluated. Thereby, it is a general concept to keep the 
formulation as simple as possible. The knowledge of the physico-chemical properties of 
the selected excipients during freezing and in the dried state if using a solid formulation 
is very important. To avoid failures in protein formulations, one has to be aware of the 
fact that the physico-chemical properties of excipients can affect protein stability and 
activity. Therefore, the focus must not be solely set on the protein alone, but on the 
formulation as a complex system. Protein formulation is an interesting and multifarious 
field that requires a structured but flexible procedure to achieve the desired goal of a 
stable formulation.  
 
 Introduction and Objective of the Thesis 
   
 
3 
2. Formulation of Hydrophobic Proteins  
2.1 Hydrophobicity of Proteins 
Proteins are macromolecules consisting of forty to several hundreds L-amino acids 
connected via peptide bonds. Both, the size of the protein and the amino acid 
composition govern the characteristics of the particular protein e.g. folding, 
hydrophobicity and solubility. When a protein is folded in an aqueous environment about 
80% of the hydrophobic amino acids are buried in the interior of the protein without 
having contact to the surrounding water molecules [10]. Various scales for the 
classification of amino acids according to their hydrophobicity are available. One example 
is the scale developed by Cowan and Whittaker (1990) using RP-HPLC which ranges from 
0 to 1 (1=high hydrophobicity), with some examples shown in Table 1 [11]. 
 
Table 1: Amino acids and hydrophobicity value classified by Cowan and Whittaker (1990) [11]. 
amino acid value 
Alanine 0.660 
Leucine 0.988 
Isoleucine 1.000 
Methionine 0.846 
Tryptophane 0.914 
Phenylalanine 0.983 
 
Basically, the residues present on the surface of a protein affect the hydrophobicity of the 
protein. Each amino acid contributes to the measured surface hydrophobicity in relation 
to the protein structure as a whole and the composition of the residues on the protein 
surface [12]. Based on this assumption a more sophisticated classification of the 
hydrophobicity of amino acids was developed by Berggren et al. (2002), by studying the 
partitioning of proteins and peptides in an aqueous two-phase system. Generally, the 
classification of the hydrophobicity of amino acids strongly depends on the experimental 
setup and therefore the various scales often differ in the prediction of the hydrophobicity 
of the different amino acids [13]. A novel approach is the prediction of the average 
surface hydrophobicity of a protein by mathematical models which are based on the 
amino acid composition and the three-dimensional structure of the protein [14,15]. 
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2.2 Hydrophobic Proteins used as Pharmaceuticals 
Many proteins that are used as pharmaceuticals, e.g. interferons, interleukins or growth 
factors are considered as hydrophobic. The hydrophobicity of these proteins is further 
increased, when they are recombinantly produced in Escherichia coli (E. coli) as host 
cells, as glycosilation is not possible in E. coli. Human Interferon beta-1b (INF-ß-1b) for 
example is glycosilated at a single site at Asn 80 at the end of helix C [16]. The lack of 
glycosilation in the recombinant human INF-ß-1b (rHINF-ß-1b), produced in E. coli 
increases the hydrophobicity of the protein, which is reflected in the retention time in  
RP-HPLC with a C18 column [17]. Two major issues that have to be overcome during 
formulation development for hydrophobic proteins are the low solubility and the 
adsorption of the active protein to surfaces, e.g. filters, tubes, pumps or primary 
packaging materials. 
 
2.3 Solubility of Hydrophobic Proteins 
The low solubility of hydrophobic proteins becomes an issue, when the target 
concentration for the formulation cannot be achieved. Already during preformulation 
studies the point of solubility needs to be addressed. For a protein it is not possible to 
determine one definite solubility value, as solubility is a function of pH, ionic strength and 
the presence of further excipients. Generally, solubility is lowest at the isoelectric point 
(pI) of a protein, due to the zero net charge of the molecules. Shaw et al. (2002) 
produced variants of ribonuclease Sa with isoelectric points from 4.6 to 10.2 (pI of the 
wild type: 3.5) by exchanging individual amino acids [18]. They showed that the 
minimum solubility of the variants lies within one pH unit around the pI and the solubility 
increases at higher and lower pH values [18]. Another example is insulin, with a 
maximum solubility below 0.1 mg/ml at its pI at pH 5.4, while the solubility is higher 
than 30 mg/ml at pH below 4.0 or above 7.0 [19]. Hydrophobic proteins often show a 
solubility below 1.0 mg/ml at physiological pH, e.g. 0.8 mg/ml for G-CSF [20] or 0.05 
mg/ml for rhINF-ß-1b [21].  
The solubility of a protein needs to be tested as function of the pH, generally in the range 
of pH 3.0 to 10.0. However, at the acidic and alkaline end of the pH-range physical and 
chemical instability reactions are more likely to occur. Table 2 summarizes chemical 
instabilities that are characteristic for acidic and alkaline pH conditions.  
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Table 2: Chemical instability reactions of proteins at low and high pH [7,22].  
acidic pH-range alkaline pH-range 
 
deamidation of asparagine and glutamine 
 
deamidation of asparagine and glutamine via a 
cyclic imid or hydrolysis (pH 7-12) 
 
oxidation of methionine (< pH 4) oxidation of cysteine 
proteolysis of aspartic acid (dilute acid) ß-elimination 
cleavage of aspartic acid-X (very acidic) shift of disulphide bonds 
 
 
Chemical and physical instability reactions of proteins, as well as potential analytical 
techniques to determine these reactions are discussed extensively in literature for 
example in the reviews of Manning et al. (1989) [7], Wang (1999 and 2005) [22,23], Chi 
et al. (2003) [8] and Reubsaet et al. (1998) [24]. For the selection of the appropriate 
formulation pH a balance between sufficient solubility and stability has to be found. 
Besides the selection of an optimum formulation pH, there are several approaches 
available to achieve the target concentration. The structural modification of a protein is 
one way to increase its solubility, with the conjugation with polyethylene glycol (PEG) 
being the most relevant method. Besides the low solubility, PEGylation can overcome 
several other problems related to the use of proteins as pharmaceuticals e.g. 
immunogenicity, susceptibility to enzymatic degradation, rapid kidney clearance and the 
related a short circulating half-live in vivo [25-27]. For the covalent conjugation PEG 
derivatives with activated functional groups are linked to reactive amino acids, e.g. 
lysine, cysteine, histidine, arginine, aspartic acid, glutamic acid, serine, treonine, tyrosine 
respectively the N-terminal amino group or the C-terminal carboxylic acid [28]. 
Another way to enhance protein solubility is the addition of excipients with surfactants, 
cyclodextrins, amino acids and salts being most effective. For parenteral protein 
formulations non-ionic surfactants, mostly polysorbate 20 and 80 are used. Besides the 
increase of solubility, surfactants can prevent adsorption of protein on surfaces and 
aggregation, which can be induced by the formation of interfaces e.g. during freeze-
thawing or agitation [8]. Several mechanisms for the stabilizing effect of surfactants are 
postulated. One is that surfactants can directly bind to the protein surface, which was 
shown for example for human growth factor (hGH) [29,30]. The binding of surfactant to 
a protein can lead to a stabilization or destabilization depending on the protein. 
Additionally, the surface tension of a protein solution is lowered by surfactants and with it 
Chapter 1 
   
 
6 
the driving force for aggregation and adsorption is decreased [22]. Surfactants compete 
with proteins for the adsorption to surfaces, which leads to a stabilization of the protein, 
which was shown by Kreilgaard et al. (1998) for recombinant human factor XIII and 
polysorbate 20 [31]. Polysorbate 80 protected lactate dehydrogenase (LDH) from 
denaturation during freeze-thawing by hindering the interaction of LDH with ice and the 
amount of polysorbate 80 required for the protection correlated with the ice crystal 
surface area [32].  
Cyclodextrins, which are cyclic oligosaccharides composed of six to eight dextrose units, 
can be used to enhance the solubility of proteins. For i.v. application chemically modified  
ß-cyclodextrins, e.g. 2-hydroxypropyl-ß-cyclodextrins (HPCD) were used to increase the 
solubility of Interleukin-2 (IL-2), ovine Growth Factor (O-GH) and Bovine Insulin [33]. 
Other examples are the use of cyclodextrins for a nasal formulation [34] or a parenteral 
formulation of Interferon-ß [35]. Furthermore, cyclodextrins can reduce aggregation and 
precipitation of proteins, but on the other hand thermal degradation can be favored 
[36,37].  
Protein solubility is further a function of the ionic strength and the used salt type. Salts, 
respectively anions and cations can be classified by their chaotrope effect (salting in), 
respectively cosmotrope (salting out) effect [38]. A stabilizing or salting out effect is 
achieved when macromolecules result in preferential hydration of the protein, whereas 
binding of salts to the protein surface often leads to a destabilizing, salting in effect 
[39,40]. In some cases, the solubility of a protein can be enhanced at its isoelectric 
points when low salt concentrations are added [41]. Especially in early developed 
formulations, HSA was frequently used to stabilize hydrophobic proteins used in low 
concentration, which is further discussed in section 3 of the introduction.  
 
2.4 Protein Adsorption  
Hydrophobic proteins, which are often used at low concentration, are susceptible to 
surface adsorption resulting in a reduced protein concentration in the final product. For 
recombinant human Interleukin-11 (rhIL-11), used at a concentration of 1 µg/ml a 
reduction of activity by more than 40% after three hours at room temperature was 
caused by the adsorption of the protein on the glass container [42]. Adsorption can occur 
on all kinds of surfaces, e.g. filling equipment, tubes, filters or packaging materials. 
Especially during filtration processes, when the protein solution gets in contact with large 
filter surfaces the risk of protein adsorption is very high. Therefore, protein adsorption 
needs to be considered during production and formulation development. The selection of 
the container material can also impact the degree of protein adsorption. Schwarzenbach 
et al. (2002) demonstrated with atomic force microscopy (AFM) that the adhesion force 
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of Interferon-α-2a (INFα-2a) was reduced by 40% when using glass type I+, which has a 
specially treated surface instead of glass type I [43].  
Norde (1995) reviewed the principles of protein adsorption on solid surfaces and 
described the different stages of the process [44]. The mechanism of adsorption is shown 
in Figure 1. Before a protein can adsorb to a surface, it needs to be transported to the 
surface (1). The basic mechanisms are diffusion and convective transport by laminar or 
turbulent flow. While the velocity of transport is increasing with protein concentration, 
the attachment of the protein to the surface is concentration independent. After binding 
to the surface (2) the protein can undergo structural reorientations (3). Adsorption is 
usually an irreversible process. However, desorption of protein (4) can be achieved by 
surface active ingredients [45]. Desorption of lysozyme from a polysulfone (PES) 
membrane with surfactants was shown by Kaplan et al. (2002) [46]. Finally the protein is 
transported away from the surface again by diffusion or convective transport (5). 
 
 
Figure 1: Protein adsorption mechanism of a protein on a surface. Psol and Pads are the native state of 
the protein in solution and after adsorption. P* are structurally perturbed states of the protein [44]. 
 
Numerous factors can impact the kinetics and the degree of adsorption of the particular 
protein on surfaces, e.g. protein concentration, temperature, pH, ionic strength and the 
presence of further excipients [44,47,48]. The hydrophobic or hydrophilic properties of 
the surface further govern the adsorption process. Spontaneous adsorption can occur 
when the change in Gibbs Energy (∆adsg ) is negative, by a decrease in enthalpy (∆adsh) or 
increase in entropy (∆adss) at a constant temperature as shown in equation (1) [46].  
 
∆adsg = ∆adsh - T∆adss   (1) 
Chapter 1 
   
 
8 
Generally, the adsorption process is driven by hydrophobic interactions and hydrogen 
bonding [49]. In addition, electrostatic interactions between charged surfaces and 
proteins, which are surrounded by counter ions to form electrical double layers, play an 
important role. The charged surface attraction occurs when protein and surface exhibit 
opposite charges. The electrical double layers can overlap and potential differences in net 
charge are balanced by the incorporation of counter ions between protein and surface 
[50]. The highest affinity of a protein to a surface is achieved, when the opposite charges 
of protein and surface result in a net charge of zero.  
Adsorption is associated with a structural reorientation of the protein on the surface, 
which often leads to irreversible denaturation. Vermeer et al. (1998) identified an 
increase in α-helical structures from 0.0% to 17% and a decrease of ß-sheet structure 
from 76% to 32% for a mouse monoclonal immunoglobulin (isotype 1) with circular 
dichroism (CD) after adsorption to Teflon particles [51]. In a formulation containing 0.05 
to 0.2 mg/ml Interleukin-2 (IL-2) more than 97% of the initial activity was lost after 
24 hours circulation in silicone rubber tubing, whereas only 20% to 30% of the activity 
loss can be attributed to adsorbed protein [52]. This indicates that activity loss is often 
more pronounced than the decline of the concentration after adsorption and associated 
with structural changes [52]. The tremendous activity loss is especially a problem when 
protein solutions are delivered via continuous infusions or when delivery devices e.g. 
micro pumps are applied. Tzannis et al. (1997) analyzed the time course of the 
adsorption process for IL-2 and found rapid adsorption after 10 minutes combined with a 
loss α-helical in favor of ß-sheet structures. After five hours the residual concentration in 
solution decreased not significantly anymore. However, the adsorbed molecules undergo 
structural changes and the ß-sheet structures disappear in favor of the original α-helix 
elements, as well as random structural elements [52]. Jørgensen et al. (1999) showed 
that already after 20 minutes the concentration of four peptide epidermal growth factor 
(EGF) receptor ligands was reduced to 33% to 73% on polyethylene, 15% to 46% on 
polystyrene and 12% to 29% on glass tubes due to adsorption [53]. 
Protein adsorption can be minimized by the addition of surfactants to the formulation. 
Zhang and Ferrari (1999) showed that Albumin adsorption onto silicon surfaces was 
reduced by polysorbate 20 [54]. Adsorption of three model proteins (hen egg white 
lysozyme, bovine serum albumin and ribonuclease A type IIA) onto different surfaces 
was reduced up to 30% by increasing the sugar concentrations, with trisaccharides being 
more effective than disaccharides and monosaccharides [48]. The addition of an excess 
of Human Serum Albumin to the active protein is another common approach to reduce 
the loss of the active protein due to adsorption.  
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3. Human Serum Albumin as Stabilizer for Proteins 
Human Serum Albumin is the most abundant protein in human plasma, where it is the 
major transport protein for fatty acids, as well as for different metabolites, drugs and 
organic compounds. After synthesis in the liver the non-glycosilated HSA is exported into 
the blood, where it is present at a concentration of about 0.6 mM. HSA is composed of 
585 amino acids and contains 17 disulphide bonds within each molecule. The dominating 
secondary structural elements are alpha-helices with about 67%. The heart-shaped 
structure consists of three repeating subdomains I-III, which contain two subdomains 
each [55]. Several binding sites in the different subdomains of HSA are characterized. 
The interaction of HSA with fatty acids and other components is extensively discussed in 
literature [56-58].  
In the pharmaceutical field HSA is used as drug substance and as excipient for the 
stabilization of other proteins. Generally, HSA is extracted from human plasma and 
therefore implicates problems associated with human blood derived products like the risk 
of blood born pathogens and batch to batch variations. Figure 2 shows a scheme of the 
production process for commercial HSA.  
 
 
Figure 2: Scheme for commercial production of HSA out of human plasma [59].  
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HSA for the application as drug substance or stabilizers in protein formulations is gained 
from pooled human plasma using the Cohn fractionation process with HSA precipitating 
in the last fraction [60]. After precipitation a wet, crude HSA paste is obtained, which 
requires further drying and purification steps. A prerequisite for the use of HSA as drug 
substance or excipient is the terminal pasteurization process for 10 hours at 60°C to 
guarantee viral inactivation [61].  
The pasteurization process imposes an extreme temperature stress for the protein, which 
leads to denaturation and aggregation if no further excipients are added. The melting 
temperature (Tm) can be used to estimate the thermal stability of a protein. Without 
stabilizers the melting temperature of HSA lies at 59.9°C at a formulation pH of 7.4 [62]. 
The sodium salt of caprylic acid and the sodium salt of the amino acid N-
acetyltryptophanate are used to increase the thermal stability of HSA by increasing 
Tm [63,64]. Arakawa and Kita (2002) postulate that the increase in Tm by Na-caprylate 
cannot solely explain the stabilizing effect and they assume that Na-caprylate binds to 
the denatured form of HSA as well and thereby reduces the tendency of the molecules to 
aggregate [65]. Na-N-acetyltryptophanate on the other hand can diminish oxidation, by 
protecting the sulfhydryl groups of HSA [62]. The FDA specifies the addition of 
0.08 mmol Na-caprylate or a combination of 0.08 mmol Na-caprylate and 0.08 mmol Na-
N-acetyltryptophanate per gram HSA at a formulation pH of 6.9 together with 0.15 M 
NaCl [61].  
In several approaches recombinant human albumin (rHA) was used to circumvent the 
mentioned problems of blood born pathogens and batch to batch variations. Tarelli et al. 
(1998) demonstrated that rHA had equal capacity to stabilize thyroid-stimulating 
hormone, Interleukin-15 and granulocyte colony-stimulating factor in lyophilized 
formulations as plasma derived HSA [66]. Matsushita et al. (2004) offered a functional 
analysis of rHA and of different sub domains for pharmaceutical applications [67]. Bosse 
et al. (2005) reported equivalent safety and pharmacodynamic behavior of rHA and 
plasma derived HSA in a double blind, randomized, phase I trial on 500 volunteers 
including three dose levels [68]. However, rHA is not routinely used in the field of protein 
formulation, due to the still high material costs. 
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3.1 HSA as Excipient in Protein Formulation 
HSA is frequently used as stabilizer in liquid and lyophilized formulations, to prevent 
protein adsorption and to stabilize the active protein. Examples for commercial products 
that contain HSA as stabilizer are shown in Table 3. 
 
Table 3: Examples for commercial protein formulations with HSA as excipient [69,70].  
protein products available 
 
Antithrombin III 
 
Atenativ® (lyophilized) 
 
Botulinum neurotoxin complex BOTOX® (lyophilized), BOTOX® COSMETIC (lyophilized) 
 
Factor VIII Fanhdi® (lyophilized), Haemate®HS (lyophilized), Monoclate-
P® (lyophilized), Recombinate® (lyophilized), Kogenate® 
(lyophilized) 
 
Immunoglobulins Gammagard® S/D (lyophilized), Sandoglobulin® (lyophilized), 
BabyBIG® (lyophilized), CytoGam® (liquid), RespiGam 
(liquid), ZevalinTM (liquid) 
 
Interferons alpha and beta Avonex® (lyophilized), Alferon N Injection® (liquid), 
Betaseron® (lyophilized), Rebif® (liquid) 
 
Modified human beta-glucocerebrosidase 
 
Ceredase® (liquid) 
Protein C Ceprotin® (lyophilized) 
 
Recombinant alpha-1-proteinase inhibitor 
 
AralastTM (lyophilized) 
Streptokinase Streptase® (lyophilized) 
 
Urokinase Abbokinase® (lyophilized) 
 
Fibrinogen (human), thrombin CrossealTM (frozen solution) 
 
For lyophilized formulations it is essential to add stabilizers that protect the active protein 
against freezing and drying associated stress. During freezing the low temperature, the 
formation of ice crystals, the increasing concentration of protein and excipients in the 
remaining amorphous phase, as well as possible phase separations and pH shifts are 
displaying stress for the protein. By the addition of cryoprotective excipients the active 
protein can be protected against freezing induced damages. Removal of the protein 
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hydration shell is the major issue during the drying process and lyoprotective excipients 
can be applied for stabilization. 
An overview and explanation of the stabilization mechanisms of different excipients is 
given in the reviews of Wang (2000) [70] and Arakawa et al. (2001) [72]. The 
mechanism of preferential exclusion explains the stabilizing effect of many cryoprotectors 
[73]. After drying water substitute hypothesis [74] and glass dynamics hypothesis [75] 
are important stabilizing mechanisms not only for proteins. Sugars like trehalose or 
sucrose, which are amorphous after lyophilization and exhibit a high glass transition 
temperature, provide a good stabilization in the dried state. Recently, it was shown by 
Cicerone et al. (2003), that the addition of glycerol to trehalose increased protein 
stability although the glass transition temperature (Tg) was substantially lowered [76].  
Human Serum Albumin can act as lyoprotector and cryoprotector during lyophilization 
and can further reduce the loss of active protein due to adsorption [71]. Anchordoquy 
and Carpenter (1996) showed that BSA is capable to stabilize Lactate Dehydrogenase 
(LDH) during lyophilization and prevent its activity by inhibiting the dissociation of the 
tetramer in the frozen state, as well as by preferential exclusion, whereby the stabilizing 
effect is increasing with BSA concentration [77].  
Because of the unspecifity of protein adsorption on surfaces, the loss of the active protein 
can be minimized by the addition of an excess of a second protein e.g. HSA which 
saturates the binding sites of a surface. Dawson et al. (1992) describe that the use of 
0.05% to 0.1% HSA inhibits protein adsorption and stabilizes different hydrophobic 
cytokines (Interleukins IL-1aα, IL-1ß, IL-3, macrophage colony-stimulating factor) during 
lyophilization [78]. The addition of 0.1% HSA to formulations of the peptides EGF and 
TGF-α can prevent absorption on polyethylene, polystyrene and glass tubes measured 
after 24 hours; while for HB-EGF and Betacellulin 0.1% HSA was not sufficient to prevent 
adsorption on glass [53].  
Development of significant analytical tools to characterize the protein and its degradation 
products is a prerequisite for a successful formulation development. In formulation with 
HSA as stabilizer, the presence of a second protein often in a 10 to 50 fold surplus 
compared to the active protein makes specific analytics difficult. In spectroscopic and 
chromatographic methods the signal of the active protein is often superimposed and 
disturbed by HSA. To analyze the active protein next to HSA, specific methods like ELISA 
[79], selective precipitation [80], western-blot or BIACORE are applied.  
Immunogenicity is often associated with the application of protein drugs. The most 
prominent example is the incidence of pure red cell aplasia (PRCA) caused by 
recombinant human erythropoietin formulations, which coincided with a formulation 
change in 1998. Here HSA was substituted by a combination of polysorbate 80 and 
glycine for the European market [81]. A controversial discussion on possible reasons for 
 Introduction and Objective of the Thesis 
   
 
13 
PRCA aroused and two main theories emerged. With the change of the formulation the 
prefilled syringes were changed and uncoated rubber stoppers were used. Leachates 
from the stopper were made responsible for the immunogenicity reaction [82]. On the 
other Hermeling et al. (2003) showed that the presence of micelle-associated epoetin in 
the formulations can induce the formation of antibodies against epoetin [83]. The theory 
was rebutted by Villalobos et al. (2005) [84]. Structural changes, in particular 
aggregation is known to induce the risk of immunogenicity reactions in the patient [85]. 
HSA itself exhibits a low risk for immunogenicity, however in presence of a second 
protein the formation of mixed aggregates can lead to immunogenicity reactions. The 
formation of mixed aggregates was shown for rhINFα [86,87] and recombinant 
streptokinase [88].  
 
3.2 Development of HSA-free Formulations 
HSA is mostly used in low dose formulations of hydrophobic proteins, due to its 
solubilizing effect, its ability to reduce protein adsorption and its stabilizing properties. In 
the development of new protein formulations HSA is omitted as far as possible, because 
of the already discussed disadvantages related to its application. Furthermore, there is 
the trend to replace existing formulations which contain HSA as excipient by HSA-free 
formulations. For the replacement of HSA, alternative approaches need to be found which 
provide sufficient stabilization and solubilization of the protein. Furthermore, the loss of 
protein due to adsorption needs to be prevented. Several examples for the replacement 
of HSA are available on the market and in literature. In Eprex® (Epoetin-α) HSA was 
replaced by polysorbate 80 and glycine as excipients. For the HSA-free formulation of 
Avonex® (Interferon-β-1a) arginine and polysorbate 20 were employed. Ruiz et al. 
(2003) describe a preformulation study for the development of a HSA-free formulation 
for recombinant human Interferon-α-2b (rhINF-α-2b), where they achieved stable 
formulations by adding polysorbate 80, EDTA-Na2 and PEG 400 [88]. In a lyophilized 
formulation of recombinant streptokinase, HSA was successfully replaced by glycine and 
sucrose in a formulation that further contained sodium glutamate and phosphate buffer 
at a pH of 7.4 [89]. For recombinant factor VIII SQ, the combination of NaCl as 
crystalline bulking agent with L-histidine and sucrose as amorphous stabilizers together 
with polysorbate 80 provided a stable lyophilized formulation without HSA [90]. From the 
described examples it is obvious that the use of non-ionic surfactants in combination with 
sugars and amino acids are common approaches for the development of HSA-free 
formulations.  
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3.2.1 Lyo- and Cryoprotection 
In its function as lyo- and cryoprotector HSA can be replaced by sugars, e.g. sucrose, 
trehalose, sugar alcohols e.g. mannitol and amino acids e.g. glycine, histidine, arginine. 
Thereby, it is important to have sufficient amorphous excipient in the lyophilized product 
to stabilize the active protein, by formation of hydrogen bonds and/or providing a glassy 
matrix [91]. Mannitol as single component can be dried in rapid processes due to its high 
eutectic temperature and thereby forms elegant cakes. However, due to its tendency to 
crystallize it is often not able to provide sufficient stabilization for the active protein [92]. 
Here mixtures of mannitol with sucrose or trehalose, respectively glycine are possible 
alternatives [93,94]. For the lyophilization of these mixed systems it is important to 
select the optimum ratio of the excipients and to adjust the lyophilization process to 
obtain a high degree of crystallization of the bulking agent. A partially crystallized bulking 
agent can lead to stability problems, if crystallization occurs upon storage. During 
crystallization, hydrate water can be released leading to an increase in residual moisture 
of the lyophilized cake. Further the hydrogen bonds between excipient and protein, which 
are necessary to stabilize the protein, can no longer be preserved in the crystalline 
state [92].  
 
3.2.2 Protein Adsorption 
When formulating hydrophobic proteins without HSA protein adsorption needs to be 
prevented. A possible approach to overcome protein adsorption is the addition of sugars 
to the formulation. Uncharged sugars can be adsorbed to negatively charged surfaces 
and can so modify the surface forces. This was shown by Claesson et al. (1996) for the 
adsorption of sucrose to an aluminosilicate which reduced the double layer force [95]. 
However, surface changes by adsorbed sugar molecules were excluded as the prevalent 
mechanism, by which sugars can reduce protein adsorption since the described effect 
was observed for different proteins independent of the hydrophobic or hydrophilic 
properties of the particular surface [48]. Thus, it was concluded that preferential 
exclusion of the sugar from the protein surface can explain the effect of a reduced 
adsorption in the presence of sugar. Adsorbed, as well as denatured protein molecules 
exhibit a larger surface area as compared to the native state, which is thermodynamically 
unfavorable and leads to a shift of the equilibrium towards the native state.  
An increase in ionic strength can also reduce protein adsorption. This was shown for 
human Apotransferrin, whose adsorption onto a silicon titanium dioxide surface at pH 8.0 
could be significantly reduced by increasing the NaCl concentrations [96]. Ramsden and 
Prenosil (1994) ascribe the reduced adsorption to a lowering of the surface potential 
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which can lead to a higher repulsive energy barrier [96]. By increasing the ionic strength 
in the formulations the electrostatic interactions between the protein and the surface can 
be weakened. Greene et al. (2005) quantified the adsorption of IgG adsorption onto 
chemically modified PPE membranes of different charges. They determined a reduced 
adsorption of IgG upon the addition of NaCl independent of the charge of the surface and 
concluded that adsorption was driven by unspecific electrostatic interactions [97].  
The degree of protein adsorption depends on formulation pH, as the pH strongly affects 
the charge of both the protein and in some cases also of the surface. Glass for example 
usually exhibits a negative charge in the pH-range feasible for protein formulations. Only 
in an extreme acidic environment far below pH 2.0 positively charged sites are present 
on the surface of glass [98]. Protein adsorption is typically most pronounced at the pI of 
the protein [96]. Maximum adsorption of Human Plasma Albumin was measured close to 
its pI at about pH 4.7 on polystyrene latex, silver iodide, polyoxymethylene, hematite 
and silica surfaces. As the highest adsorption was measured at the pI of Human Plasma 
Albumin independent of the materials, it was assumed the pH dependency of protein 
adsorption is rather due to the properties of the protein than to changed surface 
conditions at different pH values [99]. Especially for large proteins like ovalbumin and 
BSA the highest affinity to polystyrene was determined at their pI and Kondo and 
Higashitani (1992) concluded that hydrophobic interactions between the surface and the 
protein are most important [100]. On the other hand, high adsorption rates were also 
found when the protein and the surface exhibit opposite charges, which was shown for 
the IgG adsorption onto chemically modified PPE membranes of different charges [97]. 
A highly effective approach to prevent protein adsorption is the use of surfactants. 
Surfactants can reduce protein adsorption either by having an effect on the surface or by 
altering the solution properties. The hydrophobicity of a surfactant appeared to be most 
important for the reduction of Salmon Calcitonin (sCT) and BSA adsorption on glass, as 
polysorbate 20 was more effective than more hydrophilic poloxamer 188 or ionic 
surfactants [101]. Numerous other examples, describing the use of polysorbates to 
reduce adsorption are available in literature [54,101]. For example, the adsorption of 
HSA to polyethylene sheets was reduced by 35% to 40% when 0.05% polysorbate 20 
was added to the formulations [54]. Surfactants can not only prevent protein adsorption. 
Already adsorbed protein can as well be desorbed from a surface upon the addition of 
surfactants. Feng et al. (1995) showed that polysorbate 20 removed about 40% of 
absorbed HSA and 80% of adsorbed High Density Lipoproteins (HDL) from a polyethylene 
surface, while only a marginal desorbing effect was achieved for adsorbed IgG and 
fibrinogen under similar conditions [102]. 
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Besides the addition of adsorption reducing excipients to the formulation, the issue of 
adsorption can be addressed by the selection of the materials which are employed during 
processing and storage. During processing especially filter materials, which provide large 
surfaces, are critical factors. For the final formulation, special containers with reduced 
susceptibility for adsorption like glass type I+ can be employed to minimize protein 
adsorption [43].  
 
3.2.3 Protein Solubility 
During the development of HSA-free formulations the low solubility of hydrophobic 
proteins can become a major problem. Especially at physiological pH, solubility often lies 
below 1.0 mg/ml, e.g. 0.8 mg/ml for G-CSF [20] or 0.05 mg/ml for rhINF-ß-1b [21]. 
Protein solubility is a function of pH; however, the pH of optimum solubility not 
necessarily correlates with the pH of optimum stability. Rnase T1 shows the highest 
stability, determined by the free energy of unfolding ∆G (H2O) at its isolelectric point at 
pH 4.0, at which the protein exhibits the lowest solubility [103]. Therefore, a compromise 
between adequate solubility and sufficient stability of the active protein needs to be 
found when selecting the formulation pH.  
It was already described in 2.3 that protein solubility is a function of the ionic strength 
and the type of salt which is added to the formulation. As there is no general rule how 
solubility is influenced by the addition of salt, this point needs to be evaluated for the 
particular protein. Salts can stabilize proteins, which is for example described by Callahan 
et al. (2001) who showed that NaCl increased the thermal stability of brain derived 
neurotropic factor (BDNF) and thereby improved the shelf-life stability [104]. On the 
other hand, RNase A did not aggregate at pH 3.0 when exposed to 75°C for 24 hours, 
unless NaCl was added, which weakened the distinct charge-charge repulsions between 
the RNase A monomers that inhibited aggregation without NaCl [105]. Again, the 
addition of salt must not affect the stability of the active proteins. 
Furthermore, the addition of surfactants can enhance protein solubility and stability. 
Surfactants can limit protein degradation during processes in which interfaces are 
created, e.g. liquid/air interfaces during filling, liquid/solid interfaces when ice crystals 
form during freezing or liquid/air interfaces during reconstitution of lyophilized cakes 
[106]. Surfactants accumulate at the particular interfaces, thus the protein concentration 
at the interface is reduced and the protein is protected from surface-induced 
denaturation [107]. For example polysorbate 80 successfully stabilized lactate 
dehydrogenase (LDH) during freeze-thawing [32]. For the development of HSA-free 
formulations a combination of various approaches can lead to a successful stabilization of 
the active protein. 
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4. Conclusions 
Various approaches to overcome the issues of low solubility and the tendency to adsorb 
on surfaces arising during the formulation of hydrophobic proteins are available. HSA can 
be used to solve these problems as it is an excellent stabilizer and solubility enhancing 
excipient. However, its use is related with the concerns of blood born pathogens, batch to 
batch variations and immunogenicity when mixed aggregates are formed. Furthermore, 
the development of specific analytics for the active protein is often very demanding. By 
selecting optimum solution pH, ionic strength, excipients and container materials the 
solubility of a protein as well as its tendency to adsorb on surfaces can be influenced. In 
numerous cases the development of HSA-free formulations is feasible.  
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5. Objectives of the Thesis 
The goal of the thesis was to analyze the impact of the formulation conditions on the 
stabilization of a hydrophobic cytokine. A standard way to formulate the cytokine at 
physiological pH is using HSA as excipient. Based on a lyophilized formulation with 
mannitol as bulking agent and HSA as stabilizer analogous to commercially available 
systems, our intention was to elucidate the impact of HSA-stabilizers, NaCl and pH on 
particle formation and stability of the cytokine in the liquid state (Chapter 2). In addition, 
we wanted to clarify the role of NaCl on the lyophilization behavior of the system HSA-
mannitol. The goal was to understand how freezing, lyophilization and a subsequent 
storage of the formulations are influenced by NaCl and the HSA-stabilizers (Chapter 3 
and 4). The use of HSA as excipient is related to the risk of blood born pathogens, 
enhanced immunogenicity, as well as to analytical difficulties. Therefore, the second 
major objective was to replace HSA in the cytokine formulation and to develop stable 
HSA-free formulations. For the lyophilized formulations HSA should be replaced by 
sucrose as amorphous stabilizer and the first studies focused on the physico-chemical 
properties of the system mannitol–sucrose during lyophilization (Chapter 5). To achieve a 
stable HSA-free formulation, cytokine adsorption and solubility needed to be addressed 
and optimal formulation conditions had to be found for a liquid as well as a lyophilized 
formulation (Chapter 6).  
 
Thus, the main objectives of the thesis were: 
 
1. Characterization of the HSA-containing formulation of the hydrophobic cytokine 
with focus on the impact of NaCl and pH on particle formation and protein stability 
(Chapter 2). 
2. Characterization of the system HSA-mannitol during freezing and lyophilization 
with focus on the influence of NaCl and the HSA-stabilizers on the physico-
chemical properties (Chapter 3 and 4). 
3. Find the optimum formulation and lyophilization conditions for the system 
mannitol-sucrose to achieve a product of crystalline mannitol and amorphous 
sucrose, with a reduced content of mannitol hydrate (Chapter 5). 
4. Develop a stable HSA-free formulation for the hydrophobic cytokine (Chapter 6). 
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Chapter 2 
 
Characterization of Cytokine Solubility and Particle 
Formation in Presences of Human Serum Albumin 
 
 
Abstract 
The impact of pH and NaCl content on particle formation and solubility of the hydrophobic 
cytokine in a formulation with Human Serum Albumin (HSA) and mannitol as excipients 
was studied. A tremendous increase in turbidity at pH 5.0, close to the isoelectric point of 
HSA was observed. Dynamic light scattering (DLS), disc centrifugation, Atomic Force 
Microscopy (AFM) and light obscuration were used to characterize the turbidity causing 
particle formation process in the formulations. Here the high turbidity values mainly 
could be ascribed to particles of 500 to 1000 nm in size. SDS-PAGE showed that most of 
the cytokine precipitated at pH 5.0. As HSA used in the formulation further contained Na-
octanoate and Na-N-acetyltryptophante, the impact of these stabilizers on unstabilized-
HSA was evaluated. It could be shown that Na-octanoate and Na-N-acetyltryptophante 
were less effective in preventing the turbidity increase of unstabilized-HSA compared to 
NaCl. The HSA-cytokine precipitation at pH 5.0 was partially irreversible when the pH 
was re-adjusted to 7.0. Furthermore, the interactions between HSA and cytokine were 
weakened by NaCl, as determined by fluorescence spectroscopy. The positive effect of 
NaCl on the formulation could be attributed to a direct stabilization of HSA, which in 
consequence provided an overall stabilization of the cytokine.  
 
 
Keywords: human serum albumin, cytokine, pH, NaCl, particle formation  
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1.  Introduction 
When formulating the hydrophobic cytokine especially the problems of aggregation and 
adsorption on containers due to its low solubility need to be overcome. At physiological 
pH the solubility of the cytokine is less than 0.05 mg/ml [1]. One possible approach for a 
formulation at physiological pH is the use of Human Serum Albumin (HSA) as stabilizing 
excipient. Chapter 1 provides a comprehensive discussion on the use of HSA as excipient 
for protein formulations. Generally, HSA is extracted from human plasma and therefore 
implicates problems associated with human blood derived products like the risk of blood 
born pathogens and batch to batch variations. According to the US Food and Drug 
Administration, HSA has to undergo pasteurization for ten hours at temperatures of 60°C 
at the end of various processing and purification steps [2]. As stabilizing excipients 
against heat induced stress Na-octanoate [3] and the amino acid derivative Na-N-
acetyltryptophanate [4] are added. HSA is in addition stabilized by NaCl, which can 
inhibit the heat-induced aggregation of HSA [5]. NaCl and the other HSA-stabilizers 
brought into the formulations indirectly via HSA may induce problems, e.g. for proteins 
which are sensitive to ionic strength. Furthermore, they may impact the physico-chemical 
properties of other excipients, e.g. crystallization behavior or glass transitions which is 
critical in lyophilized formulations. The impact of the HSA-stabilizers on the physico-
chemical properties of formulations with HSA and mannitol during freezing and 
lyophilization is outlined in Chapter 3 and 4. For formulations with HSA limited analytical 
methods are available, because HSA, which is often employed in a 10 to 50-fold excess, 
interferes with many analytical methods for the active protein.  
In this study the hydrophobic model cytokine is used as a lyophilized formulation in 
combination with stabilized-HSA and mannitol as excipients in analogy to commercially 
available products. To estimate the role of different stabilizers on HSA, studies with 
different HSA-types were conducted, as well. The goal was to characterize the physical 
stability with special focus on aggregation in HSA–cytokine formulations under different 
pH and ionic strength conditions. To get comprehensive insight into the aggregation 
phenomena, various methods were used e.g. turbiditimetry, DLS, disc centrifugation, 
AFM and light obscuration. We further wanted to analyze possible interactions between 
the hydrophobic cytokine and HSA by using fluorescence spectroscopy to understand the 
properties of the cytokine–HSA formulation under different pH and ionic strength 
conditions.  
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2.  Materials and Methods 
2.1 Materials 
A lyophilized formulation with 0.25 mg/ml cytokine, 12.5 mg/ml mannitol and 
12.5 mg/ml stabilized-HSA in analogy to commercially available formulations was used. 
This formulation further contained between 0.08% and 0.1% NaCl, deriving from HSA 
and from pH-adjustment. Unstabilized-HSA (Fraction V, 96% to 99% purity) from Sigma-
Chemicals (Steinheim, Germany) was solid and contained no further excipients. Four 
different batches (072K7600, 072K7601, 033K7600, 033K7601) were used without 
further purification. Stabilized-HSA from Grifols (Langen, Germany) was used as 20% 
solution and contained 16 mmol Na-octanoate, 16 mmol Na-N-acetyltryptophanate, 130 
to 160 mmol/l sodium and max 2 mmol/l potassium. As HSA-free cytokine material a 
bulk with 1.2 mg/ml cytokine in 20 mM glycine at pH 3.0 was employed. The production 
of this HSA-free cytokine bulk material is described in Chapter 6. NaCl, Na-octanoate and 
N-Acetyl-DL-tryptophante were purchased from Sigma (Steinheim, Germany). KCl, LiCl, 
NaCH3COO, NH4Cl, KSCN and KI were purchased from Merck (Darmstadt, Germany). All 
salts were of reagent grade and used without further purification. 
 
2.2 Methods 
2.2.1 Turbidity Measurement 
Turbidity measurement was performed with a NEPHLA turbidimeter (Dr. Lange, 
Düsseldorf, Germany). Light (λ=860nm) was sent through the samples and the scattered 
light was measured at 90° angle. The system was calibrated with formazine as standard 
and the results were given in formazine nephelometric units (FNU).  
 
2.2.2 Light Obscuration 
Particles ≥1 µm were determined by light obscuration measurement using PAMAS – 
SVSS-C Sensor HCB-LD-25/25 (Partikelmess- und Analysensysteme GmbH, Rutesheim, 
Germany). Five aliquots of 0.3 ml were analyzed of each sample.  
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2.2.3 Dynamic Light Scattering (DLS) 
DLS, performed on a Zetasizer Nano (Malvern, Herrenberg, Germany) was used to 
characterize protein molecules and particles in the range from 1 to 1500 nm. The 
Zetasizer Nano is operating with a 4 mM He-Ne-Laser at 633 nm and non invasive back-
scatter technique (NIBS). The size distribution by intensity and volume was calculated 
from the correlation function using the multiple narrow mode of the Dispersion 
Technology Software from Malvern (version 4.00).  
 
2.2.4 Zetapotential 
The zetapotential was determined with the Zetasizer Nano (Malvern, Herrenberg, 
Germany). The measurements were performed in the automatic measurement mode 
using disposable capillary cells (Malvern DTS 1060).  
 
2.2.5 SDS-PAGE 
Non-reducing denaturating SDS-PAGE was used to analyze formulations containing HSA 
and the cytokine. NuPAGE® 10% and 12% Bis–Tris gels 1 mm, 10 wells (Invitrogen, 
Karlsruhe, Germany) and NuPAGE® MOPS running buffer was used for the separation. 
The electrophoresis was performed at a constant current of 0.03 A per gel. NuPAGE® LDS 
sample buffer was added to the samples, which were denatured for 10 minutes at 95°C. 
20 µl of the solution were loaded to each well. The amount of protein per well ranged 
between 0.1 to 0.3 µg cytokine, 5 to 15 µg HSA, or 1 to 5 µg HSA when analyzed as 
single component. The gels were stained with SilverXPress® Silver Staining Kit, 
respectively Colloidal Blue Staining Kit (Invitrogen, Karlsruhe, Germany).  
 
2.2.6 Fluorescence Spectroscopy  
Fluorescence spectroscopy was performed using a Varian Cary Eclipse (Darmstadt, 
Germany). The impact of pH on the fluorescence of cytokine, HSA and a combination was 
studied. HSA was used in a constant concentration of 0.5 mg/ml, while the cytokine 
concentration was varied. HSA-cytokine interactions were studied at pH 3.0 and pH 4.5 
with 0.0% and 0.1% NaCl, all buffered with 2 mM glycine. For the first studies the 
solutions were measured in 3.0 ml cuvettes at a constant temperature of 20°C with an 
excitation wavelength of 280 nm at an excitation slit of 5 nm. The emission was recorded 
from 260 to 450 nm at an emission slit of 5 nm and a scanning rate of 120 nm/sec. The 
PMT voltage of the detector was set to 400 V. To study protein-protein interactions 
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300 µl of the samples were analyzed in 96-well plates at a constant temperature of 20°C. 
Excitation wavelength was 280 nm at an excitation slit of 5 nm and emission was 
recorded from 260 to 450 nm at an emission slit of 5 nm and a scanning rate of 
30 nm/second. The PMT voltage of the detector was set to 600 V.  
Fluorescence quenching was monitored to evaluate the degree of HSA-cytokine 
interaction. Therefore, the fluorescence of the individual components, as well as of the 
combination was analyzed for the respective conditions. The degree of interaction was 
determined using equation (1). A high value for F0/F can be attributed to stronger 
interactions between the two proteins [6].  
 
Degree of interaction = F0/F   (1) 
 
F0 =  calculated sum of the fluorescence intensity (290 to 450nm) of the individual 
proteins 
F  = measured fluorescence intensity (290 to 450 nm) of solution containing both 
proteins 
 
2.2.7 Attenuated Total Reflection- FTIR Spectroscopy (ATR-FTIR) 
FTIR spectroscopy was performed on a Tensor 27 (Bruker Optics, Ettlingen, Germany) 
using the Bio-ATR unit. The spectra were recorded from 4000 to 850 cm-1 wavenumbers 
in attenuated total reflectance (ATR) mode at 20°C. Each measurement was the average 
of 240 scans. After analysis, the particular buffer spectrum was subtracted from the 
protein spectrum. The spectra were further processed by an off-set correction, forming 
the second derivative and vector normalization. The structural similarity between the 
second derivatives of the spectra was calculated via a spectral correlation coefficient r 
according to equation (2) [7,8].  
 
 
 
   (2) 
 
 
xi and yi are the corresponding peak intensities of various wave numbers i (second 
derivative of amide band I from 1700 to 1600 cm-1) in reference (x) and sample spectra 
(y). x* and y* are the average intensities of reference and sample spectra from 1700 to 
1600 cm-1.  
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2.2.8 Atomic Force Microscopy (AFM) 
AFM was conducted by Prof. Dr. U. Bakowsky at the Department of Pharmaceutical 
Technology and Biopharmaceutics at the Philipps University, Marburg with a Nanoscope 
VI Dimension Bioscope (Veeco Instruments, Santa Barbara, US). As imaging technique 
the tapping mode in air was used. Interactions between the sample and the tip were 
below 300 pN. Type I cantilevers with a nominal spring constant of 36 nN/nm were 
applied. The scanning speed was adjusted to the respective scanned area and ranged 
between 0.25 and 2 Hz at a resolution of 512 * 512 pixels, independent of width of the 
scanned area. All experiments were performed under atmospheric pressure at 
25°C / 60% RH. 
 
2.2.9 Disc centrifugation 
The CPS disc centrifugation system (LOT-Oriel GmbH, Damstadt, Germany) was used to 
determine the size distribution of the particles in the range of 20 nm to 2 µm. The 
measurements were performed by Dr. Stefan Wittmer, LOT Oriel Darmstadt. 200 µl of 
the protein solution was applied on the disc, which was rotating with 22000 to 
24000 rpm. A density gradient from 7% to 2% sucrose was built up within the disc. At 
the edge of the disc the particles were detected with a light source of 470 nm. The time 
required for the particles to reach the edge of the disc, as well as the absorption signal 
were transformed to a particle size distribution, using Stokes-Law and Mie-theory.  
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3.  Results and Discussion 
3.1 Characterization of Cytokine-HSA Formulations at Different pH and 
Ionic Strength Conditions  
3.1.1 Effect of pH and Salt on Turbidity  
An elevated turbidity can be a sign for the presence of larger aggregates and precipitated 
material within a formulation. Figure 1 shows the turbidity and the particles larger than 
1 µm for a formulation with 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA and 
12.5 mg/ml mannitol. At pH 7.4 a turbidity of 6 FNU was measured. When the pH of the 
formulations was lowered the turbidity increased sharply and reached a maximum of 
about 100 FNU at pH 5.0. Furthermore, light obscuration showed that the number of 
particles, in particular the particles of 1 to 2 µm in size (compare 3.1.4, Figure 16), 
increased significantly when the pH was lowered to 5.0. The correlation between the data 
from light obscuration with the turbidity data was in agreement with literature [9].  
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Figure 1: Turbidity and total number of particles larger 1 µm determined by light obscuration of 
0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA and 12.5 mg/ml mannitol between pH 3.0 and 7.4.  
 
Since turbidity measurement offered the advantage of being less time- and material 
consuming the technique was used as a characterization tool in the subsequent study.  
A possible explanation for the increased turbidity and protein precipitation at pH 5.0 
could be found when the isoelectric points (pI) of the proteins were considered. For the 
cytokine the pI, at which it shows the lowest solubility, is located at pH 9.2 [10]. For HSA 
a pI between 4.8 and 4.9 is described [11]. The turbidity maximum at pH 5.0 was close 
to the isoelectric point of HSA. At its pI, protein-protein interactions are favored due to a 
reduced interaction energy barrier, which can lead to aggregation [12]. Consequently, 
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Saso et al. (1998) described, that HSA showed that highest level of heat-induced 
aggregates in the pH range of 4.5 to 5.0 [5]. For the cytokine-HSA formulation the 
turbidity increase at pH 5.0 pointed to either a precipitation of HSA itself or a 
combination of HSA-cytokine. Furthermore, it could be possible that HSA was no longer 
capable to provide sufficient stabilization of the formulation, leading to a precipitation of 
the cytokine. 
NaCl is known to stabilize HSA against heat-induced aggregation [5] by increasing the 
melting temperature (Tm) [13]. As an increase in ionic strength can further impact the 
solubility of proteins, the turbidity of the formulation with 0.25 mg/ml cytokine, 
12.5 mg/ml stabilized-HSA and 12.5 mg/ml mannitol was studied from pH 7.4 to 3.0 
upon the addition of NaCl (Figure 2). 
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Figure 2: Turbidity of 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA and 12.5 mg/ml mannitol 
with 0.0% to 0.3% NaCl from pH 7.4 to 3.0.  
 
It was obvious that the addition of NaCl could significantly reduce the turbidity increase 
at pH 5.0, indicating a stabilizing effect of NaCl on the formulations. For NaCl 
concentrations between 0.2% and 0.9% turbidity at pH 5.0 reached a plateau phase of 
about 20 FNU. This wide plateau phase pointed at a rather unspecific stabilizing effect of 
NaCl, probably induced by electrostatic effects. At pH 7.4, the turbidity was slightly lower 
without NaCl, which required further investigations.  
To evaluate whether the turbidity preventing effect was specific for NaCl, the influence of 
various salts on the turbidity of the cytokine-HSA formulation was evaluated. It is 
generally difficult to predict the direct effect of salts on protein stability, as it is 
influenced by various factors, e.g. type of protein, pH, ionic strength, mechanism of 
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interaction [12]. Anions and cations can be classified by their chaotrope effect (salting 
in), respectively cosmotrope (salting out) effect as shown in Figure 3.  
 
      chaotrope effect - salting in - destabilization 
 
anions: SO42- > CH3COO- > Cl- > Br- > NO3- > I- > SCN- 
cations: NH4+ > K+ > Na+ > Li+ > Mg2+ > Ca2+ > Ba2+ 
 
          cosmotrope - salting out - stabilization 
Figure 3: Classification of anions and cations according to their chaotrope, respectively cosmotrope 
properties [14].  
 
A stabilizing or salting out effect is achieved when the addition of salt leads to a 
preferential hydration of the protein, whereas binding of salts to the protein often yields 
a destabilizing, salting in effect [15,16]. Low concentrations of salts usually increase the 
solubility of proteins by non-specific electrostatic interactions. Different salts (KCl, LiCl, 
NaCH3COO, NH4Cl, KI, and KSCN) were added to the formulation of 0.25 mg/ml cytokine, 
12.5 mg/ml HSA and 12.5 mg/ml mannitol at a concentration to provide an ionic 
strength of µ=0.009 or µ=0.034. Table 1 summarizes the turbidity maxima measured for 
the different salts at ionic strength of µ=0.009 and µ=0.034. The resulting turbidity 
maxima were located at pH 5.0 for all studied conditions. The exception was KSCN at an 
ionic strength of µ=0.034 where the maximum turbidity was shifted to pH 4.0. Without 
the addition of salt a maximum turbidity of about 100 FNU was measured at pH 5.0. All 
tested salts led to a decline of the maximum turbidity at pH 5.0. It was evident that the 
more chaotrope salts KSCN and KI were less effective in preventing the turbidity increase 
at pH 5.0. When used at the lower ionic strength NaCl and KCl were superior to the other 
salts in preventing the turbidity increase at pH 5.0. When increasing the ionic strength to 
0.034 NaCl, KCl, LiCl, NaCH3COO and NH4Cl all reached comparable values of about 19 to 
21 FNU at pH 5.0. The cation appeared to have a minor impact on the turbidity 
preventing effect. This pointed at an unspecific effect of electrostatic interactions which 
led to the lowered turbidity at pH 5.0. The stabilizing effect of NaCl is advantageous due 
to the physiological compatibility of NaCl and the fact that it is brought into the 
formulations as HSA stabilizer. For this reason exclusively NaCl was used to improve the 
solubility of the formulation in the further progress of the studies.  
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Table 1: Maximum turbidity in FNU at pH 5.0 for the cytokine-HSA formulation after the addition of 
different salts at ionic strength of µ=0.009 and µ=0.034. 
 
           µ = 0.009           µ = 0.0345 
 c [%] turbidity pH 5.0 
[FNU] 
c [%] turbidity pH 5.0 
[FNU] 
NaCl 0.05 34.7 0.2 18.9 
KCl 0.06 36.4 0.26 19.9 
LiCl 0.04 49.3 0.15 19.1 
NaCH3COO 0.07 49.0 0.28 21.0 
NH4Cl 0.05 54.7 0.18 18.08 
KI 0.14 65.4 0.57 37.4 
KSCN 0.06 55.8 0.23 35.4* 
 
*turbidity maximum at pH 4.0 with 86.2 FNU 
 
One point to be clarified was the reversibility of the precipitation at pH 5.0. In order to 
elucidate this issure the formulation pH was lowered to 5.0 and re-adjusted back to 7.4 
(Figure 4).  
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Figure 4: Turbidity at pH-shift from 7.4 to 5.0 of cytokine-HSA formulation (0.25 mg/ml cytokine, 
12.5 mg/ml stabilized-HSA and 12.5 mg/ml mannitol) with 0.0% and 0.2% NaCl compared to a 
placebo formulation (12.5 mg/ml unstabilized-HSA and 12.5 mg/ml mannitol).  
 
Formulations with 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA and 12.5 mg/ml 
mannitol, respectively a placebo-formulation with 12.5 mg/ml unstabilized-HSA were 
compared. Unstabilized-HSA was used to eliminate a potential effect of the HSA-
stabilizers on turbidity and to show solely the properties of HSA. The turbidity of the 
cytokine-HSA formulation increased from about 10 FNU at pH 7.4 to 85 FNU at pH 5.0. 
Immediately after the pH-shift a residual turbidity of 38 FNU was measured at pH 7.4 
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and a constant level of 33 FNU was reached after approximately 90 minutes. This 
indicated that precipitation, triggered by the lowering of the pH, was at least partially 
irreversible. When 0.2% NaCl was added to the formulations the turbidity increased from 
11 FNU at pH 7.4 to 18 FNU at pH 5.0 and remained with 13 FNU about 2 FNU higher 
than initially. For a placebo-formulation with 12.5 mg/ml unstabilized-HSA precipitation 
and elevated turbidity levels of about 40 FNU at pH 5.0 were observed as well. In 
contrast to the cytokine-HSA formulation the precipitation of unstabilized-HSA was 
completely reversible and the turbidity dropped to the initial value of about 4 FNU. This 
indicated that the cytokine or a combination of cytokine-HSA were responsible for the 
irreversibility of the precipitation.  
To further clarify the stabilizing influence of NaCl on the turbidity profile of the cytokine-
HSA formulation, the turbidity of unstabilized-HSA and cytokine as individual components 
was studied between pH 3.5 and 7.0 at increasing NaCl concentrations. In a formulation 
with 12.5 mg/ml unstabilized-HSA turbidity stepped up at decreasing pH and reached a 
maximum at pH 4.5 (Figure 5a). With 0.1% NaCl the turbidity increase was reduced and 
at 0.25% and 0.5% NaCl completely inhibited. Thus, it could be stated that NaCl offered 
a direct stabilization of HSA against precipitation at pH 5.0. A stabilizing effect of NaCl on 
HSA and BSA is also described in literature. Saso et al. (1998) showed a stabilizing effect 
of NaCl on heat induced aggregation of HSA [5]. Yamasaki and Yano (1990, 1991) 
reported that the denaturation temperature of BSA between pH 4.5 to 9.0 was increased 
with rising ionic strength after adding 0.001 to 1.0 M (0.0058% to 5.8%) NaCl. This 
stabilizing effect was ascribed to a screening effect of NaCl on the electrostatic forces and 
the inhibition of crevice formation within the molecule in the vicinity of 212Trp [17,18]. 
This screening effect of NaCl on electrostatic forces was as well reflected in the lower 
zetapotential values of HSA in presence of NaCl (compare Figure 19, section 3.2.1).  
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Figure 5: Turbidity of 12.5 mg/ml unstabilized-HSA with 0.0% to 0.5% NaCl (a) and 0.25 mg/ml 
cytokine with 0.0 to 0.9% NaCl (b) at pH 3.0 to 7.0. In (c) the turbidity of the Cytokine-HSA 
formulation is compared to the individual components.  
 
Compared to the cytokine-HSA formulation with a turbidity maximum at pH 5.0, the 
turbidity maximum was located at pH 4.5 for HSA as single component. This shift could 
be explained by the zetapotential of the formulations (Figure 6). For the cytokine-HSA 
formulation a zetapotential of 0 mV, which marks the pI was found at pH 5.2. This was 
approximately 0.5 pH-units higher than for HSA as single component, where 0 mV was 
reached at pH 4.7. Thus, the zetapotential was shifted to higher pH values due to the 
addition of the cytokine. In the studied pH range the cytokine, with its pI of 9 was highly 
positively charged. Above pH 5.5 it was not feasible to determine the zetapotential of the 
cytokine due to the beginning precipitation and its low solubility. Generally, the pI of a 
protein mixture is found between the pI values of the individual proteins depending on 
the ratio. This was for example shown by Rezwan et al. (2005) for Bovine Serum Albumin 
and Lysozyme adsorbed on colloidal particles [19].  
 
(a) (b) 
(c) 
.0% NaCl 
0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA 
12.5 mg/ml unstabilized-HSA 
12.5 mg/ml stabilized-HSA 
0.25 mg/ml cytokine 
Characterization of Cytokine Solubility and Particle Formation in Presences of Human Serum Albumin 
   
 
37 
 
-20
-10
0
10
20
30
40
2.5 3.5 4.5 5.5 6.5
pH
z
e
ta
p
o
te
n
ti
a
l 
[m
V
]
 
Figure 6: Zetapotential of 0.25 mg/ml cytokine (   ), 12.5 mg/ml HSA (   ) and a combination of 0.25 
mg/ml cytokine and 12.5 mg/ml HSA (    ) measured in a buffer with 5 mM glycine at pH 3.0 to 6.0. 
 
The cytokine as individual component revealed a completely different turbidity profile 
between pH 3.0 and 7.0 as compared to HSA (Figure 5b). The turbidity increased when 
the pH was raised from 3.0 to 7.0 when the formulation pH approached the pI of the 
cytokine at 9.2. Upon the addition of NaCl, precipitation was fostered and the turbidity 
stepped up already at lower pH values. Huang et al. (2005) demonstrated for human 
recombinant Interferon-α-2a by isothermal titration calorimetry, that the attraction 
between the protein monomers were increased by the addition of NaCl with the 
consequence of aggregation induced by hydrophobic interactions and decreasing electro-
repulsive forces between the protein molecules [20]. At pH 5.0, however, turbidity values 
below 10 FNU were found for the cytokine with 0.0% to 0.2% NaCl. This indicated a 
sufficient solubility under these conditions if the cytokine was present alone. A 
comprehensive discussion on the impact of NaCl on the cytokine aggregation and stability 
is found in Chapter 6.  
Figure 5c compares the turbidity of the cytokine-HSA formulation with those of the 
individual components. Unstabilized-HSA reached the maximum turbidity of about 
40 FNU at pH 4.5. Due to the stabilizers and NaCl this turbidity increase could be 
inhibited in formulations with stabilized-HSA, which was shown for NaCl and unstabilized-
HSA in Figure 5a. Formulations with 0.25 mg/ml cytokine were clear at pH 5.0 and the 
turbidity increase started first when the pH exceeded 5.5. For the combination of 
cytokine and stabilized-HSA the turbidity resulted in a turbidity curve, which resembled 
those of HSA as single component, however, with a higher maximum value of 100 FNU. 
In the concentration applied for the formulation the stabilizers were not capable to 
prevent the turbidity increase. Still it was unclear if the precipitation was caused by the 
cytokine, HSA or a combination of the two proteins. 
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3.1.2 SDS-PAGE of the Precipitated Material 
To analyze the composition of the precipitated material SDS-PAGE was performed at 
pH 7.0 and pH 5.0. At pH 5.0 the turbid solution (TS) was centrifuged and both the 
supernatant (SN) and the precipitated material (P) were investigated. The HSA-gel 
showed that only traces of HSA were found in the precipitated fraction (Figure 7a). In 
contrast, the cytokine was present to a similar degree in the supernatant and the 
precipitated fraction (Figure 7b). Comparing the cytokine bands it was obvious that the 
precipitated fraction contained a high portion of cytokine.  
 
 
 
Figure 7: SDS-PAGE of the cytokine-HSA formulation at pH 5.0 showing the turbid solution (TS), the 
supernatant (SN) and the precipitated fraction (P) of HSA (a) and the cytokine (b).  
 
The results from SDS-PAGE were in agreement with turbidity studies. For HSA as single 
component the HSA-stabilizers and especially NaCl provided sufficient stabilization to 
prevent a turbidity increase over the pH-range. In the presence of the cytokine, however, 
sufficient stabilization could no longer be provided.  
 
 
 
 
 
 
 
 
 
 
TS SN P TS SN P Marker Marker 
(a) (b) 
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3.1.3 Fluorescence Spectroscopy of Cytokine-HSA Mixtures 
The high turbidity of 100 FNU for the cytokine-HSA formulation compared to 10 FNU for 
the cytokine and 40 FNU for unstabilized-HSA at pH 5.0 pointed at interactions between 
the two proteins. To gain insight into the interactions between HSA and the cytokine at 
different conditions, isothermal titration calorimetry [21], nuclear magnetic resonance 
spectroscopy [22], equilibrium dialysis [23], fluorescence spectroscopy or 
chromatography [23] would be possible techniques. In the context of this project, 
fluorescence spectroscopy was used to evaluate the interaction between HSA and 
cytokine. Both proteins contain Trp residues in their amino acid sequences, HSA one at 
position 214 and the cytokine molecule two Trp near the surface (position 22 and 143) 
and one in the hydrophobic core (position 79). Trp residues of a protein can be excitated 
at 280 nm and show characteristic emission spectra with maxima between 310 to 
350 nm, depending on the environment [24,25].  
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Figure 8: Emission spectra of 0.01 mg/ml cytokine (a) and 0.5 mg/ml HSA (b) in 2 mM glycine 
between pH 2.8 and 7.8 after excitation at 280 nm.  
 
In the emission spectra of the cytokine as individual component the maximum was 
located at 340 nm independent of the formulation pH (Figure 8a). An emission maximum 
of 340 nm can be attributed to Trp residues on the protein surface, which have contact 
with bound water and other polar groups [24]. With increasing pH values the 
fluorescence intensity declined, but no shift of the maximum occurred. This revealed that 
the microenvironment of the Trp residues of the cytokine was not affected by the pH 
change and potential associated structural changes [26]. An increased intensity of 
fluorescence which is not combined with a red shift of the maximum was also described 
for Bovine Growth Hormone upon a pH shift from neutral to acid [27]. For HSA the 
lowering of the pH was accompanied with a shift of the emission maximum from 340 nm 
between pH 7.8 and pH 4.8, to 326 nm at pH 3.9 and 321 nm between pH 3.5 and 
(a) (b) 
pH 3.0 
pH 7.8 
pH 3.4 
pH 7.1 
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pH 2.8 (Figure 8b). The blue shift of the spectra at lower pH values indicated an 
exposure of the Trp residues to a less polar environment and a loss of contact to water. 
For the evaluation of protein-protein interactions increasing cytokine concentrations were 
added to a constant amount of 0.5 mg/ml HSA. The interaction was evaluated for pH 3.0 
and pH 4.5 without and with 0.1% NaCl. Due to the beginning cytokine precipitation 
above pH 5.0 it was not feasible to include higher pH values in the study. In Figure 9 the 
spectra of HSA, cytokine and the combination of HSA with cytokine are shown 
exemplarily for pH 3.0 
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Figure 9: Emission spectra of 0.5 mg/ml HSA with 0.02 mg/ml cytokine (a), 0.04 mg/ml cytokine 
(b) and 0.1 mg/ml cytokine (c) in 2 mM glycine at pH 3.0 after excitation at 280 nm.  
 
The degree of interactions was determined as F0/F, with F0 as the calculated sum of the 
fluorescence intensity (290 to 450nm) of the individual protein and F as the measured 
intensity of a solution with both proteins [6]. A higher value of F0/F indicated stronger 
protein-protein interactions. For the combination of HSA and the cytokine the interaction 
parameter F0/F was increasing at higher cytokine concentrations. At pH 3.0 the 
interaction parameter F0/F raised from about 1.1 at 0.02 mg/ml to 1.3 at 0.1 mg/ml 
(a) (b) 
(c) 
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cytokine (Figure 10a). This indicated that interactions occurred to a greater extent at 
higher cytokine concentrations when HSA was present in excess. The addition of 
0.1% NaCl did not impact the strength of the interactions determined at pH 3.0. 
Significantly stronger interactions between HSA and the cytokine were measured without 
NaCl at pH 4.5 (Figure 10b). F0/F increased from 1.15 to 1.53 when adding 0.02 and 
0.1 mg/ml cytokine to 0.5 mg/ml HSA. The addition of 0.1% NaCl weakened the 
interactions between HSA and cytokine, obvious by lower values of F0/F, which were 
comparable to pH 3.0.  
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Figure 10: Interaction parameter F0/F for the combination of 0.5 mg/ml HSA with cytokine at 
pH 3.0 (a) and pH 4.5 (b) with different NaCl concentrations.  
 
Besides the direct stabilizing effect of NaCl on HSA, the reduced interaction between HSA 
and the cytokine by adding NaCl at pH 4.5 could offer a further explanation for the 
prevention of the turbidity increase in the cytokine-HSA formulation with the maximum 
at pH 5.0. 
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3.1.4 Particle Size Analysis in Cytokine-HSA Formulations 
One goal of the study was to characterize the particle formation in cytokine–HSA 
formulations depending on pH and NaCl concentration. So far, only turbiditimetry was 
used to characterize aggregation and particle formation. However, different particle 
fractions especially very small particles below 30 nm, as well as larger particles in the 
µm-range may not sufficiently be reflected by turbiditimetry. Therefore, various methods 
complementing each other, namely DLS, disc centrifugation and light obscuration were 
used to monitor particle formation. For the DLS-measurements the short–term intensity 
fluctuations of scattered light, which are caused by random Brownian motion of the 
particles are used to calculate the particle size. The measuring range for DLS 
experiments is typically 1 nm to 5 µm, in exceptional cases up to 10 µm. The upper limit 
depends on particle density and the incipient sedimentation [28]. Particles of 1 µm and 
larger can be determined by light obscuration. Disc centrifugation is a method equivalent 
to analytical ultracentrifugation that can provide information on particles of 20 nm to 
2 µm in size. Furthermore, AFM was utilized to visualize the particles formed with pH-
changes. 
The DLS size-distribution by volume showed a peak with a mean diameter of 5 to 9 nm in 
the cytokine-HSA formulation without and with 0.2% NaCl between pH 7.0 and 5.0 
(Figure 11a,b). This first peak dominated the size distribution by volume with maximum 
intensities by volume of about 30% for all studied conditions. The cytokine-HSA 
formulation is dominated by the 50-fold excess of HSA compared to the cytokine. 
Therefore, the literature values described for HSA can be used as reference values. For 
native HSA at neutral pH, a mean diameter of 6 to 7 nm and for aggregated HSA a broad 
peak at 30 to 100 nm was described by Sotum and Christiansen (1997) [29]. Lowering 
the pH of the cytokine-HSA formulation resulted in a shift of the monomer peak from 
4.8 nm at pH 7.0 to 7.5 nm at pH 5.0 without NaCl and from 5.6 nm to 6.5 nm with 
0.2% NaCl. A second peak with a maximum between 30 and 60 nm, deriving from 
aggregated protein, with an intensity of approximately 0.1% was present in all samples. 
In samples without NaCl a third particle class with a maximum of about 500 nm at 
pH 5.5 and about 1500 nm at pH 5.0 appeared (Figure 11c,d). The tremendous turbidity 
increase below pH 5.5 in NaCl-free samples could essentially be attributed to this third 
population. 
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Figure 11: DLS size-distribution by volume of the cytokine-HSA formulation in water (a,c) and 0.2% 
NaCl (b,d) at pH 7.4 (         ), 6.0 (        ), 5.5 (         ) and 5.0 (        ). 
 
Regarding the integrated peak areas of the DLS size-distribution by volume a decline in 
the area of the first peak between 0 and 15 nm and the second species between 15 to 
120 nm in favor of larger species was obvious when the pH was lowered without NaCl 
added (Figure 12a). The fact that the integrated area between 15 and 120 nm declined 
at pH 5.5 and 5.0 demonstrated that the turbidity increase could mainly be attributed to 
particles larger than 120 nm. The addition of 0.2% NaCl could inhibit the turbidity 
increase to a maximum of 20 FNU at pH 5.0 compared to 100 FNU without NaCl. In 
samples with 0.2% NaCl less than 1.5% of integrated area of the size distribution by 
volume could be attributed to the particles larger than 120 nm (Figure 12b). This further 
strengthened the assumption that particles larger than 120 nm were mainly responsible 
for the tremendous turbidity increase at pH 5.0. The result were in agreement with 
Mahler et al. (2005) who showed for IgG1 formulations that turbidity determined at 350 
and 550 nm could be attributed to medium sized aggregates and furthermore was in 
correlation with particles of 1 to 2 µm determined by light blockage [9]. In the size 
distribution by number more than 99% of the intensity derived from particles smaller 
than 10 nm.  
(a) (b) 
(c) 
(d) 
Chapter 2 
   
 
44 
 
0
20
40
60
80
100
0-15nm 15-120 nm > 120 nm
in
te
g
ra
te
d
 p
e
a
k
 a
re
a
 [
%
]
pH 7.4 pH 6.0 pH 5.5 pH 5.0
 
0
20
40
60
80
100
0-15nm 15-120 nm > 120 nm
in
te
g
ra
te
d
 p
e
a
k
 a
re
a
 [
%
]
pH 7.4 pH 6.0 pH 5.0
 
Figure 12: Integrated peak area of the DLS size-distribution by volume in % of the total AUC for 
cytokine–HSA formulations without NaCl (a) and 0.2% NaCl (b) at pH 7.4 to 5.0.  
 
Due to the high scattering intensities of larger particles DLS experiments can reach a 
limit when samples contain multiple particle classes. These systems can be analyzed by 
disc centrifugation, which is an alternative to analytical ultracentrifugation. The size 
distribution obtained by disc centrifugation is based on the sedimentation velocity of 
particles within the density gradient of the disc. This sedimentation velocity is depending 
on particle size and density under the influence of centrifugal forces. Bondoc and 
Fritzpatrick (1998) used disc centrifugation to determine the hydrodynamic diameter of 
adenovirus monomers, dimers, trimers and aggregates [30]. Other examples found in 
literature are the application of disc centrifugation to classify the size of polymer latex 
[31,32], UV-absorbers [33], nanoparticles [34], immunoglobulins [35] and E. coli 
inclusion bodies [36]. 
With the density gradient from 7% to 2% sucrose built up within the disc the smallest 
particles to be detected were 20 nm. Particles with a size below 20 nm would require 
unfeasible runtimes of several hours. The main particle sizes determined by disc 
centrifugation ranged between 20 nm and 1 µm in cytokine-HSA formulations at pH 7.0 
and pH 5.0 without and with 0.2% NaCl (Figure 13). At pH 7.0 the size-distribution by 
weight indicated slightly larger particles for samples with 0.2% NaCl than for samples 
without NaCl. Without NaCl 50% of the intensity by weight derived from particles smaller 
than 32 nm compared to 40 nm when 0.2% NaCl was added. However, at pH 7.0 about 
95% of the intensity could be ascribed to particles smaller than 100 nm without and with 
0.2% NaCl. When lowering the pH of the NaCl-free formulation to 5.0 a significant shift of 
the size-distribution by weight to larger particles was observed. More the 50% of the 
intensity by weight could be attributed to particles larger than 100 nm. For the samples 
with 0.2% NaCl 95% of the intensity by weight derived from particles smaller than 
100 nm.  
(a) (b) 
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Figure 13: Cumulative particle size distribution by weight of cytokine-HSA with 0.0% NaCl and 0.2% 
NaCl at pH 7.0 and pH 5.0 determined with disc centrifugation. 
 
AFM was used to size and visualize particles in the nm-range. Contrary to the other 
evaluated techniques, AFM studies at pH 5.0 were omitted because of the presence of 
particles in the µm-range, which can interfere with the analytics. From the data collected 
by AFM it is possible to visualize the particles, which is exemplarily shown in Figure 14 
for the formulation at pH 7.0 focusing on the small objects smaller than 10 nm. These 
small objects between 6 and 10 nm were present at pH 7.0, 6.0 and 5.5.  
 
 
Figure 14: 3D visualization of 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA at pH 7.0.  
 
To size the objects in the samples line-scans were used, which are exemplarily shown for 
a sizing of 30 nm objects at pH 7.0 and 600 nm objects at pH 5.5 (Figure 15). At pH 7.0, 
6.0 and 5.5, small globular objects with a size between 6 and 10 nm, as well as particles 
in the size range from 22 to 35 nm were present. Thereby, the samples at pH 7.0 
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possessed the most homogenous distribution with small globular objects of 6 to 10 nm, 
and also larger objects with a medium size of 29.4 nm. At pH 6.0 objects with an 
average size of 31.2 nm and some particles with a diameter of about 80 nm were 
detected in the sample besides the aforementioned fraction at 6 to 10 nm. The incipient 
precipitation at pH 5.5 was reflected in particles with a diameter of 200 to 400 nm. 
Beside these particles, smaller particles of 6 to 10 nm and 32.4 nm were detected. 
 
 
 
 
Figure 15: Line scans to size particles of 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA at pH 7.0 
(a) and pH 5.5 (b).  
 
The so far described methods focused on the characterization of the nm-range. Light 
obscuration was used to determine the number of particles ≥ 1 µm. In the absence of 
NaCl, an immense increase in particles at pH 5.0, especially in the size range between 1 
and 2 µm was observed, due to precipitation of the protein (Figure 16a,c). This increase 
in particles was reflected in the significant turbidity increase for the formulation at 
pH 5.0. The total number of particles ≥ 1 µm at pH 7.0 and 6.0 was slightly higher 
compared to the solutions without the addition of NaCl. In the presence of 0.2% NaCl 
similar amounts of particles ≥ 1 µm were measured at pH 7.0, 6.0 and 5.0 (Figure 
16b,d). The addition of NaCl can be beneficial to inhibit the formation of particles ≥ 
1 µm, upon lowering the pH.  
 
 
 
(a) 
(b) 
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Figure 16: Cumulative particle size distribution of cytokine-HSA formulation with 0.0% NaCl (a) and 
0.2% NaCl (b) and particles per ml with 0.0% NaCl (c) and 0.2% NaCl (d) at pH 7.0, 6.0 and 5.0. 
 
A summary of the results obtained by DLS, disc centrifugation and AFM is displayed in 
Table 2. In contrast to disc centrifugation and light obscuration, DLS and AFM were 
capable to detect particles in the range of 5 to 10 nm, which represented most of the 
protein in the samples by number. Extreme long experimental times would be required to 
determine protein particles smaller than 20 nm by disc centrifugation. Despite of the 
diverse measuring principle, DLS and AFM provided comparable particle size results 
between 5 and 500 nm, whereby AFM offered no quantitative information. On the other 
hand samples containing a mixture of small and large particles e.g. the cytokine-HSA 
formulation at pH 5.0 were problematic for DLS. The intensity of the scattered light is 
proportional to the diameter to the power of 6 and therefore, the scattering signal of 
large particles could superimpose the signal of smaller particles. Particles of a medium 
size of 30 to 100 nm were detected by disc centrifugation, DLS and AFM for all pH-
values. DSL showed that the area of the medium fraction decreased from 5.5% to 1.0% 
when the pH was lowered from 7.0 to 5.0 in favor of the larger, turbidity inducing 
(a) (b) 
(c) (d) 
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particles. Particles with a size of about 1000 to 1500 nm were detected by DLS and disc 
centrifugation. In the DLS size distribution the intensity by volume was below 0.1% in 
the size range above 120 nm. However, the integrated area under the peak compared to 
the total AUC increased from 2.7% at pH 7.0 to 66.9% at pH 5.0. With disc 
centrifugation at pH 7.0 about 1% of the intensity by weight derived from particles larger 
than 100 nm compared to 48% at pH 4.8. Light obscuration showed that the number of 
particles ≥ 1 µm increased when the pH was lowered from 7.0 to 5.0. 
 
Table 2: Main particle sizes of the cytokine-HSA formulation without NaCl determined with DLS, AFM 
and disc centrifugation.  
pH DLS AFM Disc centrifugation 
 
7.4 
 
0-15 nm (max: 4.8 nm) / 91.8%(1) 
15-120 nm (max: 35 nm) / 5.5%(1) 
> 120 nm (no max) / 2.7%(1) 
 
 
6-10 nm 
29.4 nm ± 3.2 nm 
 
 
20-50 nm / 90%(2) 
50-100 nm / 96%(2) 
100-1000 nm / 99%(2) 
 
6.0 0-15 nm (max: 5.6 nm) / 84.5%(1) 
15-120 nm (max: 44 nm) / 5.9%(1) 
> 120 nm (no max) / 9.5%(1) 
 
6-10 nm 
31.2 nm ± 3.8 nm 
80 nm 
 
- 
5.5 0-15 nm (max: 7.5 nm) / 55.7%(1) 
15-120 nm (max: 58 nm) / 2.6%(1) 
> 120 nm (max: 450 nm) / 41.7%(1) 
 
6-10 nm 
32.4 nm ± 3.5 nm 
200-400 nm 
 
- 
5.0 0-15 nm (max: 7.5 nm) / 84.5%(1) 
15-120 nm (max: 60 nm) / 1.0%(1) 
> 120 nm (max: > 1000 nm) / 66.9%(1) 
Not feasible due  
to large particles 
20-50 nm / 10% 
50-100 nm / 52%(2) 
100-1000 nm /97% (2) 
(1) integrated area of the size distribution by volume      (2) cumulative intensity by weight 
 
With all methods it could be shown that particle formation was increased when the 
formulation pH was lowered from 7.0 to 5.0. It was further obvious that NaCl provided a 
stabilizing effect and could significantly reduce the formation of particles in the 
formulations.  
 
 
 
 
 
 
 
Characterization of Cytokine Solubility and Particle Formation in Presences of Human Serum Albumin 
   
 
49 
3.2 Studies on HSA-Placebo Formulations 
Within the progress of the study it was observed that stabilized-HSA behaved 
significantly different as compared to unstabilized-HSA. In addition, various batches of 
Sigma-HSA showed significant differences in their turbidity profile over the pH-range. To 
elaborate these findings two selected batches of unstabilized-HSA were compared by 
turbidity measurement, SDS-PAGE, FTIR, zetapotential measurement and DLS. For the 
cytokine-HSA formulation stabilized-HSA, which contained the excipients NaCl, Na-
octanoate and Na-N-acetyltryptophanate was used. To clarify the role of these stabilizers 
on the behavior of the formulation the impact of the stabilizers on HSA at different pH 
and ionic strength conditions was studied.  
 
3.2.1 Batch to Batch Variations of Unstabilized-HSA  
Turbidity scans of the analyzed Sigma-batches revealed significant differences in their 
profile and turbidity maximum (Figure 17). The turbidity maxima of the four different 
batches ranged between 9 and 42 FNU and were located between pH 4.5 and 4.8.  
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Figure 17: Turbidity of different batches of 12.5 mg/ml unstabilized-HSA between pH 7.0 and 3.0.  
 
For a more detailed characterization, the batches 033K7600 and 033K7601 were 
selected, as they were comparable in shelf-life, time-point of opening and storage 
conditions. Although the batches provided a comparable history, the turbidity increase for 
batch 033K7600 with a maximum above 40 FNU was more pronounced than for batch 
033K7601 (Figure 18a,b). The stabilizing effect of NaCl on the two batches was similar. 
The addition of 0.2% NaCl led to a constant low turbidity of about 3 to 4 FNU from 
pH 7.0 to 3.5 for both batches.  
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Figure 18: Turbidity of 12.5 mg/ml unstabilized-HSA batch 033K7600 (a) and 033K7601 (b) 
between pH 7.0 and 3.5 with 0.0% (          ), 0.1% (         ) and 0.2% (          ) NaCl.  
 
Analyzed by DLS the monomer peak of the more pH sensitive batch 033K7600 was 
shifted to a greater extent to larger sizes compared to batch 033K7601 when the pH was 
lowered from 7.0 to 6.0, respectively 4.8 (Figure 19a). In addition, batch 033K7600 
showed higher intensities of about 0.4% in the size range larger than 30 nm at pH 4.8 
which also could explain the higher turbidity of this batch (Figure 19b). 
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Figure 19: DLS size distribution by volume of 12.5 mg/ml unstabilized-HSA of the batches 
033K7600 and 033K7601 at pH 7.0, 6.0 and 4.8 from 0 to 15 nm (a) and 30 to 60 nm (b).  
 
 
The two compared batches of unstabilized-HSA showed similar zetapotential profiles over 
the pH-range, whereby a zetapotential of 0 mV was measured at pH 5.0 without and with 
(a) (b) 
(a) (b) 
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0.2% NaCl for both qualities (Figure 20). With 0.2% NaCl lower zetapotential values were 
measured due to the screening effect of NaCl on the charge of HSA.  
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Figure 20: Zetapotential of the two batches of 12.5 mg/ml unstabilized-HSA measured in water (a) 
and 0.2% NaCl (b) from pH 3.5 to 7.0. 
 
SDS-PAGE was used to characterize the composition of the two batches of unstabilized-
HSA, compared to stabilized-HSA with respect to monomer, aggregation and impurities 
at pH 7.0 and 4.8 (Figure 21).  
 
 
 
Figure 21: SDS-PAGE of Sigma-HSA batch 033K7600, batch 033K7601 and stabilized-HSA (6.25 µg 
protein per well) at pH 7.0 and pH 4.8, as well as the supernatant (SN) at pH 4.8 after 
centrifugation. 
 
SDS-PAGE showed no significant differences between the two batches of unstabilized-
HSA under the studied pH conditions. For both batches the HSA-monomer and dimer 
band and several bands deriving from potential impurities were found. Stabilized-HSA 
(a) (b) 
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was characterized by higher purity and far less bands. Only the monomer band and a 
small dimer band were present in the gel for stabilized-HSA. 
The secondary structure of HSA at pH 7.0 and 4.8 without and with 0.2% NaCl was 
characterized by ATR-FTIR using the second derivative of the amide I band (Figure 22). 
In the second derivative the band at 1654 cm-1 could be assigned to α-helical structures, 
which are the dominating elements within the HSA molecules. An α-helix content of 67% 
was described by He and Carter (1992), who published the crystal structure of Human 
Serum Albumin at 2.8 Å resolution [37]. A second band with a maximum at 1633 cm-1 at 
pH 7.0, which was shifted to 1628 cm-1 at pH 4.8 was present in the spectra. The band at 
1630 cm-1 was attributed to intramolecular ß-sheet within the HSA molecule as proposed 
by Wang et al. (2005) [8]. Since crystallographic studies of BSA/HSA revealed the 
absence of ß-sheet structures, Murayama and Tomida (2004) offered an extensive 
explanation for the band at 1630 cm-1 for BSA. They assigned it to short segment chains 
that are connecting α-helical segments [38]. When lowering the pH in the studied HSA-
formulations from 7.0 to 4.8 a slight shift of the band from 1633 cm-1 at pH 7.0 to 
1628 cm-1 at pH 4.8 could be observed. The presence of a band around 1620 cm-1, which 
is generally indicative for the formation of intermolecular ß-sheets [39], was not 
observed after the pH-shift to 4.8. Intermolecular ß-sheets are one sign for aggregation 
that occurs, e.g. during thermal denaturation [40].  
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Figure 22: ATR-FTIR second-derivative of 12.5 mg/ml Sigma-HSA batches 033K7600 and 033K7601 
without NaCl at pH 7.0 (a) and pH 4.8 (b).  
 
Although a significant turbidity increase at pH 4.8 was measured at least for batch 
033K7600, this was not reflected in the secondary structure measured by FTIR. The 
spectra of the two batches revealed a high degree of similarity at the studied pH 
conditions, which was also reflected in the spectral correlation coefficient (Table 3). 
(a) (b) 
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Table 3: Spectral correlation coefficient of amide I band (1700 to 1600 cm-1) setting 033K7600 as 
sample and 033K7601 as reference. 
 
 0.0% NaCl 0.2% NaCl 
pH 7.0 99.77% 99.73% 
pH 4.8 99.88% 99.86% 
 
 
Thus, the studies pointed at a difference between the HSA-batches regarding the 
precipitation behavior at pH 4.8, close to the pI of the protein, which was monitored by 
turbidity measurement and DLS. Despite this behavior, SDS-PAGE and FTIR revealed no 
significant differences in aggregation and secondary structure. A possible explanation for 
the variations between the batches could be the degree of purity. Batch 033K7600, which 
tended to higher turbidity values at pH 4.8 had a purity of 98% according to the 
certificate of analysis compared to a purity of 99% for batch 033K7601. Even though no 
definite explanation for the different behavior of batches was found, the occurrence of 
batch to batch variations needed to be taken into consideration when using the 
unstabilized-HSA as raw material.  
 
3.2.2 Impact of NaCl, Na-N-Acetyltryptophanate and Na-Octanoate on 
HSA 
When used as excipient in the cytokine-HSA formulation, HSA stabilized with Na-
octanoate, Na-N-acetyltryptophanate and NaCl was exclusively used due to regulatory 
requirements. The FDA requires the addition of 0.08 mM Na-octanoate and 0.08 mM Na-
N-acetyltryptophanate, respectively 0.16 mM Na-octanoate per gram HSA to stabilize the 
protein against heat-induced stress during the pasteurization process [2]. For a solution 
with 12.5 mg/ml HSA the addition of 2 mM stabilizers is hence required. Stabilized-HSA 
exhibited a constant turbidity below 5 FNU over the pH-range, compared to a significant 
increase above 50 FNU at pH 4.8 for some batches of unstabilized-HSA. To elucidate the 
differences between stabilized and unstabilized-HSA, the impact of the different 
stabilizers on the turbidity of unstabilized-HSA over the pH-range was to be analyzed. 
Batch 033K7600 was used, as this batch showed the most pronounced turbidity increase 
at pH 4.8 without further stabilization.  
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Figure 23: Turbidity in FNU of 12.5 mg/ml unstabilized-HSA (batch: 033K7600) with 0 to 30 mM 
NaCl (a), 0 to 5 mM Na-N-acetyltryptophanate (b) and 0 to 10 mM Na-octanoate (c) at pH 3.0 to 7.0.  
 
The initial turbidity of 12.5 mg/ml unstabilized-HSA (batch 033K7600) in water was 
7 FNU at pH 7.0. By adding increasing NaCl concentrations the tremendous turbidity 
increase at pH 4.8 could be significantly reduced (Figure 23a). At concentrations of 
30 mM NaCl (0.17%) the turbidity ranged between 7 and 10 FNU from pH 7.0 to 3.0. A 
further increase in NaCl concentration up to 175 mM (1.01%) did not lead to further 
reduction of the maximally measured turbidity (data not shown). Na-N-
acetyltryptophanate was added to HSA up to a concentration of 5 mM (0.25%). Higher 
concentrations were omitted, due to the poor solubility of the substance. The addition of 
Na-N-acetyltryptophanate led to a shift of the turbidity maximum to pH 4.5, while the 
maximum turbidity could only be decreased to values between 30 and 40 FNU (Figure 
23b). This emphasized, that Na-N-acetyltryptophanate played a minor role in the 
suppression of the precipitation at the pI of HSA. The addition of 1 to 4 mM Na-octanoate 
resulted in a less distinct decrease of turbidity compared to Na-N-acetyltryptophante. The 
(a) (b) 
(c) 
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turbidity maximum was shifted to pH 4.5, comparable to Na-N-acetyltryptophante 
(Figure 23c). A further increase in Na-octanoate to a concentration between 5 and 
10 mM initiated higher turbidities with maximum values above 110 FNU. Na-octanoate 
and Na-N-acetyltryptophante are known to bind to the same high affinity site II located 
in the subdomain IIIA of HSA [41,42]. The comparable effect on turbidity could therefore 
be assigned to the fact that both substances use the same stabilizing binding 
mechanism. In Figure 24 the impact of the Na-octanoate and Na-N-acetyltryptophante, 
respectively in combination with NaCl on unstabilized is shown.  
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Figure 24: Impact of Na-N-acetyltryptophanate (AT), Na-octanoate (Oct), NaCl and a combination of 
the stabilizers on the turbidity of 12.5 mg/ml unstabilized-HSA from pH 3.5 to 7.2. 
 
Apparently, NaCl played the major role in the prevention of the turbidity increase at 
pH 4.8, while the other stabilizers led to a shift of the turbidity maximum to lower pH 
values. The slightly better stabilization of Na-N-acetyltryptophanate compared to Na-
octanoate could be assigned to an increased ionic strength in the formulations with Na-N-
acetyltryptophanate. The ionic strength was increased for formulations with Na-N-
acetyltryptophanate, because the poorly soluble compound was dissolved above pH 11 
and the pH was adjusted to 7.0 by using HCl/NaOH. 
 
 
 
 
 
 
 
(a) (b) 
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4.  Conclusions 
For the studied formulation with 0.25 mg/ml cytokine, 12.5 mg/ml stabilized-HSA and 
12.5 mg/ml mannitol a significant increase in turbidity was observed, when the pH was 
lowered, reaching a maximum above 100 FNU at pH 5.0. SDS-PAGE revealed that at 
pH 5.0 most of the cytokine was found in the precipitate. The particle formation process 
was characterized by DLS, disc centrifugation, AFM and light obscuration. The 
formulations contained mostly monomers of 5 to 10 nm and a second particle population 
at 20 to 50 nm. In highly turbid formulations e.g. when the pH of the cytokine-HSA 
formulation was lowered to 5.0 a third population at 500 to 1000 nm emerged. Studies 
with HSA placebo formulation made clear that Na-octanoate and Na-N-
acetyltryptophanate used in the concentrations to stabilize HSA only played a minor role 
in preventing the turbidity increase at pH 5.0. However, the addition of NaCl provided a 
stabilizing effect on the formulation, as the turbidity increase at pH 5.0 could be 
significantly reduced. Fluorescence spectroscopy further revealed that the interactions 
between HSA and the cytokine were weaker in the presence of NaCl at pH 4.5. The HSA-
cytokine precipitation at pH 5.0 was partly irreversible, when the pH was adjusted back 
to 7.4. This irreversibility could become an issue e.g. during pH-adjustment with acid 
when the pH drops below 7.4 into the turbidity region at least temporarily in some areas 
of a batch. Besides of a reduction of the cytokine-HSA interactions by NaCl, it is essential 
to provide sufficient stabilization of HSA by NaCl to achieve an overall stable cytokine-
HSA formulation.  
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Chapter 3 
 
Physico-chemical Characterization of the Freezing 
Behavior of Mannitol-Human Serum Albumin 
Formulations 
 
 
Abstract 
The goal of the study was to analyze the impact of the Human Serum Albumin (HSA) 
quality (stabilized or non-stabilized HSA), the addition of NaCl and the HSA-stabilizers 
Na-octanoate and Na-N-acetyltryptophanate on the freezing behavior of mannitol-HSA 
formulations. The focus was set on crystallization, Tg’ (glass transition temperature of 
the maximally freeze-concentrated phase) and Tc (collapse temperature). Differential 
Scanning Calorimetry (DSC), cryomicroscopy and low temperature X-ray powder 
diffraction (LTXRD) were used to study the frozen state. In mannitol-HSA formulations, 
mannitol crystallization was inhibited and Tg’ lowered to a greater extend by stabilized-
HSA (containing Na-octanoate, Na-N-acetyltryptophanate and NaCl) than by unstabilized-
HSA. Detailed DSC and LTXRD studies showed that in the concentrations used for the 
stabilization of HSA, NaCl led to changes in the freezing-behavior an effect which was 
less pronounced for the other stabilizers. NaCl further lowered the Tc which was 
determined by cryomicroscopy. As the freezing behavior governs the further 
lyophilization process, the changes have to be taken into consideration for the 
development of a lyophilization cycle to avoid collapse and instabilities. 
 
 
Keywords: mannitol, HSA, NaCl, DSC, LTXRD, freezing 
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1. Introduction 
Lyophilization is still the most frequently used technique to produce dry and stable 
protein formulations. Within the lyophilization process, the applied freezing protocol and 
a potential annealing step have a major effect on the subsequent drying procedure 
regarding drying-rate and drying-time [1-3]. The freezing process also governs the 
structure and morphology of the lyophilized products [4]. Thereby, the physico-chemical 
properties of the selected excipients are influenced by the presence of salts, which are 
often added as buffer components or stabilizers [5,6]. Salts can further be introduced 
into the formulation within the bulk purification process or by pH-adjustment. A slight 
increase in salt concentration can lead to significant changes of the physico-chemical 
properties of the excipients during freezing and drying [7-10]. Therefore, it is important 
to investigate and understand how the freezing step, the low temperature behavior and 
the subsequent drying process of a formulation are influenced by the salt concentration. 
As model system a formulation with mannitol as crystallizing bulking agent and HSA as 
amorphous stabilizer is used. This combination is used to stabilize the cytokine in the 
HSA-containing, lyophilized formulation (compare Chapter 2). A combination of the HSA 
and mannitol as excipients for the stabilization of proteins is commonly described in 
literature and patents, especially for hydrophobic proteins like interleukins and 
interferons [11-13]. Mannitol is a standard excipient for lyophilization due to its excellent 
cake forming qualities. The nonreducing sugar alcohol can be dried under relatively harsh 
conditions, because of its high eutectic temperature of –1.5°C. The crystallization of 
mannitol during freezing and drying depends on various factors. Besides the employed 
mannitol concentration [4], the lyophilization process, especially the freezing rate 
[14,15] has a significant impact on mannitol crystallization and morphology. The 
presence of other excipients like lyoprotectants, buffer salts or proteins can promote and 
inhibit mannitol crystallization [16-19]. Thus, the crystallization behavior of mannitol in 
the frozen state needs to be studied to control the morphology of mannitol upon 
lyophilization. HSA is still a widely used excipient in both liquid and lyophilized protein 
formulations. Its application as stabilizing excipient in liquid and lyophilized formulations 
was already discussed in Chapter 1. According to the US Food and Drug Administration 
HSA used in protein formulations or as drug has to be pasteurized for 10 hours at 
temperatures up to 60°C [20]. Consequently, stabilization against the heat induced 
stress is required. The salt of the fatty acid Na-octanoate [21] and the amino acid 
derivative Na-N-acetyltryptophanate [22] protect HSA during the pasteurization process 
[23]. HSA is further stabilized by the addition of NaCl [20,21,24]. Thus the ionic strength 
in protein formulations stabilized with HSA increases inevitably and the physico-chemical 
properties can be affected due to the presence of the different stabilizers. The goal of this 
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study was to investigate the impact of NaCl and the other HSA-stabilizers on the physico-
chemical properties of formulations containing mannitol and HSA during freezing and at 
low temperatures.  
 
2. Material and Methods 
2.1 Materials 
Different types of HSA were used for the experiments, namely non-stabilized HSA from 
Sigma-Chemicals (Steinheim, Germany) and stabilized-HSA from Grifols (Langen, 
Germany). Stabilized-HSA from Grifols was used as 20% solution and contained 16 mmol 
Na-octanoate, 16 mmol Na-N-acetyltryptophanat and NaCl. For the experiments the 
solution was diluted to the desired concentration. Sigma-HSA was provided as a solid 
powder which contained 97% HSA according to the specifications and was used without 
further purification. Mannitol in the quality of Ph. Eur. was purchased from Caelo (Hilden, 
Germany) NaCl, Na-octanoate and N-acetyl-DL-tryptophante from Sigma (Steinheim, 
Germany). The pH of the solutions was adjusted to 7.0 ± 0.1 using HCl and NaOH. The 
declaration of the used concentrations was given in % [w/v] if not stated otherwise. 
 
2.2 Methods 
2.2.1 Differential Scanning Calorimetry (DSC) 
DSC was used to study Tg’ and crystallization behavior at low temperatures. 
Approximately 20 mg of the solution were analyzed in a crimped Al-crucible. The samples 
were frozen from 20°C to -70°C and reheated to 20°C with a standard scanning-rate of 
10°C/min in a Netzsch DSC 204 Phoenix® (Selb, Germany), calibrated with Indium. Tg’ 
(onset, point of inflection) and crystallization (onset, peak, enthalpy) of the excipients 
were determined during the heating scan.  
 
2.2.2 Cryomicroscopy 
The collapse temperature Tc, which is closely related to Tg’ was determined by 
cryomicroscopy. To determine the collapse temperature 5 µl of the solutions were frozen 
on a microscopic slide with an average cooling rate of 5°C/min to -50°C on the cooling 
stage (Linkman THM 600 S, Surrey, UK) under a microscope (Olympus BX 50, Hamburg, 
Germany). After applying vacuum to the system a moving drying front could be 
observed, due to the sublimation of ice. Subsequently, the temperature was step-wise 
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increased until collapse occurred. When the region of collapse was identified the sample 
was re-cooled and smaller steps of 0.5°C with a lower heating rate were applied to 
bracket the collapse temperature. Tc was defined as the temperature at which the 
coherent and compact structure of drying front became fragile with pores.  
 
2.2.3 Low Temperature X-ray Powder Diffraction (LTXRD) 
Crystallization was studied with LTXRD using Cu-Kα1-radiation (λ=154.06 pm) on the 
powder diffractometer Stadi P from STOE (Darmstadt, Germany) with parafocussed 
transmission geometry. Germanium was used as primary monochromator and the 
scattered X-rays were detected with a linear PSD area detector. The solutions were 
frozen in the rotating capillary (diameter 0.5 mm) in the cooling stage (Oxford 
Cryosystem) of the X-ray diffractometer. The diffraction patterns were analyzed with the 
program WinXPOW from STOE (Darmstadt, Germany). For the LTXRD experiment a 
temperature profile similar to the conditions during lyophilization was chosen. The 
samples were frozen to -40°C with a cooling rate of 0.5°C/min. At -40°C the first 
measurement under isothermal conditions was performed. The temperature was 
subsequently increased to -20°C at 1°C/min and several measurements were performed 
at designated time intervals. The temperature of -20°C was chosen as it represents the 
annealing temperature applied during lyophilization (compare Chapter 4). For mannitol it 
is possible to crystallize in the α-, β- and δ-modification. Furthermore crystallization of 
mannitol as hydrate during freezing and after lyophilization was reported [29]. Table 1 
summarizes the characteristic mannitol peaks. 
 
Table 1: Assignment of X-ray diffraction peaks to the different mannitol-modifications. 
 
mannitol 
modification 
main peaks 
[°2-θ] 
intensity  
[%] 
peaks used 
for identification [°2-θ] 
references 
 
α-mannitol 
 
13.6 
17.2 
18.7 
 
20 
45 
100 
 
 
13.6 
17.2 
 
JCPDS-database 
Walter-Levy (1968) 
β-mannitol 14.6 
16.8 
18.8 
23.4 
65 
85 
100 
90 
 
 
14.6 
16.8 
23.4 
JCPDS-database 
Walter-Levy (1931) 
δ-mannitol 9.7 
20.4 
100 
50 
 
9.7° 2-θ 
no peak at 17.9°2-θ 
 
JCPDS-database 
Walter-Levy (1968) 
mannitol 
hydrate 
9.6 
17.9 
80 
100 
9.6° 2-θ 
17.9° 2-θ 
Yu et al. (1999) [29] 
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3. Results and Discussion 
3.1 DSC Studies of Stabilized-HSA and Mannitol  
DSC is an important tool to study the frozen state of formulations. Thereby, the glass 
transition of the maximally freeze-concentrated solution (Tg`), crystallization and 
melting processes can be measured. This information can be important for the frozen 
storage of protein formulations and at most for the development of appropriate 
lyophilization cycles. 
For the first set of experiments the total solid content of the solutions was kept constant 
at 2.5% [w/v] and the ratio of mannitol to stabilized-HSA was varied. DSC analysis of the 
freezing process for a 2.5% mannitol solution indicated partial crystallization of mannitol 
during cooling. At low temperatures the nucleation of mannitol crystals prevailed [26]. 
Because of the remaining amorphous mannitol fraction, two glass transition points  
Tg’1= -29.9°C and Tg’2= -26.1°C (point of inflection) followed by a crystallization with an 
onset of -25°C where the nuclei grow to mature crystals [26] were detected during the 
rewarming of the solution (Figure 1). 
 
0.15
0.2
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0.35
0.4
0.45
-60 -50 -40 -30 -20 -10
temperature [°C]
h
e
a
t 
fl
o
w
 [
m
W
/
m
g
]
 1.5% M, 1.0% stab-HSA
 2.0% M, 0.5% stab-HSA
 2.5% M
 
Figure 1: DSC heating scans of solutions with variable ratios of mannitol (M) to stabilized-HSA 
(HSA) at a total solid content of 2.5%. 
 
This was in agreement with literature, which described the glass transition points at  
–32°C (Tg’1) and –25°C (Tg’2) for 10% mannitol [27,28]. Furthermore, it was described 
that at a higher cooling rate of 20°C/min mannitol crystallization in solutions with 5% to 
15% [w/v] cannot be observed during freezing, whereas reduced cooling rates of 5 to 
10°C/min led to partial crystallization. Even at slow cooling rates e.g. 1°C/min, that are 
typically used during lyophilization, mannitol only crystallizes partially during cooling, 
leading to additional crystallization during warming [14,27]. The addition of stabilized-
exo 
Physico-chemical Characterization of the Freezing Behavior of Mannitol-Human Serum Albumin Formulations 
   
 
65 
HSA as non-crystallizing solute had the effect that mannitol crystallization was delayed 
and inhibited (Figure 1). Onset and peak maximum of the crystallization were shifted to 
higher temperatures. A similar effect has been described for mannitol-BSA formulations 
in phosphate buffer [29]. The Tg’ of the formulations was shifted to lower temperatures 
with increasing amounts of stabilized-HSA added (Table 2). The formulations with 2.5% 
mannitol respectively 2.0% mannitol and 0.5% stabilized-HSA showed nearly identical 
transition temperatures and crystallization behavior. At equal amounts of mannitol and 
stabilized-HSA in the solution the crystallization of mannitol was completely suppressed. 
 
Table 2: Tg’, onset and peak maximum of mannitol crystallization in presence of stabilized-HSA in 
formulations with 2.5% total solid content. 
 
 
 
 
 
 
 
 
 
 
 
 
Stabilized-HSA itself contains NaCl, Na-octanoate and Na-N-acetyltryptophanate. It is 
well known that NaCl suppresses the crystallization of mannitol during freezing [5] and 
potentially lowers the Tg’ of amorphous excipients [9].  
 
3.2 Impact of HSA-Quality on the Freezing-Behavior of Mannitol  
In order to study the impact of the HSA-quality on the low temperature behavior of 
mannitol in the formulation, increasing amounts of unstabilized-HSA, respectively 
stabilized-HSA were added to a constant mannitol concentration of 6.25%. With the 
constant amount of mannitol the crystallization enthalpies (area of the crystallization 
peak) of the different samples could be compared. The higher mannitol concentration 
was used because it was required for the LTXRD measurements due to the detection limit 
of the method.  
 
 
 
mannitol 
[%] 
stabilized-HSA 
[%] 
Tg’1  
Tg’2 
[°C] 
crystallization 
onset  
[°C] 
peak 
maximum 
[°C] 
2.5 0 -26.1 
-29.9 
 
-25.3 -22.1 
2.0 0.5 -26.4 
-30.5 
 
-25.3 -21.1 
1.5 1.0 -34.9 
 
-17.3 -11.6 
1.25 1.25 -35.2   
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Figure 2: DSC heating scan of 6.25% mannitol with 0.0% to 6.25% stabilized-HSA (a) and 0.0% to 
6.25% unstabilized-HSA (b) at 10°C/min. 
 
In the DSC, mannitol crystallization was delayed and finally completely suppressed with 
increasing amounts of stabilized-HSA at a scanning rate of 10°C/min (Figure 2a and 
Table 3). In addition, stabilized-HSA influenced the Tg’ of the formulations during 
freezing. Two Tg’ values were detected up to a concentration of 3.125% stabilized-HSA, 
whereas only one Tg’ was left at higher concentrations. The position of the Tg’ was 
shifted to lower temperatures. Both results were in agreement with the studies 
conducted with 2.5% total solid content (compare 3.1). The same set of experiments was 
performed with unstabilized-HSA. By the addition of 3.125% to 6.25% unstabilized-HSA 
the crystallization of mannitol was delayed to higher temperatures and the crystallization 
enthalpy was decreasing (Figure 2b). This showed that HSA itself inhibited and delayed 
the crystallization of mannitol. However, Tg’ was unaffected when adding unstabilized-
HSA to the formulations. In the range of 1.25% to 6.25% unstabilized-HSA Tg’1 was 
found at -31.5°C and Tg’2 around -26°C. Both HSA-qualities had a significant impact on 
the crystallization behavior of mannitol during the heating scan of the DSC. At a 
concentration of 1.25% HSA, the onset of mannitol crystallization (-24.5°C) was 
unaffected by the addition of both, unstabilized and stabilized HSA (Figure 2). The peak 
maximum of the crystallization was located at -23.4°C for pure mannitol and was shifted 
to -22.5°C with the addition of 1.25% unstabilized-HSA, respectively to -20.9°C for 
stabilized-HSA. However, a higher crystallization enthalpy in the heating-scan was 
measured for 1.25% unstabilized-HSA containing mannitol solutions (-26.8 J/g) 
compared to 6.25% pure mannitol (17.1 J/g) or 6.25% mannitol with 1.25% stabilized-
HSA (-17.0 J/g). The inhibitory effect of unstabilized-HSA on mannitol crystallization was 
less pronounced than that of stabilized-HSA, resulting in the increased crystallization 
6.25% 6.25% 
5.0% 
3.125% 
3.125% 
1.25% 
1.25% 
0.0% 
0.0% 
exo exo 
(a) (b) 
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enthalpy during the rewarming for unstabilized-HSA. The lower crystallization enthalpy 
for mannitol as single component could be explained by the fact that mannitol had the 
chance to crystallize during the cooling scan, seen by an exothermal peak at -40°C (data 
not shown). A complete inhibition of mannitol crystallization was achieved by adding 
6.25% stabilized-HSA, but not with 6.25% unstabilized-HSA. The DSC-data suggested 
that the studied HSA-qualities both had the ability to inhibit mannitol crystallization, with 
a stronger inhibitory effect seen for stabilized-HSA. Stabilized-HSA contained further 
additives, presumably NaCl which is known to inhibit mannitol crystallization. 
 
Table 3: Tg’1, Tg’2 and crystallization (onset, peak maximum and enthalpy) of 6.25% mannitol with 
unstabilized-HSA and stabilized-HSA measured with DSC at 1°C/min, 5°C/min and 10°C/min. 
 
UNSTABILIZED-HSA  STABILIZED-HSA 
10°C/min 10°C/min 5°C/min 1°C/min 
HSA 
[%] 
Tg’1 
Tg’2 
crystalli- 
zation 
Tg’1 
Tg’2 
crystalli- 
zation 
Tg’1 
Tg’2 
crystalli- 
zation 
Tg’1 
Tg’2 
crystalli- 
zation 
 
0 
(5:0)* 
 
-31.2°C 
-27.1°C 
 
-25.4°C(1) 
-23.1°C(2) 
-17.1 J/g(3) 
 
-31.2°C 
-27.1°C 
 
-25.4°C(1) 
-23.1°C(2) 
-17.0 J/g(3) 
 
-34.0°C 
-29.4°C 
 
-27.2°C(1) 
-25.3°C(2) 
-10.4 J/g(3) 
 
-34.2°C 
-31.6°C 
 
-28.9°C(1) 
-27.9°C(2) 
-5.0 J/g(3) 
 
1.25 
(5:1)* 
-32.0°C 
-27.2°C 
-24.6°C(1) 
-22.6°C(2) 
-26.8 J/g(3) 
-32.9°C 
-28.1°C 
-25.1°C(1) 
-21.0°C(2) 
-17.0 J/g(3) 
-34.1°C 
-29.4°C 
-27.9°C(1) 
-26.5°C(2) 
-12.9 J/g(3) 
-35.1°C 
-31.8°C 
-30.0°C(1) 
-28.7°C(2) 
-5.3 J/g(3) 
 
3.125 
(5:3)* 
-31.4°C 
-25.0°C 
-20.2°C(1) 
-14.6°C(2) 
-12.5 J/g(3) 
-39.5°C 
-32.7°C 
-22.5°C(1) 
-18.4°C(2) 
-11.4 J/g(3) 
-34.6°C -26.9°C(1) 
-24.0°C(2) 
-8.8 J/g(3) 
-36.1°C -31.4°C(1) 
-29.6°C(2) 
-6.3 J/g(3) 
 
6.25 
(5:5)* 
-31.4°C 
-25.0°C 
-20.2°C(1) 
-14.6°C(2) 
-12.5 J/g(3) 
-37.7°C no 
cryst. 
-39.0°C -14.6°C(1) 
-11.3°C(2) 
-1.1 J/g(3) 
-40.4°C -29.0°C(1) 
-25.0°C(2) 
-6.6 J/g(3) 
* ratio of mannitol : HSA      (1) onset     (2) peak maximum     (3) enthalpy of crystallization 
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3.3 Influence of the Applied Scanning Rate on Thermal Behavior of 
Mannitol-HSA Formulations 
In order to reflect the conditions predominating during lyophilization and to investigate 
how the scanning rate influences Tg’ and the crystallization behavior of mannitol, the 
DSC was operated at 1°C/min, 5°C/min and 10°C/min for the heating and cooling-scans. 
At the scanning rates 1°C/min and 5°C/min 6.25% mannitol in a solution with 
6.25% stabilized-HSA had the chance to crystallize during the cooling scan. As a 
consequence less material crystallized during heating resulting in a lowered 
crystallization enthalpy of -5.0 J/g at 1°C/min and -10.4 J/g at 5°C/min compared to  
-17.1 J/g at 10°C/min (Figure 4). It was already shown that mannitol crystallization was 
completely suppressed by the addition of more than 3.125% stabilized-HSA to 6.25% 
mannitol at a scanning rate of 10°C/min. At a scanning rate of 1°C/min and 5°C/min 
mannitol crystallization was detected up to a concentration 6.25% stabilized-HSA.  
Comparing the results obtained with the different scanning rates it became obvious that 
the thermal events occurred at lower temperatures, when 1°C/min, respectively 5°C/min 
were used (Table 3). Tg’ is a kinetic parameter and therefore depends on the applied 
scanning rate [26] with a shift to lower temperatures at reduced scanning rates [30]. 
This has to be considered for the development of a lyophilization cycle due to the lower 
cooling rates that are frequently used. 
 
3.4 Influence of Na-Octanoate, Na-N-Acetyltryptophanate and NaCl on 
the Freezing Behavior of Mannitol 
A more pronounced inhibitory effect on crystallization and the lowering of Tg’ was 
noticeable for stabilized-HSA compared to unstabilized-HAS (compare 3.2). The solution 
of 6.25% stabilized-HSA used for the DSC experiments contained 5 mM (0.08%)  
Na-octanoate and 5 mM (0.13%) Na-N-acetyltryptophanate and at least 31.5 mM 
(0.19%) NaCl. In the concentrations actually used for stabilizing HSA,  
Na-N-actyltryptophanate and Na-octanoate showed no significant inhibition of mannitol 
crystallization (Figure 3). Whereas 5 mM Na-octanoate showed no impact on Tg’, Tg’1 
was lowered by 1.0°C and Tg’2 by 1.5°C in the presence of 5 mM  
Na-N-actyltryptophanate. In contrast NaCl had a major influence on the low temperature 
behavior of mannitol. At a concentration of 0.19% NaCl the suppression of mannitol 
crystallization and the decrease of Tg’1 by 3.9°C and Tg’2 by 2.8°C. The HSA-stabilizers, 
principally NaCl were responsible for the differences in the low-temperature behavior in 
formulations with stabilized and unstabilized-HSA 
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Figure 3: DSC heating scan of 6.25% mannitol with 5 mM Na-N-acetyltryptophanate (Trp), 5 mM 
Na-octanoate (Oct) and 0.19% NaCl at 10°C/min. 
 
The impact of 0.05% to 1.0% NaCl on the low temperature behavior of 6.25% mannitol 
solution is shown in Figure 4a. The addition of NaCl inhibited mannitol crystallization and 
delayed it to higher temperatures. At the same time Tg’ was significantly lowered in a 
linear way (Figure 4b).  
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Figure 4: DSC heating scan at 10°C/min of 6.25% mannitol with 0.0% to 1.0% NaCl (a) and Tg’1 
and Tg’2 plotted for 0.0% to 1.0% NaCl. 
 
The shift of Tg’ in formulations with NaCl could be due to the very low Tg’ of NaCl itself, 
which lies below -60°C [31]. NaCl can act as plasticizer by increasing the amount of 
unfrozen water in the amorphous phase, leading to a lowering of the Tg’ of amorphous 
excipients. As lyophilization has to be conducted at product temperatures below Tg’ 
exo 
exo 
1.0% 
0.75% 
0.5% 
0.2% 
0.125% 
0.1% 
0.075% 
0.05% 
0.0% 
(a) (b) 
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[32,36], the samples with the lowered Tg’ have to be dried at reduced product 
temperatures resulting in longer, less efficient drying processes.  
 
3.5 Influence of Na-Octanoate, Na-N-Acetyltryptophanate and NaCl on 
the Freezing Behavior of Unstabilized-HSA and Mannitol  
The impact of the stabilizers was further investigated using the DSC heating scan at 
10°C/min for the more complex formulations composed of 6.25% mannitol and 6.25% 
unstabilzed-HSA. Mannitol crystallization was less affected by 5 mM Na-octanoate or 
5 mM Na-N-acetyltryptophanate than by the addition of 0.19% NaCl (Figure 5). By 
adding a combination of the stabilizers (5 mM Na-N-acetyltryptophanate, 5 mM  
Na-octanoate, 0.19% NaCl) to a solution with 6.25% mannitol and 6.25% unstabilized-
HSA, the low temperature behavior of the formulation resembled that of a formulation 
with stabilized-HSA.  
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Figure 5: DSC heating scan at 10°C/min of 6.25% unstabilized-HSA and 6.25% mannitol, without 
additives, 5 mM Na-octanoate (Oct), 5 mM Na-N-acetyltryptophanate (Trp), 0.19% NaCl and a 
combination of all stabilizers compared to 6.25% stabilized-HSA and 6.25% mannitol. 
 
The crystallization of mannitol was inhibited and Tg’ was shifted to lower temperatures. 
These data demonstrated that the HSA-stabilizers, especially NaCl, were responsible for 
the changed freezing behavior of mannitol-HSA. 
 
exo 
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3.6 Influence of NaCl on Freezing Behavior of Mannitol with Stabilized-
HSA 
As it is crucial to consider the lowered Tg’ for the development of a lyophilization cycle to 
avoid collapse, the impact of NaCl was further investigated. The focus was set on NaCl, 
as it had the most pronounced effect of the HSA-stabilizers during freezing. Therefore, 
the addition of NaCl to mixtures of mannitol and stabilized-HSA at a ratio of 1:1 was 
analyzed with DSC and LTXRD. This ratio was chosen for the more detailed studies as it 
is often found in protein formulation and commercial lyophilized products [12]. Due to 
the detection limit of the LTXRD, the solutions with a higher total solid content of 6.25% 
HSA, respectively mannitol were used. DSC revealed a significant shift of Tg’ to lower 
temperatures upon the addition of NaCl (Figure 6). 
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Figure 6: DSC heating scan of 6.25% mannitol and 6.25% stabilized-HSA, 0.05 to 2.5% NaCl (a) and 
Tg’ and Tc of 6.25% mannitol and 6.25% stabilized-HSA compared to 1.25% mannitol and 1.25% 
stabilized-HSA plotted against the ratio of NaCl to mannitol (b). 
 
The addition of 0.5% NaCl lowered the Tg’ of 1.25% mannitol and 1.25% stabilized-HSA 
in a linear way from -37°C to -47°C. The results could be confirmed by solutions 
containing the 5-fold total solid. With the addition of 0.5% to 2.5% NaCl to a solution of 
6.25% stabilized-HSA and 6.25% mannitol a comparable depression of Tg’ was detected 
(Figure 6a). At a Tg’ near -50°C measured for the high NaCl concentrations, the 
development of a feasible and economical lyophilization process is hardly possible. The 
results showed that it is not the total amount of NaCl present in the sample but the ratio 
of NaCl to other excipients in a formulation that determined the degree of the lowering of 
the Tg’ (Figure 6b). This can be ascribed to the fact that the Tg’ is concentration 
independent for diluted systems [34]. 
exo 
0.0% 
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3.7 Determination of Tc with Cryomicroscopy  
Cryomicroscopy was used to determine the collapse temperature Tc of the solutions. Tc 
is the temperature at which the interstitial water in the frozen matrix becomes 
significantly mobile [35]. To avoid collapse during lyophilization the product temperature 
has to be kept below Tc. The collapse temperature approximately coincides with the Tg’ 
measured by DSC [32,33] and usually lies about 2°C higher than Tg’ [36]. In Figure 7 
the behavior of 1.25% mannitol and 1.25% stabilized-HSA with 0.2% NaCl as an 
example is visualized.  
 
 
Figure 7: Cryomicroscopy of 1.25% mannitol and 1.25% stabilized-HSA, 0.2% NaCl from -50°C to  
-45°C. The arrow marks the collapsed area. 
 
The dark section represents the moving drying front. The bright section derives from the 
frozen solution, with colors created by the utilization of polarization filters to achieve a 
better contrast between the drying front and the frozen solution. At temperatures 
between -50°C and -45°C the drying front was compact and did not shows structural 
changes. At -43°C the drying front lost its compact structure. Holes and cracks appeared, 
through which the colored background became visible. The collapse temperature was 
approximated to range between -45°C and -43°C. In the progress of the experiment 
smaller temperature steps were used and Tc was finally determined to be -44.5°C. 
Tc and Tg’ both were lowered by the addition of NaCl (Figure 6b). The results from the 
cryomicroscopic experiment suggested substantial differences between Tc and Tg’ with 
higher values for 0.0% and 0.1% NaCl and lower values for 0.2% to 0.3% NaCl. This 
could be explained by the different experimental set ups and time-temperature profiles 
used in DSC and cryomicroscopy. While DSC is working with a constant dynamic heating 
scan of 10°C/min, cryomicroscopy is working with isothermal and dynamic segments and 
lower scanning rates. The lower scanning rates could explain the steeper decline of Tc 
and the shift to lower temperatures compared to the DSC experiments. In the DSC 
thermal events were shifted to lower temperatures when the scanning rate was reduced. 
Knopp et al. (1998) determined lower values for the Tc of sucrose solutions using 
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cryomicroscopy compared to Tg’ with a Tc of -37.7°C measured for 5% and 10% 
sucrose, while the Tg’ lies at -32.0°C [37]. However, sucrose solutions at higher 
concentrations (above 40%) can exhibit two transitions. The transition at -40°C is usually 
assigned to the real glass transition, while the transition at -32°C is due to the onset of 
melting of ice crystals [38]. The Tc below -45°C for mannitol stabilized-HSA formulations 
with 0.2% and 0.3% NaCl could become critical during lyophilization.  
 
3.8 Analytics of the Mannitol Freezing Behavior with LTXRD 
DSC offers information on crystalline and amorphous phases in the frozen state. 
However, it is not possible to identify and characterize the crystalline phases according to 
their composition and modifications [39]. With LTXRD it is possible to identify and 
characterize multiple crystalline phases [40,41]. Because of the detection limit of LTXRD 
the higher mannitol concentration of 6.25% had to be used. 
 
 
Figure 8: LTXRD of 6.25% mannitol and 6.25% stabilized-HSA with 0.0% NaCl (a), 1.25% NaCl (b) 
and 2.5% NaCl (c) after cooling to -40°C and during the 3 scans of the annealing phase at -20°C. 
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After freezing a solution with 6.25% mannitol and 6.25% stabilized-HSA to -40°C in the 
LTXRD no peaks of crystalline material could be detected besides the peaks of ice. After 
the temperature was increased to -20°C mannitol crystallized in the δ-modification, as 
could be seen by the peak at 9.7° 2-θ and 20.4° 2-θ and the absence of a signal at 17.9° 
2-θ (Figure 8a). The addition of 1.25% NaCl delayed the crystallization of mannitol. Here 
at the end of the first scan at -20°C after approximately 20 minutes a peak at 20.4° 2-θ 
appeared. In the further course of the annealing phase the peaks gained in intensity 
(Figure 8b). Increasing the NaCl concentration to 2.5% led to a complete inhibition of 
crystallization and no crystalline material was detected with the LTXRD (Figure 8c). 
Unlike in LTXRD, no crystallization was measured in the heating scan of the DSC for 
solutions with 6.25% mannitol and 6.25% stabilized-HSA. Generally, the kinetic 
mechanism of crystallization is influenced by temperature [42]. During the dynamic 
heating scan of the DSC at 10°C/min mannitol did not have the chance to crystallize, 
while the isothermal steps in the LTXRD provided enough time for crystallization. 
 
4. Conclusions 
DSC showed that unstabilized-HSA, stabilized-HSA and NaCl can delay and inhibit the 
crystallization of mannitol, which was confirmed by LTXRD. Thereby, stabilized-HSA 
showed a different behavior than unstabilized-HSA because of the presence of NaCl, Na-
octanoate and Na-N-acetyltryptophanate. In the particular concentration used for the 
stabilization of HSA, NaCl had the most distinct impact on the low temperature behavior 
of mannitol. Already the addition of small quantities of NaCl shifted Tg’ and Tc of 
mannitol formulations to lower temperatures, which could become critical for a freeze-
drying process with respect to collapse. The study showed that the freezing step had a 
significant effect on the physico-chemical properties of mannitol–HSA formulations, which 
can affect the subsequent drying process and the physico-chemical properties of the 
lyophilized products. The study demonstrated that already the freezing step has a 
significant effect on the behavior of the formulations with mannitol and HSA. It can be 
assumed that this affect the subsequent drying process and the physico-chemical 
properties of the lyophilized products. The lyophilization behavior of the formulations with 
stabilized-HSA and mannitol are described in Chapter 4 of the thesis.  
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Chapter 4 
 
Physico-chemical Lyophilization Behavior of Mannitol-
Human Serum Albumin Formulations 
 
 
Abstract 
The lyophilization behavior is influenced by the presence of salts. The impact of NaCl on 
drying-time and the morphology after lyophilization was studied for formulations with 
mannitol and HSA, using different freezing-protocols. The drying-process was monitored 
by thermocouples and microbalance technique. Karl-Fischer titration, DSC, XRD and SEM 
were used to study the products after lyophilization and 6 months storage at 2-8°C, 
25°C / 60% RH and 40°C / 75% RH.  
NaCl decreased the drying-time of mannitol-HSA formulations, indicating morphological 
changes, which was confirmed by XRD and SEM. Without NaCl exclusively δ-mannitol was 
formed, which remained physico-chemically stable upon storage for 6 months. With 
increasing NaCl concentrations more β-mannitol and finally amorphous products were 
formed, whereby the freezing-protocol determined how much NaCl was needed to 
achieve an amorphous product. Upon storage, the amorphous state could not be 
preserved and mannitol and NaCl crystallized, which could damage proteins in the 
formulations. However, regarding the stability of HSA in the lyophilized products, 
monitored by turbidimetry and HP-SEC, the addition of NaCl could prevent increases in 
turbidity and the loss of HSA-monomers upon storage. Here the benefit of NaCl on HSA 
stability outbalanced the potential drawbacks that morphological changes, like 
crystallization impose on protein stability in the lyophilized products.  
 
 
Keywords: lyophilization, mannitol, HSA, morphology, storage stability 
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1. Introduction 
For the development of lyophilized formulations it is essential to add excipients that 
stabilize proteins against stress and damage during freezing, drying and upon storage. 
One common way to achieve elegant and stable lyophilized products is combining a 
crystalline bulking agent, e.g. mannitol or glycine with a second excipient that remains 
amorphous and acts as lyoprotector e.g. sucrose, trehalose or human serum albumin 
(HSA) [1-4]. Morphology and physico-chemical properties of the selected excipients used 
to stabilize the active protein can be influenced by the presence of salts [5,6]. Therefore, 
it is important to investigate and understand how the lyophilization process and the 
lyophilized products are influenced by the salt concentration. As model system a 
formulation with mannitol as cake forming agent and HSA as amorphous stabilizer is 
used, based on the formulation of the hydrophobic cytokine. For mannitol it is described 
in literature, that both the applied lyophilization process [7,8] and the presence of other 
excipients like lyoprotectants, buffer salts or proteins have an impact on the morphology 
of mannitol and can both promote and inhibit mannitol crystallization [1,9,10]. HSA is 
used as cyro- and lyoprotector for lyophilization, especially in older formulations. HSA is 
stabilized against the heat induced stress during the required pasteurization process by 
Na-octanoate [11] and Na-N-acetyltryptophanate [12]. Further, HSA is stabilized by NaCl 
[12-15] with the consequence that the ionic strength in protein formulations stabilized 
with HSA is inevitably increased and the physico-chemical properties can be affected due 
to the presence of NaCl brought into the formulation.  
Detailed studies of the low temperature behavior of formulations with mannitol and HSA 
are described in Chapter 3. It could be shown that mannitol crystallization was inhibited 
by the addition of HSA and NaCl. Comparing the different HSA-stabilizers, NaCl had the 
most pronounced effect on the low temperature behavior of the formulations. NaCl 
further led to a significant depression of the collapse temperature (Tc) and the glass 
transition of the maximally freeze-concentrated solutions (Tg’) of the formulations. The 
outcome of the freezing-studies has to be taken into consideration for the development 
of the lyophilization process, as freezing governs the physico-chemical properties of the 
excipients during and after lyophilization. To avoid collapse for example the product 
temperature during the process has to be kept below the collapse temperature [16,17]. 
The focus of Chapter 4 was set on the impact of NaCl on the lyophilization process of 
mannitol-HSA-based formulations and the physico-chemical properties of the lyophilized 
products. Stabilized-HSA, which enhances the complexity of the formulations, was 
selected as excipient as it was the exclusively used HSA-quality in the lyophilized 
cytokine formulation. 
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2. Materials and Methods 
2.1 Materials 
Stabilized-HSA from Grifols (Langen, Germany) was used as 20% solution and further 
contained 16 mmol Na-octanoate, 16 mmol Na-N-acetyltryptophanate and 3.0% NaCl as 
stabilizers. For the experiments the solution was diluted to the desired concentration. 
Mannitol was purchased from Caelo (Hilden, Germany) and NaCl from Sigma (Steinheim, 
Germany). The basic formulation contained 1.25% mannitol and 1.25% stabilized-HSA. 
Based on this formulation the fraction of the excipients, the total solid concentration and 
the NaCl concentration was varied. The pH of the solution was adjusted to 7.0 ± 0.1 
using NaOH or HCl. 
 
2.2 Methods 
2.2.1 Lyophilization Process  
1.2 ml of the solution were dried in 2 R vials from Schott (Mainz, Germany) in the Epsilon 
2-12 D freeze-drier from Christ (Osterrode, Germany). Four different freezing-protocols I 
to IV were used for the production of the samples (Table 1). Primary drying was 
conducted at a shelf-temperature of -5°C and a pressure of 0.1 mbar. For secondary 
drying the shelf-temperature was increased to 30°C, while the pressure was kept 
constant at 0.1 mbar. 
 
Table 1: Lyophilization programs I-IV used for the studies. 
program freezing-protocol freezing-rate 
I within 2 h to -50°C 0.46°C/min 
II within 2 h to -50°C 
Annealing at -20°C for 2 h 
0.46°C/min 
III within 1 h to -50°C 0.92°C/min 
IV freezing on pre-cooled shelves (-50°C) 2.3°C/min 
 
The lyophilization process was monitored by measuring the product temperature of 
selected vials with thermocouples [18]. The end point of primary-drying was reached 
when the temperature in the vial was exceeding the shelf-temperature. As second tool to 
monitor the drying process, a microbalance type CWS-40 (Christ, Osterrode, Germany) 
was used. With the microbalance it is possible to determine the actual drying-rate during 
the process. The end of the primary drying is reached when the drying rate falls below 
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3 mg/h [19]. The thermocouples were placed into vials on a completely filled shelf as 
well as in vials, which were located on an extra shelf in a distance of 5 cm to each other. 
The vials were placed separately to assure the comparability of the results with the data 
form the microbalance. The microbalance was also placed separately on an extra shelf in 
the freeze-drier. 
 
2.2.2 X-ray Powder Diffraction (XRD) 
The morphology of the lyophilized products was analyzed with X-ray powder diffraction 
(XRD) from 5-40° 2-Θ, with steps of 0.05° 2-Θ and a duration of 2 seconds per step on 
the X-ray diffractometer XRD 3000 TT (Seifert, Ahrenburg, Germany), equipped with a 
copper anode (40 kV, 30 mA, wavelength 154.17 pm). 
 
2.2.3 Differential Scanning Calorimetry (DSC) 
The samples were analyzed with the Netzsch DSC 204 Phoenix® (Selb, Germany), 
calibrated with indium from 0°C to 150°C with a rate of 10°C/min. Approximately 10 mg 
of the lyophilized samples were analyzed in sealed Al-crucibles. The thermal events were 
analyzed in the heating scan of the DSC. 
 
2.2.4 Karl-Fischer Titration 
The residual moisture of the samples was analyzed by coulometric Karl-Fischer titration 
using the Aqua 40.00 titrator with a headspace module (Analytik Jena AG, Halle, 
Germany). For the measurement at least 10 mg of the lyophilized sample was heated to 
80°C. The evaporated water was transferred into the titration solution and the amount of 
H2O was determined.  
 
2.2.5 Turbiditimetry 
The turbidity of the samples in formazine nephelometric units (FNU) was measured by 
90° light scattering at λ=860 nm with the NEPHLA turbidimeter (Dr. Lange, Düsseldorf, 
Germany) calibrated with formazine as standard. To evaluate the degree of turbidity the 
reference solutions I-IV of the European Pharmacopoeia method 2.2.1 (clarity and 
degree of opalescence of liquids) were used [20]. A stock solution was prepared by 
mixing hydrazine-sulfate (10 mg/ml) and hexamethylenetetramine (100 mg/ml) at a 
ratio of 1:1. After 24 hours the stock solution was further diluted with water to 
concentrations of 0.075 mg/ml hydrazine sulfate and 0.75 mg/ml 
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hexamethylenetetramine. The reference solutions were prepared by diluting the stock 
solution according to the Ph. Eur. and the corresponding turbidity in FNU was measured 
(Table 2). 
 
Table 2: Composition of the reference solutions according to Ph. Eur., corresponding turbidity and 
degree of opalescence. 
reference 
solution 
diluted stock 
solution [ml] 
water  
[ml] 
turbidity 
[FNU] 
degree of  
opalescence 
I 5 95 3.2 clear (≤ Ref I) 
II 10 90 6.1 slightly opalescent (≤ Ref II) 
III 30 70 17.8 opalescent (≤ Ref III) 
IV 50 50 29.4 very opalscent (≤ Ref IV) 
 
2.2.6 High Pressure Size Exclusion Chromatography (HP-SEC)  
HSA-aggregation was determined by HP-SEC on a HP1100 (Agilent Technologies, 
Waldbronn, Germany) using a TSKgel G3000SWxl column (Tosoh Biosep, Stuttgart, 
Germany) with a guard column. The running buffer was composed of 20 mM NaH2PO4 
and 100 mM NaCl (pH 6.8). The analytics were performed at a flow rate of 0.5 ml/min 
with UV-detection at 280 nm.  
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3. Results and Discussion 
3.1. Lyophilization of the System Mannitol-HSA-NaCl 
3.1.1 Drying Process 
The drying process, basically the length of primary drying is depending on the structure 
of the frozen matrix and with it the dry layer resistance. Thereby, the composition of the 
formulation and the applied freezing procedure, which determines the size of the ice 
crystals can influence the duration of primary drying [21,22]. The impact of the freezing 
protocol and the addition of NaCl to formulations with 1.25% mannitol and 1.25% 
stabilized-HSA on primary drying time were investigated using thermocouples and the 
microbalance technique. Samples dried after a regular freezing with 0.45°C/min 
(program I) exhibited the shortest primary drying time (7.6 h ± 0.3 h, n=3) after vacuum 
was applied. Longer primary drying times were observed when the vials were frozen with 
a higher freezing-rate by placing them on pre-cooled shelves (8.9 h ± 0.7 h, n=3) and 
after freezing with an annealing step (9.9 h ± 0.1 h, n=3). Annealing can both increase 
and decrease the drying-rate. Searles et al. (2001) showed that annealing at a 
temperature above Tg’ leads to a 3.5 fold increase in the primary-drying rate of sucrose-
hydroxyethyl starch formulations, due to increased ice-crystal size and simplified 
amorphous structures [23]. On the other hand, Pikal et al. (2004) determined prolonged 
primary drying times for mannitol-trehalose-NaCl based formulations after annealing, as 
partial collapse was inhibited by the highly crystallized mannitol, leading to a more 
compact structure that offers a higher dry-layer resistance [24].  
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Figure 1: Primary drying time of 1.25% mannitol and 1.25% stabilized-HSA dried with program I. 
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The changes in primary drying time after the addition of NaCl to 1.25% mannitol and 
1.25% stabilized-HSA dried with program I are shown in Figure 1. Thermocouples in 
separately placed vials and vials placed on a filled shelf, as well as the microbalance 
demonstrated shorter drying times with the addition of salt, indicating morphological and 
physico-chemical differences resulting from the presence of NaCl. Overall, the vials on 
the filled shelf required a longer drying time than individually vials placed on a separate 
shelf, due to the reduced energy transfer on a filled shelf [25]. 
 
3.1.2  Residual Moisture Content 
The residual moisture of the samples with 1.25% mannitol and 1.25% stabilized-HSA 
was affected by NaCl (Figure 2). Up to 0.1% NaCl the water content ranged below 0.5%. 
For samples with 0.2% NaCl the residual moisture was drastically increased to 
approximately 2%, offering another indication for morphological or physico-chemical 
changes with an increase in NaCl concentration. It was shown in the freezing studies, 
that mannitol crystallization in mannitol-HSA formulations could be inhibited by the 
addition of NaCl, leading to a higher amorphous degree. The increase of the amorphous 
fraction can offer a possible explanation for the increase in residual moisture. 
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Figure 2: Residual moisture content of 1.25% mannitol and 1.25% stabilized-HSA with 0.0% to 
0.2% NaCl after lyophilization with program I, II and III. 
 
The higher residual moisture can affect protein stability during storage, as it can promote 
physical and chemical instabilities [26]. Water can act as reactant or product in chemical 
reactions [27]. The residual moisture in the amorphous lyophilized product further can 
promote crystallization and lead to a depression of the glass transition Tg, as water is 
acting as plasticizer [28,29].  
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3.1.3 Morphology, Crystallinity and Thermal Properties of Lyophilized 
Products with Mannitol, Stabilized-HSA and NaCl  
Previous freezing studies had shown that mannitol crystallization could be inhibited by 
the addition of NaCl or HSA. This can affect the drying process and the physico-chemical 
properties of the lyophilized products. To explain the shorter primary drying time and 
higher residual moisture content for increasing NaCl concentrations, the morphology of 
lyophilized products with mannitol, HSA and NaCl was analyzed with XRD, DSC and SEM. 
After freeze-drying a 2.5% mannitol solution, peaks of all modifications (α-, β- and δ-
mannitol) were found in the XRD pattern (Figure 3).  
 
5 10 15 20 25 30 35 40
° 2-Theta
 
Figure 3: XRD diffraction pattern of variable ratios of mannitol (M) to stabilized HSA (HSA) 
lyophilized with program I from solutions with a total solid content of 2.5%. 
 
With increasing amounts of stabilized-HSA, the α-modification disappeared first when 
0.5% stabilized-HSA was added to the formulations. This was followed by a 
disappearance of the β-modification at 1.0% stabilized-HSA, leaving solely  
δ-mannitol. The critical ratio of mannitol to stabilized-HSA was 1:1, as the products were 
partially crystalline comprising δ-mannitol independent of the lyophilization program. The 
products were amorphous according to XRD when more than 50% of the lyophilized 
product was composed of HSA. For formulation with 1.25% mannitol and 1.25% 
stabilized-HSA the impact of NaCl and the applied freezing process on the morphology of 
the lyophilized products were studied with XRD. After lyophilization with program I, 
mannitol was present in the δ-modification for 0.0% to 0.1% NaCl (Figure 4a). By 
increasing the NaCl concentration to 0.15% the β-modification augmented. 0.2% NaCl 
led to pure β-mannitol and amorphous mannitol was found for 0.3% NaCl. Peaks of 
2.5% M 
1.5% M, 1.0% HSA 
1.25% M, 1.25% HSA 
1.0% M, 1.5% HSA 
δ 
ß 
ß 
2.0% M, 0.5% HSA 
α 
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crystalline NaCl (31.7° 2-Θ) could be detected when NaCl was used in concentrations 
higher than 0.1%. 
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Figure 4: XRD diffraction pattern of 1.25% mannitol and 1.25% stabilized-HSA, 0.0% to 0.3% NaCl 
dried with program I (a), program II (b) and program III (c). 
 
The change from crystalline to amorphous mannitol could also be visualized with SEM. 
Products without NaCl exhibited a relatively compact structure with ordered shaped 
edges and layers of crystalline appearance, which was in agreement with XRD data 
(Figure 5a). Increasing the NaCl content to 0.3% resulted in products, with a smooth 
network, an amorphous structure and first signs of collapse (Figure 5b). This could be 
used as an explanation for the decreased drying time of the samples with increasing NaCl 
content. The looser structure offered less product resistance during drying and therefore 
the sublimation rate was higher compared to products without NaCl.  
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Figure 5: SEM of 1.25% mannitol and 1.25% stabilized-HSA without NaCl (a) and 0.3% NaCl (b). 
 
For samples lyophilized with program I a broad peak with a maximum at 95°C to 100°C 
in the DSC heating scan could be detected in products containing 0.0% to 0.2% NaCl 
(Figure 6). The broad peak derived from HSA, as stabilized-HSA lyophilized without 
further excipients showed this characteristic peak as well. For formulations with mannitol 
and stabilized-HSA DSC did not detect a glass transition (Tg) which was indicative for the 
presence of amorphous material. This was in agreement with XRD for the samples 
without NaCl which demonstrated that these samples mainly consisted of crystalline 
mannitol. With increasing amounts of NaCl, mannitol remained partly amorphous 
according to XRD. However, no Tg was detected with DSC, which could be due to the 
broad peak, deriving from HSA that superimposed the signal of a possible Tg. At 
0.3% NaCl, amorphous mannitol crystallized with an onset of 64°C and a maximum at 
75°C. Between 120°C and 180°C the melting peaks of the different mannitol-
modifications were detected. It is described in literature that δ-mannitol is transformed to 
β-mannitol at 130°C, with a subsequent melting at 150°C to 158°C [30]. The melting of 
the β- and the α-modification was found at 166°C to 168°C. As the lyophilized products 
were mixtures of HSA, NaCl and mannitol the melting points could differ from that of 
pure mannitol. NaCl shifts the melting points of the mannitol modifications to lower 
temperatures [31]. Overall, no Tg and no changes in the DSC chromatogram in the 
temperature range of 0°C to 40°C, which is relevant for storage, could be detected for 
the formulations consisting of 1.25% mannitol and 1.25% stabilized HSA with 0.0% to 
0.3% NaCl (Figure 6).  
 
(a) (b) 
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Figure 6: DSC heating-scan of 3% HSA and 1.25% mannitol and 1.25% stabilized-HSA with 0.0%, 
0.2% and 0.3% NaCl dried with program I. 
 
Drying the formulation with an additional annealing step (program II) led to samples with 
a higher crystallinity (Figure 4a). In this case peaks of crystalline β-mannitol were found 
for 0.3% NaCl, while these products were amorphous after the lyophilization with 
program I. The annealing was conducted at -20°C, which was above the onset of 
mannitol crystallization in DSC at -25°C, allowing mannitol to crystallize. The contrary 
effect of more amorphous samples could be achieved by applying a faster freezing rate of 
0.9°C/min (program III) or placing the vials on pre-cooled shelves (program IV), where 
an average freezing-rate of 2.3°C/min was measured. The XRD patterns were equal for 
program III and IV, whereby NaCl stayed amorphous (Figure 4c).  
For all studied lyophilization programs δ-mannitol was formed in the absence of NaCl, 
while the addition of NaCl led to a mixture of δ- and β-mannitol followed by β-mannitol 
and finally amorphous products. The lyophilization process affected at which NaCl 
concentration the transitions occurred.  
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3.2 Storage Stability of the Lyophilized Formulations 
Excipients in the amorphous state are more suitable to stabilize proteins. Therefore, a 
potential crystallization of amorphous material during storage needs to be prevented. 
The addition of NaCl to formulations with 1.25% mannitol and 1.25% stabilized-HSA led 
to more amorphous products. It was evaluated whether the samples consisting of 1.25% 
mannitol and 1.25% stabilized-HSA with 0.0% to 0.2% NaCl were physico-chemically 
stable upon storage for 6 months at 2-8°C, 25°C / 60% RH and 40°C / 75% RH. Besides 
the physico-chemical stability, the impact of storage on HSA-stability at the different 
storage conditions was evaluated using turbiditimetry and HP-SEC.  
 
3.2.1 Changes in the Product Morphology upon Storage 
After lyophilization formulations with 1.25% mannitol and 1.25% stabilized-HSA 
contained only δ-mannitol independent of the applied freezing protocol. Upon storage for 
6 months no significant changes in the morphology could be observed at any 
temperature, indicating a morphologically stable system. It was described in literature 
that the δ-modification was less stable than the α- and β-modification [32]. Especially at 
elevated moisture levels e.g. during wet granulation δ-mannitol converts to β-mannitol 
[33]. The increase in residual moisture in the lyophilized products from 0.5% before 
storage to 1.5% to 3.0% (depending on the storage temperature) did not lead to a 
change in modifications. NaCl inhibited mannitol crystallization during lyophilization. The 
applied freezing-protocol determined the NaCl concentration at which complete inhibition 
of mannitol crystallization could be achieved (compare 3.1.3). After adding 0.2% NaCl to 
the formulation lyophilized with program I, peaks of β-mannitol at a very low intensity 
and NaCl (31.7° 2-Θ) with an overall high content of amorphous material were detected 
(Figure 7a). When performing lyophilization with an annealing step (program II), a partly 
crystalline mixture of β- and δ-mannitol was achieved for formulations with 0.1% NaCl 
(Figure 7b). The low intensity of the NaCl peak at 31.7° 2-Θ indicated an incomplete NaCl 
crystallization during the freeze-drying process. Lyophilization at a faster freezing rate 
(program III) resulted in amorphous products, when 0.1% NaCl was added (Figure 7c). 
During storage at 2-8°C, 25°C / 60% RH and 40°C / 75% RH mannitol and NaCl 
crystallized, indicated by an intensity increase of the peaks, with mannitol crystallizing 
prior to NaCl. This was in agreement with literature data for the crystallization order in 
the liquid state during freezing and rewarming, where NaCl crystallization takes place 
after the crystallization of mannitol, which is necessary for NaCl to inhibit the 
crystallization of mannitol [31]. During 6 months storage a formation of new mannitol 
modifications did not occur. Similar results were obtained by Cannon and Trappler (2000) 
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for lyophilized products with mannitol as single component stored for one year at room 
temperature [34]. 
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Figure 7: XRD of 1.25% mannitol and 1.25% stabilized-HSA, 0.1% (b,c) and 0.2% NaCl (a) dried 
with program I (a), program II (b) and program III (c) after 1 and 6 months at 2-8°C, 
25°C / 60% RH and 40°C / 75% RH. 
 
However, the amorphous or partially amorphous state created by adding NaCl to 
formulations with 1.25% mannitol and 1.25% stabilized-HSA could not be preserved over 
storage time. A stable amorphous state was for example achieved by increasing the 
fraction of stabilized-HSA to 1.5%, where mannitol remained amorphous after 
lyophilization and 24 months at 25°C / 60% RH (Figure 8).  
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Figure 8: XRD of 1.5% stabilized-HSA and 1.0% mannitol without and with 0.1% NaCl, lyophilized 
with program I after lyophilization and 24 months at 25°C / 60% RH. 
 
When adding 0.1% NaCl, the peak at 31.7° 2-Θ was present and increased in intensity 
over time, while mannitol remained amorphous. It could be shown that the amorphous 
state created by NaCl was not stable upon storage. If NaCl is required e.g. as stabilizer 
for the active ingredient the fact that it crystallizes upon storage needs to be considered.  
 
3.2.2 Stability of HSA during Storage 
More important than the physico-chemical stability of the lyophilized product is the 
stability of a protein upon storage. To evaluate the stability of HSA over time, turbidity in 
FNU was monitored over the pH range from 7.5 to 3.0 and compared to the reference 
solutions I-IV of the European Pharmacopoeia method 2.2.1 [20]. By the pH scan the 
differences between the formulations became more obvious, as the increase in turbidity 
at pH 4.5 to 5.0 was more pronounced for stressed products. Additionally, aggregation 
was monitored with HP-SEC. Here the samples lyophilized with program I after 24 
months at 25°C / 60% RH are shown exemplarily. Independent of the applied 
lyophilization process, clear solutions (turbidity < Ref I of Ph. Eur.) were obtained after 
reconstitution with water. The pH turbidity profile did not change after 6 months at 2-8°C 
(Figure 9a). After storage at 25°C / 60% RH and 40°C / 75% RH the turbidity increase at 
pH 5.0 was more obvious (Figure 9b-e). After 6 months at 25°C / 60% RH, respectively 
40°C / 75% RH turbidities of 25-30 FNU, respectively 45-55 FNU were measured at pH 
5.0, indicating damage of the protein at elevated temperatures. Furthermore, the 
turbidity of samples lyophilized with program II was about 4 FNU (25°C / 60% RH) and 
10 FNU (40°C / 75% RH) higher compared to preparations dried with the other 
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programs. The more pronounced crystallinity and possible phase separation after 
annealing offered possible explanations.  
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Figure 9: Turbidity of 1.25% mannitol and 1.25% stabilized-HSA upon storage at 2-8°C for 6 
months (a), storage at 25°C / 60% RH for 1 month (b) and 6 months (c) and storage at 
40°C / 75% RH for 1 month (d) and 6 months (e).  
 
The addition of NaCl improved the stability over storage time for all applied freezing 
protocols. After 6 months storage at 2-8°C and 25°C / 60% RH there was no significant 
increase in turbidity at pH 4.5 to 5.0 for 0.1% and 0.2% NaCl (Figure 10). Consistent 
turbidities of 3.5 to 4.6 FNU over the studied pH-range, comparable to the solutions 
before lyophilization were measured. The turbidity increase at pH 4.5 to 5.0 could not 
completely be inhibited by NaCl after storage at 40°C / 75% RH. However, the turbidity 
maximum stayed below 10 FNU and the degree of opalescence was lower than Ref III of 
the European Pharmacopoeia with 7.6 FNU for 0.1% NaCl, respectively 6.4 FNU for 0.2% 
NaCl.  
 
 
 
 
 
 
(a) (b) (c) 
(d) (e) 
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Figure 10: Turbidity of 1.25% mannitol and 1.25% stabilized-HSA with 0.1% NaCl (a) and 
0.2% NaCl (b) dried with program I after 6 months storage at 2-8°C, 25°C / 60% RH and 
40°C / 75% RH. 
 
The stabilizing effect of NaCl on HSA seen in the turbidity data was further confirmed 
with HP-SEC. It was shown by HP-SEC for samples lyophilized with program I after 24 
months storage at 25°C / 60% RH that higher monomer contents were found with 
increasing NaCl concentrations (Figure 11). The monomer content after lyophilization was 
93% ± 0.5% independent of the NaCl concentration.  
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Figure 11: HSA-monomer content after reconstitution of 1.25% mannitol and 1.25% stabilized-HSA 
formulation with 0.0% to 0.2% NaCl, lyophilized with program I and 24 months storage at 
25°C / 60% RH. 
 
A stabilizing effect of NaCl on HSA, respectively BSA is also described in literature. In the 
solid state HSA generally exhibits a good thermo-reversible structural stability, which was 
(a) (b) 
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determined by FTIR from Wang et al. (2005) [35]. Higher melting temperatures (Tm) are 
detected by DSC with increasing NaCl concentrations in HSA solutions in the pH range 
from 5.6 to 7.0 [36]. Costantino et al. (1995a) showed for lyophilized recombinant 
human albumin (rHA) that aggregation upon high humidity incubation was reduced by 
NaCl due to the uptake of water in the vicinity of rHA by NaCl [37]. The secondary 
structure of rHA, was not significantly affected by the addition of NaCl [38]. Structural 
changes, in particular aggregation is known to induce the risk of immunogenicity 
reactions in the patient [39]. HSA itself exhibits a low risk for immunogenicity, however 
in presence of a second protein the formation of mixed aggregates can lead to 
immunogenicity reactions, which was e.g. shown for rhINFα [40,41].  
Overall, the turbidity data showed a good stability of stabilized-HSA upon storage at  
2-8°C for all studied lyophilization programs. At higher storage temperatures the samples 
produced with annealing (program II) exhibited higher turbidity values at pH 5.0, 
indicating destabilization. By NaCl addition, mannitol remained amorphous after 
lyophilization, but crystallized upon storage. Crystallization is known for its potential 
negative impact on protein integrity [3]. However, the addition of NaCl enhanced the 
stability of HSA independent of the applied freeze-drying program and the crystallization 
of mannitol upon storage. This indicated that the stabilizing effect of NaCl on HSA 
prevailed over a possible detrimental effect of mannitol crystallization upon storage.  
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4. Conclusions 
The lyophilization behavior and the physico-chemical properties of the dried products are 
influenced by the presence of salts in the formulations. Therefore, the impact of NaCl on 
drying-time, crystallization and morphology was studied for formulations with mannitol 
and stabilized-HSA, using different freezing-protocols. A shorter drying-time for 
formulations with 1.25% mannitol and 1.25% stabilized-HSA was observed for three 
different lyophilization programs with increasing amounts of NaCl, due to morphological 
changes and a less compact cake structure. It could be shown by DSC, XRD and SEM 
that both NaCl-concentration and applied freezing-protocol had a significant impact on 
the physico-chemical properties of the formulations after lyophilization with differences in 
crystallinity and existing modifications. Without NaCl the lyophilized samples contained 
exclusively δ-mannitol for all studied freezing-protocols and remained physico-chemically 
stable upon storage for 6 months at 2-8°C, 25°C / 60% RH and 40°C / 75% RH. With 
increasing NaCl concentrations a larger fraction of β-mannitol was detected and finally 
amorphous products were formed. The applied freezing-protocol determined how much 
NaCl was needed to achieve an amorphous product. However, upon storage the 
amorphous state could not be preserved with the consequence that mannitol and NaCl 
crystallized. The data indicated that products without NaCl were more stable in their 
modifications. However, regarding the stability of HSA in the lyophilized products, 
monitored by a turbidity scan from pH 3.0 to 7.0 and HP-SEC, the addition of NaCl 
improved the stability of HSA upon storage. This could be referred to a direct stabilizing 
effect of NaCl on HSA upon storage, which is described in literature. For the studied 
systems the benefit of NaCl on protein stability outbalanced the potential drawbacks that 
morphological changes, like crystallization imposed on lyophilized products. Concluding, 
it can be stated that it is important to understand how NaCl is affecting the morphology 
and the protein in the formulation during lyophilization.  
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Chapter 5 
 
Impact of Freezing Procedure and Annealing on the Physico-
chemical Properties and the Formation of Mannitol Hydrate in 
Mannitol-Sucrose-NaCl Formulations 
 
 
Abstract 
The goal was to investigate the excipient system mannitol-sucrose as alternative HSA-
free lyophilized formulations for the cytokine. Thereby, the impact of NaCl on the 
physico-chemical properties of mannitol-sucrose formulations during freezing and drying, 
with special focus on mannitol hydrate formation was investigated. Differential Scanning 
Calorimetry (DSC) and Low-temperature X-ray Powder Diffraction (LTXRD) were used to 
study the frozen solutions. After lyophilization the products were analyzed with DSC, 
Temperature-modulated DSC (TMDSC), X-ray Powder Diffraction (XRD) and Karl-Fischer 
titration. DSC showed an inhibition of mannitol crystallization by sucrose and NaCl during 
freezing. Tg’ was lowered by both mannitol and NaCl. By the application of an annealing 
step during lyophilization mannitol crystallinity could be increased. However, 
lyophilization with an annealing step promoted the formation of mannitol hydrate. 
Mannitol hydrate is known to undergo conversion into the anhydrous polymorphs of 
mannitol upon storage with the consequence that the hydrate water is released. LTXRD 
revealed that mannitol hydrate was formed at temperatures below -30°C, but not at  
-27°C. The tendency that mannitol hydrate is predominantly formed at lower 
temperature was confirmed by XRD of lyophilized products, produced at different 
annealing temperatures. 
 
 
Keywords: freezing, lyophilization, annealing, NaCl, mannitol hydrate 
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1. Introduction 
In the HSA-containing cytokine formulation, mannitol was used as crystalline bulking 
agent and HSA as lyo- and cryoprotector. This combination of a crystalline bulking agent, 
e.g. mannitol or glycine with a second excipient that remains amorphous e.g. sucrose, 
trehalose or human serum albumin is a common way to achieve elegant lyophilized 
products [1-3]. Combinations of glycine with sucrose, respectively mannitol with sucrose 
are often employed. Johnson et al. (2002), as well as Passot et al. (2005) used a 
combination of 4% mannitol and 1% sucrose to successfully stabilize different proteins 
[4,5]. Liao et al. (2005) have studied the impact of an incooperated protein on the 
physical state of mannitol in formulations with mannitol and sucrose [6]. During 
lyophilization mannitol can crystallize in the α- β- or δ-modification or as mannitol 
hydrate depending on the applied freezing protocol, a potential annealing step and the 
process conditions during primary and secondary drying [7-9]. The presence of other 
excipients like buffer components, lyoprotectants or proteins can both inhibit and 
promote mannitol crystallization [10-12]. Especially salts, that are added as buffer 
components, isotonicity agents or stabilizers can have a major impact on the physico-
chemical properties of mannitol and other excipients [13,14]. A slight increase in salt 
concentration can lead to significant changes of the physico-chemical properties of the 
excipients during freezing and drying [15-18]. The impact of NaCl on the system 
mannitol-HSA during freezing and lyophilization is subject of Chapter 3 and 4. Besides 
the anhydrous modifications, mannitol can exist as a metastable crystalline hydrate after 
lyophilization [19]. The presence of mannitol hydrate can lead to stability problems 
during storage due to the release of hydrate water upon its conversion into the 
anhydrous crystal forms. Therefore, it is important to develop lyophilization cycles that 
result in products free of mannitol hydrate. Johnson et al. (2002) showed that mannitol 
hydrate content can be reduced when performing the secondary drying at temperatures 
above 40°C [4]. Little is known about how an annealing procedure influences the 
formation of mannitol hydrate during lyophilization. Annealing is often applied for 
formulations with mannitol as bulking agent to maximize mannitol crystallization during 
the freezing-step. On the other hand, several approaches are described to produce 
amorphous mannitol as lyoprotector, e.g. by adding NaCl, boric acid or sodium 
tetraborate [13,20,21]. Only in the amorphous state mannitol is able to adequately 
stabilize the active protein via molecular interactions [22,23]. However, amorphous 
mannitol tends to crystallize upon storage and thereby looses its ability to stabilize the 
protein [2]. Therefore, the employment of mannitol as crystalline bulking agent in 
combination with an amorphous lyoprotector is the more promising approach. Thereby, it 
is essential to ensure mannitol crystallization during lyophilization. The crystallization of 
Impact of Freezing Procedure and Annealing on the Physico-chemical Properties and the Formation of Mannitol 
Hydrate in Mannitol-Sucrose-NaCl Formulations 
   
 
99 
an excipient upon storage can reduce storage stability. This was described by Kreilgaard 
et al. (1999) for Humicola languinosa Lipase formulated with sucrose, who attributed the 
reduced stability after crystallization to an increase in moisture content and a reduced 
glass transition (Tg) value of the remaining amorphous phase [24].  
With respect to the planned development of HSA-free formulations for the cytokine, HSA 
was replaced by sucrose in its function as lyo- and cryoprotector. Different combinations 
of mannitol, sucrose and NaCl were used as model formulations for the studies. The 
impact of NaCl on the physico-chemical properties of the formulation during freezing, 
annealing and drying was investigated. For the frozen state the glass transition of the 
maximally freeze-concentrated solution (Tg’) of the formulations and the crystallization of 
mannitol were monitored. The lyophilized products were analyzed regarding mannitol 
modifications, Tg and residual moisture. Special focus was set on the presence of 
mannitol hydrate in relation to the applied annealing steps, to find the optimum 
lyophilization conditions for the formulations.  
 
2. Materials and Methods 
2.1 Materials 
Mannitol was obtained from Caelo (Hilden, Germany), sucrose from Suedzucker 
(Mannheim, Germany) and NaCl from Sigma (Steinheim, Germany).  
 
2.2 Methods 
2.2.1 Low Temperature X-ray Powder Diffraction (LTXRD) 
Crystallization was studied with LTXRD using Cu-Kα1-radiation (λ=154.06 pm) on the 
powder diffractometer Stadi P from STOE (Darmstadt, Germany) with parafocussed 
transmission geometry. Germanium was used as primary monochromator and the 
scattered X-rays were detected with a linear PSD area detector. The sterile filtrated 
solutions were frozen in the rotating capillary (diameter 0.5 mm) in the cooling stage 
(Oxford Cryosystem) of the X-ray diffractometer. For the LTXRD experiment a 
temperature profile similar to the conditions during lyophilization was chosen. The 
samples were frozen to -50°C with a cooling rate of 0.5°C/min. At -50°C the first 
measurement under isothermal conditions was performed. The temperature was 
subsequently increased to the different annealing temperatures at 1°C/min and several 
measurements were performed at designated time intervals. The diffraction patterns 
Chapter 5 
   
 
100 
were analyzed with the program WinXPOW from STOE (Darmstadt, Germany). The 
assignment of the XRD diffraction peaks of mannitol was performed according to 
Chapter 3. 
 
2.2.2 Differential Scanning Calorimetry (DSC) of the Frozen Solutions 
DSC was used to study the glass transition of the maximally freeze-concentrated solution 
(Tg’) and the crystallization behavior of formulations with a total solid content of 
5% [w/v] at low temperatures. Thereby, the ratio of mannitol to sucrose was varied and 
0.05% to 0.2% NaCl were added to the formulations. Approximately 20 mg of the sterile 
filtrated solutions were analyzed in crimped Al-crucibles. The samples were frozen from 
20°C to -70°C and reheated to 20°C with a standard scanning-rate of 10°C/min in a 
Netzsch DSC 204 Phoenix® (Selb, Germany), calibrated with Indium. Tg’ (onset and point 
of inflection) and crystallization (onset, peak, enthalpy) of the excipients were 
determined during the heating scan. 
 
2.2.3 Lyophilization  
1000 µl of the formulations were dried in 2 R vials from Schott (Mainz, Germany) in the 
Epsilon 2-12 D freeze-drier from Christ (Osterrode, Germany). The samples were frozen 
to -50°C with a standard cooling rate of 0.45°C/min. Different annealing steps were used 
for the production of the samples (Table 1). Primary drying was conducted at a shelf-
temperature of -15°C and a pressure of 0.045 mbar. For secondary drying the shelf-
temperature was increased to 20°C, respectively 40°C at a pressure of 0.01 mbar. 
 
Table 1: Lyophilization cycles used for the production of the samples. 
 
process annealing secondary drying 
I without 20°C for 10 h 
II -20°C for 2 h 40°C for 8 h 
III -25°C for 2 h 40°C for 8 h 
IIIa -25°C for 2 h 20°C for 10 h 
IV -30°C for 2 h 40°C for 8 h 
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2.2.4 Differential Scanning Calorimetry (DSC) of Lyophilized Products 
The lyophilized samples were analyzed with the Netzsch DSC 204 Phoenix® (Selb, 
Germany) from 0 to 150°C using scanning rates of 10°C/min. Approximately 10 mg of 
the lyophilized samples were analyzed in sealed Al-crucibles. The thermal events were 
analyzed in the heating scan of the DSC. 
 
2.2.5 Temperature-Modulated-DSC (TMDSC) of Lyophilized Samples 
The lyophilized samples were further analyzed with the Mettler Toledo DSC 822e 
(Giessen, Germany) in the modulating mode using 40 µl Al crucibles with Pin (ME 
27331). The samples were scanned from 0 to 80°C at an average heating rate of 
1.0°C/min at an amplitude of 0.5°C and a period of 0.8 minutes. The glass transitions 
were detected in the reversing heat curve.  
 
2.2.6 X-ray Powder Diffraction (XRD) 
The morphology of the lyophilized products was analyzed by X-ray powder diffraction 
(XRD) from 5-40° 2-Θ, with steps of 0.05° 2-Θ and a duration of 2 seconds per step on 
the X-ray diffractometer XRD 3000 TT (Seifert, Ahrenburg, Germany), equipped with a 
copper anode (40 kV, 30 mA, wavelength 154.17 pm). 
 
2.2.7 Karl-Fischer Titration 
The residual moisture of the samples was determined by coulometric Karl-Fischer 
titration using the Aqua 40.00 titrator with a headspace module (Analytik Jena AG, Halle, 
Germany). For the measurement at least 10 mg of the lyophilized sample was heated to 
80°C for 10 minutes. The evaporated water was transferred into the titration solution and 
the amount of H2O was determined. As reference material Apura Water Standard Oven 
1% (Merck, Darmstadt Germany) was used and the recovery was considered for the 
calculation of the residual moisture of the samples. 
To determine the amount of mannitol hydrate in the lyophilized sample Karl-Fischer was 
performed in the dynamic mode. The sample was heated with a heating rate of 5°C/min 
from 30 to 90°C and the water was simultaneously titrated. 
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3. Results and Discussion 
3.1 Impact of NaCl on the Physico-chemical Properties of Mannitol-
Sucrose Formulations 
For the HSA-free formulations of the cytokine a total solid content of 5.0% [w/v] was 
planned, with mannitol as crystalline bulking agent and sucrose as amorphous stabilizer. 
The optimum ratio of mannitol to sucrose to produce formulations with crystalline 
mannitol and amorphous sucrose had to be found. The ratio of mannitol to sucrose was 
varied and 0.0% to 0.2% NaCl were added to the formulations. Before performing 
lyophilization, the physico-chemical properties of the formulations regarding Tg` and 
crystallization were studied in the frozen state.  
 
3.1.1 DSC of Mannitol-Sucrose-NaCl Formulations in the Frozen State 
DSC indicated partial crystallization of mannitol during cooling for a 5.0% mannitol 
solution at scanning rates of 10°C/min. During the cooling scan the nucleation of 
mannitol crystals prevailed [25]. Because of the remaining amorphous mannitol fraction, 
two glass transitions Tg’1 at -29.8°C and Tg’2 at -25.5°C were measured, which were in 
agreement with literature [26,27]. The glass transition events were followed by mannitol 
crystallization with a peak maximum at -19.3°C during the rewarming of the sample. 
Here the nuclei, formed at low temperatures grow to mature crystals [25]. The addition 
of sucrose inhibited mannitol crystallization in the heating scan, indicated by a decreased 
enthalpy of crystallization and a shift of the peak maximum to higher temperatures 
(Figure 1a, b). When the sucrose fraction in the formulation exceeded 50%, mannitol 
crystallization was completely suppressed in the heating scan. In formulations with 4.0% 
mannitol and 1.0% sucrose three glass transition events Tg’1 at -41.5°C, Tg’2 at -32.2°C 
and Tg’3 at -27.8°C could be detected. For a similar formulation with 4.0% mannitol, 
1.0% sucrose in 10 mM Tris buffer Passot et al. (2005) described two glass transitions 
Tg’1 at -41°C and Tg’2 at -31°C, while Tg’3 was not measured [5]. However, it is often 
difficult to detect the Tg’ which is close to the onset of mannitol crystallization, even in 
solutions with mannitol as single component, as it can overlap with the subsequent 
mannitol crystallization [26]. The origin of multiple glass transition processes was 
discussed by Liao et al. (2005) who focused on the lowest Tg’ for their studies [6]. With 
increasing amounts of sucrose, the two glass transitions at higher temperatures were no 
longer present, with only the glass transition at lower temperature remaining. The glass 
transition at lower temperatures was raised from -41.8°C for 4.0% mannitol and 1.0% 
sucrose to -33°C for 5.0% sucrose (Figure 1c).  
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Figure 1: DSC heating curve (10°C/min) of mannitol (M) - sucrose (S) formulations with total solid 
content of 5.0% and different ratios of mannitol to sucrose (a and b). Tg’ determined with DSC 
(n=3) with increasing sucrose concentrations (total solid content 5.0%) is shown in (c). 
 
Liao et al. (2005) showed a constant Tg’ of -43°C for mannitol to sucrose ratios between 
1.5 and 3 and increasing Tg’ values for mannitol to sucrose ratios below 1.5 for 
formulations with a total solid content of 7.0% using cooling rates of 20°C/min and 
heating rates of 5°C/min for the DSC measurements [6]. Upon the addition of NaCl to 
mannitol-sucrose formulations the Tg’ of the formulations was lowered for all studied 
mannitol-sucrose combinations (Table 2).  
 
 
 
(a) (b) 
exo 
exo 
5% M, 0% S 
4% M, 1% S 
3% M, 2% S 
2.5% M, 2.5% S 
2 % M, 3% S 
1 % M, 4% S 
0 % M, 5% S 
(c) 
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Table 2: Tg’ for mannitol-sucrose formulations with increasing amounts of NaCl. 
 
 
Tg’ [°C] 
0.0% NaCl 
Tg’ [°C] 
0.05% NaCl 
Tg’ [°C] 
0.1% NaCl 
Tg’ [°C] 
0.2% NaCl 
 
4.0% M - 1.0% S 
 
-41.8 
 
-42.1 
 
-42.3 
 
-43.3 
3.0% M - 2.0% S -41.2 -41.1 -41.7 -42.7 
2.5% M - 2.5% S -39.7 -40.4 -40.9 -41.9 
2.0% M - 3.0% S -39.1 -39.4 -40.9 -41.1 
1.0% M - 4.0% S -36.5 -37.5 -38.2 -38.8 
0.0 %M - 5.0% S -33.7 -34.0 -35.9 -37.3 
 
The shift of Tg’ in formulations with NaCl could be due to the very low Tg’ of NaCl which 
lies below -60°C [28]. NaCl could act as plasticizer by increasing the amount of unfrozen 
water in the amorphous phase, leading to a depression of Tg’. The lowered Tg’ in the 
formulations could further be indicative for the amorphous state of NaCl in the frozen 
state in the presence of mannitol and sucrose. When mannitol was present in the 
formulations the depression of Tg’ by NaCl was less pronounced. While Tg’ was lowered 
by 1.5 to 2.5°C in mannitol containing formulations, a decrease of 3.5°C is measured for 
5.0% sucrose in the presence of 0.2% NaCl. In the amorphous state, mannitol itself can 
act as plasticizer and increase the amount of unfrozen water in the amorphous phase 
[12]. Even at the highest concentration of 4.0% mannitol and 1.0% sucrose, amorphous 
mannitol was existent, evident by the crystallization in the DSC heating-scan with an 
onset of -25°C (Figure 1a). At higher sucrose concentrations mannitol crystallization was 
further inhibited and the Tg’ of the amorphous phase was lower compared to the Tg’ of 
mannitol and sucrose as single components. This was ascribed to a higher amount of 
unfrozen water within the freeze-concentrate with increasing mannitol to sucrose ratio by 
Lueckel et al. (1998) [12]. A lowering of Tg’ has to be considered for the development of 
the lyophilization cycles to avoid the higher mobility of the amorphous phase above Tg’ 
and potential collapse during lyophilization. To avoid collapse the product temperature 
has to be kept below Tc, which ranges about 1 to 3°C higher than Tg’ [29]. Besides the 
depression of Tg’ NaCl inhibited mannitol crystallization in the DSC heating scan, 
exemplarily shown for 4.0% mannitol and 1.0% sucrose in Figure 2. 
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Figure 2: DSC heating scan of 4.0% mannitol and 1.0% sucrose with 0.0% to 0.2% NaCl. 
 
3.1.2. DSC and XRD of Lyophilized Mannitol-Sucrose Formulations 
For the stabilization of proteins the presence of an amorphous fraction in the lyophilized 
product is beneficial. Many attempts have been made to achieve amorphous mannitol to 
stabilize proteins, e.g. by using fast freezing rates or adding excipients that inhibit 
crystallization [13,20,21]. However, mannitol frequently crystallizes upon storage which 
can lead to stability problems for the protein. Crystalline mannitol looses its molecular 
interaction with proteins and with it the ability to stabilize the protein [2]. This indicates 
that the approach to produce amorphous mannitol as protein stabilizing component in a 
lyophilized formulation often fails. Therefore, a high degree of mannitol crystallization 
and the addition of a second amorphous stabilizer e.g. sucrose or trehalose is the favored 
route. To ensure sufficient mannitol crystallization during the lyophilization process the 
formulation compositions, as well as the lyophilization processes have to be optimized. 
The addition of amorphous excipients can inhibit mannitol crystallization, leading to 
partially crystalline system. This was shown for formulations with a total solid content of 
5.0% and varying ratios of sucrose to mannitol. After lyophilization without annealing the 
products were largely amorphous when more than 2.5% sucrose was present 
(Figure 3a). In the DSC no crystallization was detected for 2.5% sucrose and 2.5% 
mannitol during freezing and rewarming. However, the lyophilized products were partially 
crystalline, indicating that crystallization occurred to a great extent during the drying 
process. This observation is in agreement with Pyne et al. (2001) [30]. The LTXRD 
experiments further supported this finding, as no peaks for crystalline mannitol appeared 
after freezing the samples to -50°C (Figure 8). In formulations with a 1:1 mannitol to 
0.0% NaCl 
0.05% NaCl 
0.1% NaCl 
0.2% NaCl 
exo 
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sucrose ratio, peaks of δ-mannitol (9.7° 2-Θ) and β-mannitol (23.4° 2-Θ) were detected. 
Furthermore, mannitol hydrate indicated by the peak at 17.9° 2-Θ was present. 
 
5 10 15 20 25 30 35 40
° 2-Theta
5 10 15 20 25 30 35 40
° 2-Theta
 
Figure 3: XRD of mannitol (M) - sucrose (S) formulations after lyophilization with process I (a) and 
with process IIIa which included an annealing step at -25°C for 2 hours (b). 
 
In the first DSC heating scan of 2.5% mannitol and 2.5% sucrose, lyophilized with 
program I two glass transitions (Tg) at 12°C and 36°C followed by mannitol 
crystallization with an onset of 43.3°C and a peak maximum of 55.5°C were detected 
(Figure 4).  
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Figure 4: DSC heating scans of 2.5% mannitol and 2.5% sucrose lyophilized with program I. 
 
(a) (b) 
4% M, 1% S 
3% M, 2% S 
2.5% M, 2.5% S 
2% M, 3% S 2% M, 3% S 
3% M, 2% S 
4% M, 1% S 
exo 
1st scan 
2nd scan 
crystallization 
Tg 
Tg 
Tg 
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The first glass transition at 12°C could be attributed to the amorphous mannitol fraction. 
For amorphous mannitol a Tg of 13°C was described by Kim et al. (1998) [11]. After the 
crystallization in the first DSC scan mannitol was present in the crystalline form, as 
confirmed by XRD (data not shown). Therefore, only the higher Tg at 42°C, which 
corresponds to sucrose remained in the second DSC-scan. Increasing the mannitol 
content to 3.0% and 4.0% led to a higher intensity of the mannitol peaks in the XRD. 
However, formulations with 3.0% mannitol and 2.0% sucrose, dried with program I also 
showed a crystallization event in the first scan pointing at the presence of amorphous 
mannitol. For 4.0% mannitol and 1.0% sucrose no crystallization was detected in the 
DSC heating scan. This could be ascribed to a high degree in mannitol crystallinity after 
lyophilization, which could be confirmed by the high sucrose Tg of 58°C. For lyophilized 
sucrose formulations with a residual moisture of 0.7% to 2.0% a Tg between 59°C and 
63°C is described by te Booy et al. (1992) [31]. 
After lyophilization with annealing (program IIIa) a higher degree of crystallinity was 
achieved (Figure 3b). Thereby, mannitol crystallized mainly in the β-modification in 
formulations consisting of 2.0% mannitol and 3.0% sucrose, which were amorphous after 
lyophilization without annealing. Formulations with more than 2.0% mannitol were 
composed of β- and δ-mannitol, comparable to lyophilization without annealing. However, 
a larger fraction of mannitol hydrate (peak at 17.9° 2-Θ) was present after drying the 
samples with annealing. This could be due to the fact that mannitol hydrate is a 
modification which emerges mainly at low temperatures during lyophilization. In the 
further progress of the study, the impact of annealing on the formation of mannitol 
hydrate was studied. Thereby, the focus was set on formulations consisting of 4.0% 
mannitol and 1.0% sucrose, as a high degree of mannitol crystallization can be achieved.  
 
3.1.2 Impact of NaCl on Lyophilized Mannitol-Sucrose-Formulations  
NaCl inhibited the crystallization of mannitol during freezing, which was shown by DSC 
for formulations with 4.0% mannitol and 1.0% sucrose (Figure 2). After lyophilization of 
4.0% mannitol and 1.0% sucrose mannitol crystallization was observed for all studied 
NaCl concentrations and lyophilization cycles. Figure 5 shows the XRD diffraction patterns 
after lyophilization with program III.  
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Figure 5: XRD of 4.0% mannitol and 1.0% sucrose with 0.0% to 0.8% NaCl (*marks characteristic 
peak of NaCl) lyophilized with program III. 
 
For 0.0% to 0.8% NaCl mannitol crystallized as a mixture of the β- and δ-modification 
and mannitol hydrate (17.9° 2-θ), with a slight decline of the mannitol hydrate fraction at 
0.8% NaCl. No crystallization events were measured in the DSC of the lyophilized 
products as well, indicating that mannitol and NaCl have crystallized during lyophilization. 
However, the Tg of the formulations was affected by the addition of NaCl. Both DSC and 
TMDSC showed that the Tg of the formulations was decreased by approximately 25°C 
when 0.4% NaCl was added to the formulations (Figure 6).  
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Figure 6: Tg determined with TMDSC and DSC (second scan) and residual moisture of 4.0% 
mannitol and 1.0% sucrose with 0.0% to 0.5% NaCl after lyophilization with program III. 
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The residual moisture increased from 0.8% without NaCl to 1.7% with 0.5% NaCl. This 
could explain the lowered glass transitions as water acts as plasticizer for the amorphous 
phase. Although mannitol crystallization was not affected by increasing NaCl 
concentrations, the lowered glass transition temperatures of the lyophilized products 
needs to be considered for the storage stability of a protein. A higher Tg is often 
beneficial for protein stability upon storage which was for example shown by Prestrelski 
et al. (1995) for Interleukin-2 [32]. However, Chang et al. (1996) demonstrated that 
storage of lyophilized recombinant human interleukin-1 receptor antagonist formulations 
below Tg was necessary, but not always sufficient to ensure long-term stability e.g. when 
the protein was already damaged during lyophilization process [33]. On the other hand, 
Davidson and Sun (2001) demonstrated for sucrose–raffinose formulations that an 
increase in Tg of the lyophilized samples was not related to a higher recovery of Glucose-
6-phosphate Dehydrogenase activity after reconstitution when stored above Tg [34].  
 
3.2 Impact of Annealing on the Formation of Mannitol Hydrate 
To study the impact of annealing on the formation of mannitol hydrate, formulations with 
4.0% mannitol and 1.0% sucrose were lyophilized with different lyophilization cycles. 
Furthermore, LTXRD was used to monitor crystallization of mannitol during an annealing 
step at low temperatures. For the LTXRD experiments solutions with higher 
concentrations (8.0% mannitol and 2.0% sucrose) were used, due to the detection limit 
of the method. 
 
3.2.1 LTXRD of Mannitol-Sucrose-Formulations at Different Annealing 
Conditions 
DSC offers information on crystalline and amorphous phases in the frozen state. 
However, with DSC it is not possible to identify and characterize the composition and 
modifications of the crystalline phase [35], which is on the other hand possible with 
LTXRD [36,37]. After freezing a formulation of 8.0% mannitol and 2.0% sucrose to -50°C 
with a cooling rate of 0.5°C/min no peaks of crystalline mannitol were detected 
(Figure 7). The cooling rate of 0.5°C/min was chosen as it is comparable to the cooling 
rate used during lyophilization. After an isothermal phase of one hour at -50°C the 
temperature was increased with 1.0°C/min to the annealing temperatures of -23°C,  
-27°C and -32°C, where three measurements were performed under isothermal 
conditions. After heating the samples to the annealing temperatures peaks of crystalline 
mannitol were detected. At -23°C and -27°C mannitol crystallized in the δ-modification, 
Chapter 5 
   
 
110 
seen by peaks at 9.7° 2-Θ and 20.4° 2-Θ (Figure 7a). Annealing at -32°C on the other 
hands led to a crystallization of mannitol hydrate which was evident by the peak at 
17.9° 2-Θ (Figure 7b). In the DSC heating scan mannitol crystallized with an onset of  
-25°C. At -32°C the crystallization process was decelerated as indicated by the lower 
intensity of the peaks in the first scan at -32°C.  
 
 
Figure 7: LTXRD of 8.0% mannitol and 2.0% sucrose after freezing to -50°C and during an 
isothermal annealing step at -27°C, with crystallization of δ-mannitol (a) and -32°C with 
crystallization of mannitol hydrate (marked with *) (b). 
 
Thus, according to LTXRD annealing at a temperature of -32°C is not suitable due to 
formation of mannitol hydrate. To investigate whether the findings of the LTXRD could be 
transferred to formation of mannitol hydrate in lyophilized products, lyophilization was 
conducted at different annealing temperatures and the dried samples were analyzed by 
XRD. 
 
3.2.2 XRD of Lyophilized Samples Produced with Different 
Lyophilization Cycles 
The impact of annealing and secondary drying on the formation of mannitol hydrate 
during lyophilization was investigated for formulations of 4.0% mannitol and 1.0% 
sucrose without and with 0.2% NaCl. Annealing during lyophilization was conducted for 2 
hours at shelf-temperatures of -20°C, -25°C or -30°C (Table 1). All processes resulted in 
a crystalline formulation, which was confirmed by DSC (data not shown). XRD revealed 
the presence of β- and δ-mannitol, as well as different amounts of mannitol hydrate 
(Figure 8a). The characteristic peak of mannitol hydrate at 17.9° 2-Θ is enlarged in 
Figure 8b.  
 
(a) (b) 
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Figure 8: XRD of lyophilized 4.0% mannitol and 1.0% sucrose after different annealing (A) and 
secondary drying (SD) parameters (a) and mannitol hydrate peak at 17.9° 2-Θ (b). 
 
To compare the amount of mannitol hydrate formed after the different processes, the 
peak area and the relative intensity of the mannitol hydrate peak at 17.9° 2-Θ were 
considered (Figure 9). The peak area was calculated by integrating the area under the 
peak from 17.4° 2-Θ to 18.4° Θ in the diffraction pattern. For the relative intensity the 
height of the mannitol hydrate peak was compared to the highest peak of the diffraction 
pattern, which was set as 100%. In formulations dried without annealing the lowest 
fraction of mannitol hydrate was formed, although secondary drying was performed at 
20°C. Comparing the different annealing conditions the formation of mannitol hydrate 
was more distinct at lower annealing temperatures. This was in agreement with LTXRD, 
where mannitol hydrate was also formed at a lower temperature. The addition of 0.2% 
NaCl to the formulations slightly inhibited the formation of mannitol hydrate during 
lyophilization with annealing. However, NaCl tended to promote the formation of 
mannitol hydrate when annealing was waived. Comparing the different secondary drying 
temperatures less mannitol hydrate was formed when secondary drying was conducted 
at 40°C, which was in agreement with Johnson et al. (2002) [4]. However, the effect was 
less pronounced than the impact of the selected annealing temperature.  
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Figure 9: Peak area (a) and relative intensity (b) of mannitol hydrate peak after lyophilization of 
4.0% mannitol and 1.0% sucrose without and with 0.2% NaCl using different annealing (A) and 
secondary drying (SD) conditions (n=3). 
 
To estimate the amount of mannitol hydrate in the lyophilized formulation with 4.0% 
mannitol and 1.0% sucrose dried with program IV dynamic Karl-Fischer titration was 
performed (Figure 10). Water was released in two steps from the lyophilized product 
upon heating. The first step between 30 and 45°C could be attributed to the release of 
sorbed water and the second step from about 55 to 70°C mainly to the release of 
hydrate water from mannitol. In the second step about 0.6% water was released an in 
total the residual moisture content 1.1%. The data showed that about 15% to 20% of 
mannitol was present as hydrate, when calculated as hemihydrate in the worst case of 
annealing at -30°C. 
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Figure 10: Water loss from 30 to 90°C determined with dynamic Karl-Fischer titration for 4.0% 
mannitol and 1.0% sucrose dried with program IV.  
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LTXRD and XRD both showed that annealing can promote the formation of mannitol 
hydrate. Although there were differences in volumes and containers used during 
lyophilization and for the LTXRD experiment it was evident that mannitol hydrate was 
formed especially at lower temperatures. Therefore, it is beneficial to conduct 
lyophilization without annealing if possible. For the formulations with 4.0% mannitol and 
1.0% sucrose lyophilization without annealing was feasible, because mannitol crystallinity 
comparable to the processes with an extra annealing step was achieved. If annealing is 
required it is important to select a shelf temperature during annealing above -30°C to 
keep the level of mannitol hydrate as low as possible.  
 
4. Conclusions 
DSC results of the system mannitol-sucrose at low temperatures indicated a lowering of 
Tg’ with increasing amounts of mannitol due to the plasticizing effect of mannitol on the 
amorphous phase. The addition of NaCl further reduced the Tg’ of the formulations, 
which was more pronounced for formulations with lower mannitol contents. Mannitol 
crystallization during freezing was inhibited by sucrose and NaCl, resulting in partially 
crystalline systems. Lyophilization of 4.0% mannitol and 1.0% sucrose resulted in an 
extensive crystallization of mannitol, even without annealing. However, the Tg of these 
formulations was depressed by NaCl. Annealing increased mannitol crystallinity, but a 
higher mannitol hydrate content was often found after lyophilization of 4.0% mannitol 
and 1.0% sucrose with annealing. LTXRD of formulations with 8.0% mannitol and 2.0% 
sucrose showed that mannitol hydrate was preferably formed at lower annealing 
temperatures, while annealing at higher temperatures led to the formation of δ-mannitol. 
The results of LTXRD were confirmed by XRD after lyophilization, which showed that the 
highest amount of mannitol hydrate was formed after annealing at -30°C. NaCl enhanced 
the formation of mannitol hydrate when lyophilization was conducted without annealing. 
Compared to the impact of annealing the secondary drying temperature only played a 
minor role on the formation of mannitol hydrate. If annealing during lyophilization is 
necessary, a sufficient high temperature needs to be selected to avoid the formation of 
mannitol hydrate. 
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Chapter 6 
 
Development of Stable, HSA-free Formulations for a 
Hydrophobic Cytokine 
 
 
Abstract 
Chapter 6 describes the characterization of the hydrophobic cytokine with respect to the 
influence of pH and ionic strength on aggregate formation and the thermal stability of the 
cytokine, as well as the development of HSA-free formulations. When the formulation pH 
exceeded 5.5 a precipitation of the cytokine led to a significant turbidity increase. 
Thereby, the increase in aggregates and turbidity determined by HP-SEC and DLS were 
more pronounced at a higher ionic strength. Especially at higher pH values protein 
adsorption was more distinct compared to pH 3.0. Protein adsorption could be minimized 
by the addition of polysorbate 20 or the use of glass type I+. FTIR showed that the 
denaturation temperature was decreased when the formulation pH was raised, indicating 
enhanced stability at lower pH values, which was confirmed by DLS.  
Five liquid formulations in the pH range 3.5 to 4.5 and five lyophilized formulations in the 
pH range 4.0 to 5.0 were stored for 6 months at 2-8°C, 25°C / 60% RH and 
40°C / 75% RH. The stability of these formulations was evaluated regarding aggregation 
and chemical modification. The stability was in each case better at lower pH values, 
which was in agreement with the higher denaturation temperatures measured by FTIR 
for the cytokine formulated at lower pH. For the lyophilized formulation at pH 4.0 stored 
at 40°C / 75% RH a discoloration of the reconstituted solutions was observable, which 
could be ascribed to an inversion of sucrose. Both liquid formulations at pH 3.5 and 4.0 
and lyophilized formulations at pH 4.0 to 5.0 showed good stability when stored at  
2-8°C. Thus, freeze-drying allowed formulating the cytokine at significantly higher pH. To 
avoid protein adsorption the addition of polysorbate 20 and the use of glass type I+ were 
feasible.  
 
Keywords: hydrophobic cytokine, HSA-free formulation, protein adsorption, stability 
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1. Introduction 
The model protein for the studies was a recombinant human cytokine with a molecular 
weight of about 20 kDa, which can be specified as very hydrophobic. The cytokine is 
produced in E. coli and therefore non-glycosilated [1]. During formulation development 
the hydrophobicity and the corresponding low solubility and adsorption phenomena were 
the major concerns that had to be overcome. One possible way is a formulation of the 
cytokine with HSA, which is an excellent stabilizer in liquid and lyophilized formulations. 
The properties of a HSA-containing formulation of the cytokine were characterized and 
discussed in Chapter 2. HSA can act as lyoprotector and cryoprotector during 
lyophilization [2]. Moreover, it reduces the loss of active protein due to adsorption, which 
poses a problem especially for low dose formulations of hydrophobic proteins [3,4]. 
However, HSA as excipient is generally extracted from human plasma and implicates the 
problems associated with human blood derived products. Besides the risk of blood born 
pathogens, batch to batch variations can occur. HSA itself exhibits a low risk of 
immunogenicity, whereas in presence of a second protein the formation of mixed 
aggregates can lead to immunogenicity reactions, which was e.g. shown for rhINFα [5,6]. 
Other issues emerging for HSA-containing formulations are the difficulties that occur 
during the development of analytical methods for the active protein in the formulations. 
With HSA, a second protein often present in a 10 to 50 fold excess compared to the 
active protein is brought into the formulation. This makes selective analytics of the active 
protein, as well as its aggregates and degradation products difficult and often impossible. 
Specific methods like ELISA [7], selective precipitation [8], western-blot or BIACORE are 
required to solve this analytical problem. For these reasons, HSA is avoided in the 
development of new formulations as far as possible. In its function as lyo- and 
cryoprotector, HSA can be replaced by other excipients e.g. sugars, sugar alcohols or 
amino acids. The concern of protein adsorption can be overcome by the addition of 
sugars [9] and most important by surfactants [10,11], e.g. poloxamer 188 or 
polysorbate 20 and 80. Another approach to minimize protein adsorption is the use of 
special containers with reduced susceptibility for adsorption, like glass type I+ [12]. 
The first studies focused on the optimization of formulation buffer and pH. Changes of 
the cytokine in relation to pH, ionic strength and temperature were evaluated using 
different analytical techniques to get an understanding of its structural characteristics. 
For selected pH and buffer conditions short-term stability studies over two weeks were 
conducted. In this context, the impact of NaCl and glycine concentration and the addition 
of further excipients (mannitol, trehalose, polysorbate 20) on the formation of 
aggregates were evaluated. Furthermore, the problem of protein adsorption needed to be 
considered, when selecting the containers and the constituents of the formulation. The 
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impact of pH, ionic strength and the presence of surfactants on the degree of protein 
adsorption were rated for different container materials. Besides these studies the freeze-
thaw stability of the cytokine was tested, which was important for the subsequent 
development of lyophilized formulations. For the lyophilized cytokine formulations a 
combination of mannitol with sucrose was selected based on the results of the studies 
described in Chapter 5. Depending on the results of the preliminary studies five liquid 
formulations and five lyophilized formulations were to be selected. The stability of the 
formulations was evaluated over 6 months at 2-8°C, 25°C / 60% RH and 
40°C / 75% RH.  
 
2. Materials and Methods 
2.1 Materials 
2.1.1 Proteins and Excipients 
The starting material contained 1.0 mg/ml cytokine formulated with 0.1% sodium 
dodecyl sulfate (SDS) at pH 5.5. Preparative size-exclusion chromatography was used to 
remove SDS using Sephadex G-25 columns (Amersham Biosciences, Uppsala, Sweden) 
equilibrated with 10mM NaOH (pH 12) as eluting buffer. The protein content of the 
fractions was determined with UV-spectroscopy at 280 nm. The fractions were further 
analyzed for the presence of SDS according to the European Pharmacopoeia. Therefore, 
0.1 ml of the fraction was mixed with 0.1 ml 0.1% methylene blue solution and 2.0 ml 
diluted H2SO4 (5.5 ml concentrated H2SO4 in 100 ml H2O). The aqueous solution was 
shaken out with 2.0 ml dichloromethane (DCM), whereby the ionic pair of methylene blue 
(Sigma, Steinheim, Germany) and SDS colored the DCM-phase blue. The samples were 
evaluated visually by means of reference solutions with known SDS contents. SDS from 
Merck (Hohenbrunn, Germany) was used for the reference solutions. After the buffer 
exchange with Sephadex-G25 column, the cytokine was intermediately formulated in 
10 mM NaOH at pH 12. A concentrated stock solution of the particular buffer (200 mM) 
was added to the formulations and the pH was instantly adjusted with HCl.  
As excipients for formulation development sucrose from Suedzucker (Mannheim, 
Germany), mannitol from Caelo (Hilden, Germany), polysorbate 20 from Serva 
(Heidelberg, Germany) and glycine and NaCl from Sigma (Steinheim, Germany) were 
employed without further purification. 
 
 
Development of Stable, HSA-free Formulations for a Hydrophobic Cytokine 
   
 
119 
2.1.2 Containers 
2 R glass vials were a donation of Schott AG (Mainz, Germany). Two qualities of glass 
were employed, standard borosilicate glass type I and SCHOTT type I plus®, which are 
based on standard type I glass. An additional layer of 0.1 to 0.2 µm of SiO2 is coated 
onto the inner surface using the Plasma Impulse Chemical Vapor Deposition (PICVD) 
process. The vials were closed with unsiliconized butyl-lyophilization stoppers (Firma 
West, Eschweiler, Germany). BD Hypak SCFTM glass prefilled 1 ml syringes were a 
donation of Becton Dickinson GmbH (Heidelberg, Germany). The prefilled syringes were 
used for the stability study of the liquid cytokine formulation. For the stability study 
1.0 ml of the particular formulation was filled into the syringe barrel and subsequently 
the plunger, consisting of a stopper and a rod, was attached to the barrel from the back.  
 
2.2  Methods 
2.2.1 Turbiditimetry 
The NEPHLA turbidimeter (Dr. Lange, Düsseldorf, Germany) was used for turbidity 
measurements. The principle of turbidity measurement is 90° scattered light photometry. 
Light (λ=860 nm) is sent through the samples and the scattered light is measured at 90° 
angle. The system is calibrated with formazine as standard and the results are given in 
formazine nephelometric units (FNU). To evaluate the degree of turbidity the reference 
solutions I-IV of the European Pharmacopoeia method 2.2.1 (clarity and degree of 
opalescence of liquids) were used [13]. A stock solution was prepared by mixing 
hydrazine sulfate (10 mg/ml) and hexamethylenetetramine (100 mg/ml) at a ratio of 
1:1. After 24 hours the stock solution was diluted with water to concentrations of 
0.075 mg/ml hydrazine sulfate and 0.75 mg/ml hexamethylenetetramine (both from 
Sigma-Aldrich, Steinheim, Germany). The reference solutions were prepared with the 
diluted solution according to Table 1 and the turbidity in FNU was measured.  
 
Table 1: Composition of the opalescence reference solutions and turbidity. 
 
reference 
solution 
diluted stock 
solution [ml] 
water R 
[ml] 
turbidity 
[FNU] 
degree of  
opalescence 
I 5 95 3.2 clear (≤ Ref I) 
II 10 90 6.1 slightly opalescent (≤ Ref II) 
III 30 70 17.8 opalescent (≤ Ref III) 
IV 50 50 29.4 very opalescent (≤ Ref IV) 
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The method is not specific for proteins and therefore sample preparation is very 
important. To avoid disturbance by dust, all used buffer solutions were filtered (0.45 µm 
PES membrane). Further, the samples were degassed for about 20 seconds in an 
ultrasonic bath prior to the measurement.  
 
2.2.2 UV-Spectroscopy 
To determine the degree of protein adsorption, the protein content in the samples was 
determined with UV-spectroscopy using the Thermo Spectronic UV 1 from Thermo 
Electron Cooperatrion (Dreieich, Germany). The UV-absorption was measured at 
λ=280 nm. The protein content calculated using a molar extinction coefficient of 1.7. 
 
2.2.3 High Pressure Size Exclusion Chromatography (HP-SEC) 
Protein aggregation was determined by HP-SEC on a HP 1100 (Agilent Technologies, 
Waldbronn, Germany). A TSKgel G3000SWxl column (Tosoh Biosep, Stuttgart, Germany) 
with an adequate guard column was used. The running buffer was composed of 175 mM 
NaH2PO4 and 0.1% SDS with a pH adjusted to 6.8. The analytics were performed at a 
flow rate of 0.5 ml/min with UV-detection at 210 nm. The chromatograms were 
integrated manually with ChemStation (Agilent Technologies, Waldbronn, Germany) 
exemplarily shown in Figure 1 
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Figure 1: Example for integration of a HP-SEC chromatogram of 0.25 mg/ml cytokine. 
 
Aggregation in % was determined by comparing the area under the curve (AUC) of 
dimers and lower aggregates with the AUC of the monomer peak. Further changes in the 
AUC over the storage time were considered. 
 
glycine 
cytokine monomer 
aggregates 
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2.2.4 Reversed Phase High Pressure Liquid Chromatography (RP-HPLC) 
With RP-HPLC oxidation of methionine can be detected. RP-HPLC was performed 
according to Geigert et al. (1988) [14], using a Jupiter C4 column with 300 Å 5 µm 
250*4.6 mm i.d. and a security guard C4, 4*3 mm (Phenomenex, Aschaffenburg, 
Germany), which was kept at 30°C for the analytics. A flow-rate of 1.0 ml/min was used 
and UV-detection at 214 nm. An elution gradient (Figure 2) was applied, using 10% 
acetonitrile (ACN) with 0.1% trifluoroacetic acid (TFA) and 100% acetonitrile with 0.1% 
trifluoroacetic acid (TFA) as eluents. The chromatograms were manually integrated with 
ChemStation (Agilent Technolgies, Waldbronn, Germany). 
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Figure 2: Elution gradient used for the RP-HPLC analytics. 
 
2.2.5 Dynamic Light Scattering (DLS) 
DLS performed on a Zetasizer Nano (Malvern, Herrenberg, Germany) was used to 
characterize the protein molecules and particles in the range from 1 nm to 1 µm. The 
Zetasizer Nano is operating with a 4 mW He-Ne-Laser at 633 nm and non invasive back-
scatter technique (NIBS) at a constant temperature of 25°C. The measurements were 
conducted in the manual mode using 20 sub runs of 10 seconds. The size distribution by 
intensity and volume was calculated from the correlation function using the multiple 
narrow mode of the Dispersion Technology Software version 4.00 (Malvern, Herrenberg, 
Germany). Thereby, the resulting size distributions show the hydrodynamic diameter. 
The multiple narrow mode is an algorithm based on the non-negative least square 
method that deconvolutes the particle size distribution form the measured correlogram. 
To avoid a misinterpretation of signals deriving from noise a regulating parameter, the 
alpha-parameter defining the degree of smoothness in the distribution results is included 
in the NNLS algorithm. The alpha-parameter that represents the degree of noise in the 
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measured correlogram was set to 0.001 for the multiple narrow mode. To study the 
impact of temperature on changes of the protein, DLS was performed at a temperature 
profile from 20 to 75°C using steps of 2°C. At each temperature the samples were 
allowed to equilibrate for 2 minutes before the measurement consisting of 20 sub runs of 
10 seconds.  
 
2.2.6 Attenuated Total Reflection-FTIR Spectroscopy (ATR-FTIR) 
FTIR-spectra were measured with the Tensor 27 (Bruker Optics, Ettlingen, Germany) 
using the Bio-ATR unit and the transmission cell. The spectra were recorded from 
wavenumbers of 4000 to 850 cm-1 in the attenuated total reflectance (ATR) mode, 
respectively transmission mode at controlled temperatures. Each measurement was the 
average of 240 scans. After the analysis, the particular buffer spectrum was manually 
subtracted from the protein spectrum. The absorption spectra were further processed by 
an off-set correction and the second derivatives additionally by vector normalization. In 
the spectra the amide I band, deriving from C=O stretching vibrations is located at 
wavenumbers from 1700 to 1600 cm-1. Hydrogen bonding influences the amide I and 
therefore changes in the secondary structure of the protein are reflected in the amide I 
band [15]. At wavenumbers from 1600 to 1500 cm-1 the amide II band, deriving from  
N-H and C-N bending vibrations is found. In the second derivatives of the absorption 
spectra, the band components under the amide I and II band can be resolved. The 
structural similarity between the second derivatives of the spectra was calculated using 
the spectral correlation coefficient r [16,17]. The spectral correlation coefficient was 
calculated according to equation (1). 
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In the equation, xi and yi are the corresponding peak intensities of various wave numbers 
i (second derivative of amide band I from 1700 to 1600 cm-1) in reference (x) and 
sample spectra (y). x* and y* are the average intensities of reference and sample 
spectra from 1700 to 1600 cm-1. To evaluate changes in the secondary structure with 
increasing temperatures, ramps from 20 to 90°C using 5°C steps were applied. At each 
temperature the sample was allowed to equilibrate for 120 seconds before the 
measurement. 
 
 (1) 
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2.2.7 Microcalorimetry 
Microcalorimetry was performed with a VP-DSC (MicroCal®, Milton Keynes, United 
Kingdom). All solutions with a protein concentration of 1 mg/ml were degassed for 
5 minutes prior to the measurement. The scans were recorded from 20 to 90°C at a 
scanning rate of 1.0°C/min. Each measurement consisted of three scans: water against 
water, buffer against buffer and protein against buffer scan. The buffer scan was 
subtracted from the protein scan by the Origin® software.  
 
2.2.8 Lyophilization  
1000 µl of the formulations were dried in 2 R vials in the Epsilon 2-12 D freeze-drier from 
Christ (Osterrode, Germany). The samples were frozen to -50°C with a standard cooling 
rate of 0.45°C/min and kept at -50°C for 2 hours. Primary drying was conducted at a 
shelf-temperature of -15°C with a pressure of 0.045 mbar for 20 hours. For secondary 
drying the shelf-temperature was increased to 40°C for 10 hours. The vials were closed 
under N2 atmosphere at a pressure of 800 mbar. 
 
2.2.9 Powder X-ray Diffraction (XRD) 
The morphology of the lyophilized products was analyzed with X-ray powder diffraction 
(XRD) from 5-40° 2-Θ, with steps of 0.05° 2-Θ and a duration of 2 seconds per step on 
the X-ray diffractometer XRD 3000 TT (Seifert, Ahrenburg, Germany), equipped with a 
copper anode (40 kV, 30 mA, wavelength 154.17 pm). 
 
2.2.10 Karl-Fischer Titration 
The residual moisture of the samples was analyzed by coloumetric Karl-Fischer titration 
using the Aqua 40.00 titrator with a headspace module (Analytik Jena AG, Halle, 
Germany). The headspace method was validated against conventional Karl-Fischer 
titration, where anhydrous methanol was used to extract water from the lyophilized 
products. For the measurement at least 10 mg of the lyophilized sample was heated to 
80°C for 10 minutes. The evaporated water was transferred into the titration solution and 
the amount of H2O was determined. As reference material apura Water Standard Oven 
1% (Merck, Darmstadt Germany) was used.  
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3. Results and Discussion 
3.1 Impact of pH and Ionic Strength on Cytokine Aggregation 
3.1.1 Turbidity and HP-SEC Studies 
The selection of the optimum buffer composition and formulation pH is a prerequisite for 
the subsequent formulation development. According to literature a low pH combined with 
a low ionic strength is beneficial for the stability and the solubility of the used cytokine 
[18]. Thereby, glycine is suggested as appropriate buffering substance [18]. Based on 
this information the cytokine was formulated in 20 mM glycine at pH 3.0 as starting 
material for further studies. To investigate the impact of ionic strength and buffer 
concentration, glycine and NaCl concentrations were varied at a constant cytokine 
concentration of 0.25 mg/ml. The formulation pH was step-wise increased by adding 
NaOH and the corresponding turbidity was monitored from pH 3.0 to pH 9.0 (Figure 3).  
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Figure 3: Turbidity of 0.25 mg/ml cytokine with 5 to 50 mM glycine (a) and with 20 mM glycine and 
0.0% to 0.2% NaCl (b) form pH 3.0 to 9.0. 
 
From 5 to 20 mM glycine turbidity ranged from 1 to 3 FNU at a pH between 3.0 and 5.0. 
The solutions were less turbid than reference solution I (3.2 FNU) of the European 
Pharmacopoeia and the degree of opalescence could be evaluated as clear. At these 
conditions the cytokine exhibited an adequate good solubility. A precipitation of the 
cytokine, noticeable by a steep increase in turbidity was measured when the pH was 
raised above 5.5 for all studied formulations. The turbidity increase could be ascribed to 
the declining solubility of the cytokine, as the pH approached the protein pI. A pI of 9.2 
(a) (b) 
Development of Stable, HSA-free Formulations for a Hydrophobic Cytokine 
   
 
125 
was determined with isoelectric focusing for the cytokine by Hershen et al. (1989) [19]. 
At its isoelectric point a protein exhibits a net charge of zero and with it its lowest 
solubility in aqueous media [20]. With increasing glycine concentrations the onset of the 
turbidity increase was shifted to lower pH values and maximum values above 150 FNU 
were measured. While samples with 5 to 20 mM glycine reached maximum turbidity 
values between 100 and 150 FNU at pH 9.0, maximum values of 200 FNU were 
measured at 50 mM glycine (Figure 3a). A similar effect was achieved when adding 0.1% 
(17 mM) and 0.2% (34 mM) NaCl to formulations containing 20 mM glycine. Here 
maximum turbidities of about 180 FNU were reached when 0.2% NaCl was added to the 
formulation (Figure 3b). With increasing NaCl concentrations in the formulations the 
onset for the turbidity increase was also shifted to lower pH-values. Turbidity was 
exceeding 3.2 FNU at approximately pH 4.5 for 0.0% to 0.2% NaCl, whereas it exceeded 
3.2 FNU already at pH 3.6 for 0.9% NaCl (data not shown). However, the addition of 
NaCl had less impact on the turbidity increase compared to the addition of glycine. The 
effect of glycine can be partially attributed to its buffering effect. To increase the pH in 
presence of glycine, which has a pKa of 2.4 [21], more NaOH was required to increase 
the pH. For formulation development it is important to note that the low pH range from 
3.0 to 4.5 was appropriate due to low turbidity values.  
Turbidity measurement detects larger protein aggregates, and all kind of particles in the 
formulations. To specify the formation of aggregates HP-SEC was employed to determine 
dimers and lower aggregates in formulations with 20 mM glycine from pH 3.0 to pH 6.0 
(Figure 4).  
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Figure 4: Turbidity and aggregation determined by HP-SEC and of 0.25 mg/ml cytokine formulated 
in 20 mM glycine between pH 3.0 and 6.3. 
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The starting material at pH 3.0 already contained about 3.5% aggregates, which 
probably can be assigned to the complex preparation method of the SDS-free bulk 
material which was described in point 2.1 of this chapter. However, no reference values 
concerning dimers and small aggregates in the HSA-containing formulation were 
available. Due to the 50-fold excess of HSA in the formulation it was not possible to 
separate the cytokine and its aggregated species from HSA by HP-SEC. In the HSA-free 
formulation, aggregation ranged from 3.6% to 4.4% between pH 3.0 and 5.5. Above 
pH 5.5 the area of the peaks of aggregated protein relative to area of the monomer peak 
significantly stepped up to 6.0%. The presence of larger aggregates, indicated by the 
high turbidity values above pH 5.5 was reflected in a substantial decrease of the total 
AUC of monomer and aggregates in the HP-SEC chromatograms. Larger aggregates, as 
well as precipitated protein were retained by the guard column and therefore not 
detected, but reflected in the decline of the AUC. Thus, HP-SEC revealed that the 
turbidity increase was associated with an aggregation of the cytokine at increasing pH 
values. For the formulations at pH 3.0 and pH 4.5 the aggregate content in presence of 
0.2%, 0.5% and 0.9% NaCl was determined by HP-SEC. HP-SEC indicated an average 
increase in aggregates by 0.4% in samples with 0.0% to 0.9% NaCl when the pH was 
changed from pH 3.0 to 4.5 (Figure 5).  
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Figure 5: Aggregation determined by HP-SEC of 0.25 mg/ml cytokine in 20 mM glycine with 0.0% to 
0.9% NaCl at pH 3.0 and 4.5. 
 
For the samples with 0.9% NaCl, particularly at pH 4.5 the AUC of the chromatograms 
was slightly decreased. Here again precipitation of the cytokine occurred and was 
confirmed by the increased turbidity of about 20 FNU. To further clarify the impact of 
NaCl on cytokine formulations short-time stability studies are necessary, because a 
possible detrimental effect of an increased ionic strength can be amplified during storage.  
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The studies revealed a correlation between turbidity and formulation pH, respectively 
ionic strength. Thus, for formulation development the pH range from 3.0 to 4.5 appeared 
to be suitable, with lower glycine and NaCl concentrations being beneficial. Within the pH 
range from 3.0 to 4.5 no significant increase in aggregation was monitored at 5 to 20 mM 
glycine. However, the impact of pH and ionic strength on the cytokine needs to be 
studied in more detail with respect to structural changes during storage.  
 
3.1.2 Dynamic Light Scattering (DLS) 
Various methods are available to monitor protein aggregation e.g. HP-SEC, SDS-PAGE, 
turbiditimetry, DLS or light obscuration. Thereby, each method is appropriate to detect 
certain species of aggregates. While dimers, trimers and oligomeric aggregates can be 
analyzed by HP-SEC, DLS covers the size range from 1 nm to 1 µm and light obscuration 
detects particles larger than 1 µm. To gain comprehensive insight into aggregation within 
a particular formulation the use of more than one technique is obligatory. Mahler et al. 
(2005) showed that DLS, turbiditimetry and light obscuration were capable to detect 
different types of aggregates in monoclonal IgG1 antibody formulations upon mechanical 
stress in relation to surfactant concentration [22].  
Aggregation of the cytokine was monitored with DLS as additional technique besides the 
already described HP-SEC and turbidity measurement. Thereby, changes in the size 
distribution by volume from pH 3.0 to 4.5 were studied for formulations with 0.25 mg/ml 
cytokine in 20 mM (Figure 6a). The cytokine monomers were reflected in the size 
distribution by volume in the main peak at a diameter of 5.1 nm. In comparison, for ß-
Lactoglobulin, a protein of 18.5 kDa the monomer peak was located at a diameter of 
5.4 nm [23]. The second peak with a maximum at 13.5 nm could be assigned to 
aggregated protein [24]. A well-defined separation of monomers and dimers is generally 
not possible with DLS as the size resolution of the method is too low. The radii of 
particles have to differ by a factor higher than 2, the mass respectively by a factor of 8 in 
order to be resolved as two peaks [25]. However, the change of the size distribution can 
be used to evaluate the state of the cytokine at different conditions like pH or ionic 
strength. When the pH was raised from 3.0 to 4.5, the intensity of the peak at 13.5 nm 
increased linearly from 1.0% at pH 3.0 to 4.0% at pH 4.5 (Figure 6b). Similarly, HP-SEC 
pointed at a linearly increasing aggregation in the cytokine formulations from pH 3.0 to 
4.5. Turbidity measurement showed that the formulations from pH 3.0 to pH 4.5 were all 
clear with turbidities below 3.2 FNU (data not shown). 
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Figure 6: DLS size distribution by volume of 0.25 mg/ml cytokine in 20 mM glycine (a) and 
maximum intensity at 13.5 nm and aggregation determined by HP-SEC (b) for pH 3.0 to 4.5. 
 
To evaluate how aggregation determined with HP-SEC was reflected in the size 
distribution by volume, cytokine samples with 0.9% to 13% aggregates were analyzed 
with DLS. Therefore, stressed (13% aggregates) and unstressed (0.9% aggregates) 
SDS-containing bulk material was mixed, DLS performed and aggregation determined 
with HP-SEC. Turbiditimetry revealed that all used solutions were clear with a turbidity 
less than reference solution I. Before using the SDS-containing material, the size 
distribution by volume was compared with that of the cytokine formulated in glycine 
(Figure 7).  
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Figure 7: Size distribution by volume of SDS-bulk (1.7 mg/ml cytokine) with 0.9% and 13% 
aggregates and glycine bulk (0.25 mg/ml cytokine) with 3.5% aggregates. 
 
The unstressed SDS-containing bulk material with 0.9% aggregates and the glycine bulk 
with 3.5% aggregates resulted in equal size-distributions in the DLS-measurements, only 
(a) (b) 
maximum intensity 13.5 nm 
aggregation HP-SEC 
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differing in the intensity at 15 nm. In the size-distribution of the stressed SDS-containing 
bulk material (13% aggregates) the first peak was no longer present and the intensity at 
15 nm increased significantly from 0.0% to 23.2%. 
For the studied formulations DLS determined higher intensities between 10 and 30 nm 
when more aggregates were determined by HP-SEC. Figure 8 shows that the maximum 
intensity between 10 and 30 nm was rising with increasing aggregation values present in 
the formulation. At the same time the cumulative intensity from 0 to 8.7 nm dropped 
with more aggregates in the sample. A disappearance of the first peak in the DLS 
chromatogram was observed, when aggregation exceeded 7.5%. 
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Figure 8: Maximum intensity between 10 and 30 nm and cumulative intensity from 0 to 8.7 nm in 
relation to aggregation (HP-SEC) for 1.7 mg/ml cytokine in SDS. 
 
The data revealed that changes in aggregation determined with HP-SEC were reflected in 
the DLS size-distribution by volume. Contrary to HP-SEC, DLS measurements offered the 
advantage of performing the analytics of formulations in their native state. More 
precisely, larger turbidity-inducing aggregates, which were retained by the guard column 
during HP-SEC, were detected by DLS. The formulations studied by DLS were all clear 
with turbidity values below 3.2 FNU. Turbid samples of the HSA-containing cytokine 
formulations resulted in a peak at hydrodynamic radii of 50 to 70 nm and at 500 to 
1500 nm (compare Chapter 2, section 3.1.4). Mahler et al. (2005) also showed that 
turbidity is often induced by medium-sized protein aggregates and as well that turbidity 
could be correlated with particle sizes of 1 and 2 µm determined by light obscuration 
[22]. Generally, DLS appeared to be a sensitive tool for formulation development, 
detecting subtle changes of protein monomers, as well as dimers and turbidity inducing 
aggregates. Based on these results, DLS was selected as analytical method for the 
stability studies.  
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3.2 Temperature Induced Changes of the Cytokine 
Microcalorimetry is typically used to determine the melting temperature (Tm) of proteins. 
In the Differential Scanning Calorimentry (DSC) measurement the heat capacity of a 
protein solution is measured as function of temperature [26]. With increasing 
temperature, proteins begin to loose their native confirmation and undergo unfolding, 
which is reflected by an endothermic transition in the DSC chromatograms [27]. The 
midpoint of the denaturation transition is defined as melting temperature or denaturation 
temperature [26]. This can be used to predict protein stability at different formulation 
conditions e.g. pH or excipients. A decreasing Tm is often correlated with an inferior 
thermal stability, which was for example shown by Remmele et al. (1998) for 
Interleukin-1 Receptor upon the addition of different preservatives [28]. However, an 
exception from this case is for example the lowering of Tm by PEG, although PEG is 
known to increase the stability of formulations at room temperature [29]. 
The DSC-scans of 1.0 mg/ml cytokine in 20 mM glycine at pH 3.0 and 5.0 are shown in 
Figure 9. At pH 3.0 no clear transition was detected. At pH 5.0 an exothermic shift of the 
baseline starting at approximately 57°C was found which could be attributed to 
aggregation occurring at higher temperatures [26].  
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Figure 9: DSC-scan (protein scan minus buffer scan) of 1.0 mg/ml cytokine in 20 mM glycine at pH 
3.0 and pH 5.0 from 20 to 100°C at 1.0°C/min. 
 
Thus, microcalorimetry was not suitable to determine the melting temperature of the 
cytokine between pH 3.0 and 5.0, which would be important for formulation 
development. Therefore, the use of FTIR and DLS as alternative methods to determine 
the denaturation temperature for the cytokine was evaluated.  
 
Development of Stable, HSA-free Formulations for a Hydrophobic Cytokine 
   
 
131 
3.2.1 FTIR-Studies 
FTIR-spectroscopy is an important tool to analyze the secondary structure of a protein. 
Changes in the secondary structure and the strength of the respective hydrogen bonding 
are reflected in the position and intensity of the C=O stretching vibrations located 
between wavenumbers of 1700 and 1600 cm-1 and the N-H and C-N bending vibrations 
located between 1600 and 1500 cm-1. Therefore, structural changes of a protein e.g. 
induced by increased temperature result in changed FTIR spectra [15]. FTIR 
spectroscopy can be performed in transmission and in attenuated total reflection (ATR) 
mode. In the transmission mode the IR-beam passes the sample cell and measures the 
solution properties over the whole path lengths. Only clear solutions can be analyzed in 
the transmission cell applied for the study, as precipitating material can damage the cell. 
Furthermore, light scattering effects in the transmission cell can interfere with the 
analytics. In the ATR mode the IR-beam is reflected within the crystal and only protein in 
close contact to the crystal surface is analyzed. Thereby, the penetration depth of the IR-
beam depends on sample properties. The advantage of the ATR mode lies in the 
possibility to analyze turbid solutions and suspensions as well [30]. However, care must 
be taken, when proteins susceptible to adsorption are analyzed.  
For the FTIR-studies higher concentrated solutions containing 1.2 mg/ml cytokine were 
applied to achieve a better reproducibility. In order to evaluate the impact of adsorption 
on the measurements, solutions with 1.2 mg/ml cytokine at pH 3.0 and 5.0 were 
measured both in ATR and transmission mode (Figure 10).  
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Figure 10: Comparison of spectra measured in ATR and transmission mode for 1.2 mg/ml cytokine 
at pH 3.0 (a) and pH 5.0 (b).  
 
In the transmission mode the intensities of the absorption spectra at pH 3.0 and pH 5.0 
were comparable, whereas a 5-fold higher intensity was measured at pH 5.0 compared to 
pH 3.0, when using the ATR-mode. This outcome supported the assumption that 
(a) (b) 
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adsorption is more pronounced at higher pH values, which is further discussed in section 
3.3 of this chapter. ATR-FTIR was used to detect changes in the secondary structure of 
the cytokine with increasing temperature. Therefore, temperature was increased from 20 
to 90°C and spectral changes were monitored for formulations with 1.2 mg/ml cytokine 
in 20 mM glycine between pH 3.0 and 5.5. The spectral intensities were increasing with 
the pH, indicating that protein adsorption was more pronounced at pH 5.5 compared to 
the lower pH values. At 20°C the absorption spectra at pH 3.0 and pH 3.5 exhibited a 
distinct peak at 1619 cm-1 in the amide I region. In contrast only a shoulder was present 
at pH 4.2 and 5.5 (Figure 11a). In the second derivatives a better resolution of the bands 
was achieved (Figure 11b). The band at 1619 cm-1 could be assigned to β-sheet 
structures, while the band at 1653 cm-1 derived from α-helical structures [31,32].  
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Figure 11: ATR-FTIR absorption spectra (a) and vector-normalized second derivatives (b) of 
1.2 mg/ml cytokine in 20 mM glycine at pH 3.0 to 5.5. 
 
When the pH was changed from 3.0 to 5.5 the intensity at 1619 cm-1 (β-sheet) was 
decreasing, while an increased intensity at 1653 cm-1 (α-helix) was measured. According 
to literature, an increased intensity at 1620 cm-1 can be attributed to the formation of 
intermolecular β-sheets within aggregated protein molecules [33]. Meersman et al. 
(2002) determined a rising band at 1618 cm-1, when myoglobin aggregated at elevated 
temperatures [34]. An increase in intensity at 1615 and 1685 cm-1 for BSA [35], at 
1620 cm-1 for HSA [16] and at 1614 and 1685 cm-1 for Interferon-γ [36] was detected 
when intermolecular ß-sheets were formed due to the aggregation process.  
However, for the cytokine HP-SEC revealed a higher degree in aggregation with 4.5% at 
pH 5.5, compared only 3.5% aggregates at pH 3.0. This indicated that the increase of 
the intensity at 1619 cm-1 was not solely deriving from intermolecular aggregation. Fan 
et al. (2005) demonstrated structural changes as a function of pH, by a changed CD 
spectrum below pH 4.0 for a glycosilated form of the cytokine. Below pH 4.0 the 
pH 5.5 
pH 3.0 
pH 5.5 
pH 3.0 
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glycosilated cytokine exhibited a larger amount of soluble micro-aggregates and showed 
an improved stability resulting in a lower degree of precipitation when the temperature 
was increased [37]. This changed structure below pH 4.0 could be an indication for the 
increased intensity at 1619 cm-1 for the cytokine at pH 3.0. On the other hand, when 
comparing transmission and ATR spectra at pH 3.0 it became evident that the band 
intensity at 1619 cm-1 was less pronounced in the transmission mode, indicating that 
adsorbed material in the ATR-mode could be responsible for this effect.  
Figure 12 shows the unprocessed absorption spectra of formulations containing 
1.2 mg/ml cytokine in 20 mM glycine at a formulation pH between 3.0 and 5.5 heated 
from 20 to 90°C.  
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Figure 12: ATR-FTIR absorption spectra of 1.2 mg/ml cytokine in 20 mM glycine at pH 3.0 (a), 
pH 3.5 (b), pH 4.2 (c) and pH 5.5 (d). The arrows mark the changes when the temperature is 
increased from 20 to 90°C. 
 
Generally, the intensity of the adsorption spectra increases with temperature, due to 
precipitation caused by the denaturation [38]. However, at pH 3.0 and 3.5 the intensity 
of the spectra decreased when the temperature was ramped up (Figure 12a,b). This 
indicated the lack of precipitation during the measurement, which was supported by the 
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fact that visual inspection showed clear solutions after the measurement. The cytokine, 
with its substantial hydrophobicity tends to adsorb on surfaces. Adsorption per se can be 
measured with ATR-FTIR, which was described for human calcitonin by Bauer et al. 
(1994), who found that the intensity of the amide I band increased by a factor of 3.4 due 
to adsorption [39]. The tendency of the cytokine to adsorb was pH-dependent and more 
distinct at pH 4.5 than at pH 3.0 (compare 3.3). A possible explanation for the decrease 
in spectral intensity at pH 3.0 and 3.5 is the removal of adsorbed protein from the ATR-
crystal at rising temperatures. This hypothesis can be further supported by the basic 
principles of adsorption, considering the adsorption rate constant Kads, shown in 
equation (2) [40].  
 
logKads= (∆H/2.303 R)*1/T + C   (2) 
 
Kads is reciprocally proportional to temperature T, with H as enthalpy, R as the universal 
gas constant and C as the concentration, indicating a declining strength of adsorption 
with increasing temperatures.  
At pH 3.5 the intensity of the spectra decreased at higher temperatures. Thereby, the 
intensity at 1619 cm-1 was decreasing less than at 1653 cm-1, pointing at the formation 
of new ß-sheet structures, potentially due to aggregation. At pH 4.2 the intensity in the 
adsorption spectra was increasing at 1619 cm-1, while only a slight reduction of overall 
intensity was measured in the areas of the amide I and amide II band. At pH 5.5 the 
intensity of the spectra raised with temperature, demonstrating that protein was 
precipitating, which was confirmed by the turbid nature of the solutions after the 
measurement.  
The vector-normalized second derivatives, shown in Figure 13 offered a deconvolution of 
the spectra and the possibility to itemize changes in the different structural components 
underlying the amide I and II bands.  
Overall, at pH 3.0 the spectra of the cytokine were relatively stable, with only a slight 
intensity increase at 1619 cm-1 respectively decline at 1653 and 1548 cm-1 suggesting a 
good thermal stability of the secondary structure of the cytokine. The spectral changes 
were more pronounced at increasing pH-values, which was already obvious in the 
absorption spectra. The evaluation of the second derivatives revealed that at higher pH-
values the loss of α-helical structure and the formation ß-sheet were more pronounced. 
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Figure 13: ATR-FTIR vector-normalized second derivatives of 1.2 mg/ml cytokine in 20 M glycine at 
pH 3.0 (a), 3.5 (b), 4.2 (c) and 5.5 (d). The arrows mark the changes with increasing the 
temperature from 20 to 90°C. 
 
Different methods are possible to evaluate spectral changes and determine the 
denaturation temperature at varying conditions e.g. increasing temperatures by FTIR 
[41]. One possible approach is plotting the intensities of the α-helical, respectively ß-
sheet bands over the changing temperature. This was described by Meersman et al. 
(2002) for Myoglobin using the bands at 1624 and 1560 cm-1 and by Dong et al. (1997) 
for Factor XIII using the bands at 1641 and 1626 cm-1 [34,42]. For the cytokine the 
bands of 1619 and 1653 cm-1 were monitored over the temperature range of 20 to 90°C 
(Figure 14).  
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Figure 14: Intensity at 1653 cm-1 (       ) and at 1619 cm-1 (         ) at pH 3.0 (a), pH 3.5 (b), pH 4.2 
(c) and pH 5.5 (d) in the temperature range from 20 to 90°C. 
 
At pH 3.0 and 3.5 the initial intensities of the α-helical band at 1653 cm-1 and the 
ß-sheet band at 1619 cm-1 were similar. A continuous, almost linear intensity decrease at 
1653 cm-1, respectively intensity increase at 1619 cm-1 over the temperature range was 
monitored. Thereby, the absolute value of the slope was greater at pH 3.5 than at 
pH 3.0, pointing at a higher structural stability at pH 3.0. At pH 4.2 and pH 5.5 a higher 
initial intensity was measured at 1653 cm-1 compared to 1619 cm-1. After a linear phase 
from 20 to 40°C the shape of the curve changed to sigmoid with a clear inflection point. 
This revealed a higher degree of structural alternation during the temperature increase at 
pH 4.2 and 5.5 compared to pH 3.0 and 3.5. At pH 3.0 and 3.5 the spectral change 
already started at 25°C and progressed in a linear way.  
Wang et al. (2003, 2005) used a spectral correlation coefficient to show the similarity 
between spectra [16,17]. According to their method, the spectral correlation coefficient r 
was calculated for the amide I using the wavenumbers from 1700 to 1600 cm-1 (compare 
2.8). The second derivatives of the spectra at 20°C were set as reference spectra and the 
spectra at higher temperatures as sample spectra. Furthermore, the ratio of the 
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intensities at 1619 and 1653 cm-1, comparable to Goosens et al. (2003) [36] were 
plotted over the temperature range between 20 to 90°C and compared to the spectral 
correlation coefficient (Figure 15).  
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Figure 15: Spectral correlation coefficient (    ) and intensity ratio of 1619 cm-1 to 1653 cm-1  
(         ) at pH 3.0 (a), 3.5 (b), 4.2 (c) and 5.5 (d) in the temperature range from 20 to 90°C. 
 
At pH 3.0 both the intensity ratio and the spectral correlation coefficient showed a linear 
change in intensities. Here, the alternations were obvious already at temperatures above 
25°C. First at pH 3.5 it was possible to detect an inflection point for the intensity ratio 
offering a value of 74°C as denaturation temperature. For pH 4.2 and pH 5.5 on the 
other hand constant spectral correlation coefficients, respectively intensity ratios were 
existent from 20 to 45°C, which is relevant for the storage of the formulations. For the 
higher pH-values the spectral correlation coefficient and the intensity ratio began to 
change at temperatures above 40 to 45°C.  
For the cytokine the denaturation temperatures calculated from the intensities at 1619 
and 1653 cm-1, respectively the intensity ratio and the spectral correlation coefficient r 
are compared in Table 2.  
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Table 2: Denaturation temperatures (Tm) of the formulations determined from the ATR-FTIR 
spectra. 
 
 
 
intensity 
1619cm-1 
intensity 
1653cm-1 
ratio 
1619cm-1/1653cm-1 
Spectral correlation 
coefficient r 
Tm 
(average) 
pH 3.0 - - - -  
pH 3.5 - - 74°C - 74°C 
pH 4.2 53°C 60°C 55°C 60°C 57°C 
pH 5.5 50°C 47.5°C 50°C 50°C 49°C 
 
 
At pH 3.0 it was not possible to determine an accurately defined transition temperature 
with the four different approaches. The spectra changed already above 25°C. Especially 
the spectral correlation coefficient and the intensity ratio revealed a linear change with 
increasing temperatures. At pH 3.5 only the intensity ratio of 1619 to 1653 cm-1 offered a 
value of 74°C for Tm. The structural changes with increasing temperatures were still not 
pronounced enough to get results from the other methods. The transition temperature 
was shifted from of 57°C at pH 4.2 to 49°C at pH 5.5, indicating a decreased thermal 
stability. 
Besides the evaluation of changes at increasing temperature, the application of FTIR-
spectroscopy as tool to monitor structural changes of proteins upon storage is often 
found in literature. For example Kerwin et al. (1998) used FTIR spectroscopy to monitor 
the stability of recombinant haemoglobin upon long term storage at -20°C [43]. The 
application of FTIR as technique to monitor changes of the secondary structure of the 
cytokine was evaluated for a concentration of 1.0 mg/ml in 20 mM glycine at pH 4.0 
(Figure 16). After 2 weeks storage at 2-8°C and 40°C aggregation was determined with 
HP-SEC and secondary structure monitored with FTIR spectroscopy. Aggregation 
measured by HP-SEC increased from 4.0% before storage to 4.3% after 2 weeks at  
2-8°C respectively 12% at 40°C. In the FTIR spectra no significant changes were visible 
after 2 weeks at 2-8°C. Upon storage at 40°C on the other hand a second peak with a 
maximum at 1619 cm-1, deriving from intermolecular ß-sheet structures emerged. This 
experiment showed the ability of FTIR-spectroscopy to detect changes in the protein 
structure during storage, when using formulations with 1.0 mg/ml cytokine. As routine 
tool for the planned stability studies with 0.25 mg/ml cytokine on the other hand, FTIR 
was not suitable. The more complex formulations containing 0.25 mg/ml cytokine and 
further stabilizers (sugars, surfactants) showed only poor reproducibility of the spectra 
due to the low cytokine concentrations (data not shown). 
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Figure 16: Adsorption spectra (a) and second derivates (b) of 1.0 mg/ml cytokine in 20 mM glycine, 
pH 4.0 before storage (       ) and after 2 weeks 2-8°C (       ) and 40°C (        ). 
 
Summarizing, it can be stated that unlike microcalorimetry, FTIR-spectroscopy was 
capable to determine melting temperatures of the cytokine. At pH 3.0 and 3.5 a steady 
change in the spectrum was obvious starting already at 25°C. With increasing pH value 
the structural changes were more distinct and the melting temperature (average of all 
approaches) declined from 57°C at pH 4.2 to 49°C at pH 5.5. The melting temperature 
can be indicative for the stability of the protein during stability studies, especially at 25°C 
and 40°C storage. Therefore, higher pH values appear to be more critical regarding 
thermal stability of the protein during storage.  
 
3.2.2 Dynamic Light Scattering Studies 
Besides alternations in secondary structure, detectable by FTIR-spectroscopy, the size 
distribution of the cytokine molecules can as well change with temperature. These 
changes in size, induced by aggregation or precipitation might be reflected in DLS 
experiments. Therefore, DLS was applied to study the impact of an increasing 
temperature on the size distribution of 0.25 mg/ml cytokine formulated between pH 3.0 
and pH 4.6. At pH 3.0 the size distribution by volume did not significantly change up to 
70°C (Figure 17a). At 74°C the peak at 5 to 6 nm disappeared, whereas the second peak 
at 13.5 nm gained in intensity. For the formulation at pH 4.6 the enhanced formation of 
the second population with a maximum at 21 nm already occurred at 50°C (Figure 17b). 
This revealed the decreased thermal stability of the cytokine at higher pH values, which 
was already shown by FTIR-spectroscopy (compare 3.2.1). 
 
 
(a) (b) 
wavenumber [cm-1] wavenumber [cm-1] 
Chapter 6 
   
 
140 
 
       
1 10 100
size [nm]
       
1 10 100
size [nm]
   
12
14
16
18
20
22
24
20 30 40 50 60 70 80
temperature [°C]
Z
a
v
e
ra
g
e
 [
n
m
]
pH 4.0
pH 3.5
pH 3.0
10
15
20
25
30
35
40
20 30 40 50 60
temperature [°C]
Z
a
v
e
ra
g
e
 [
n
m
]
 
 
Figure 17: Size distribution by volume of 0.25 mg/ml cytokine in 20 mM glycine at pH 3.0 (a) and 
pH 4.6 (b) with increasing temperatures. Change in z-average of 0.25 mg/ml cytokine in 20 mM 
glycine at pH 3.0, 3.5 and 4.0 (c) and pH 4.6 (d) with increasing temperature. 
 
As a method to determine the melting temperature of a protein, the z-average can be 
plotted as function of the temperature [44]. The use of z-average as parameter for 
protein solutions needs to be considered as critical, as protein solutions generally show a 
multimodal distribution. Z-avarage as the medium intensity weighted average of the 
correlation function offers a value for the protein size in a formulation, which is not 
necessarily reflecting the genuine size. However, changes of z-average with temperature 
can be considered to visualize changes of a protein at different conditions e.g. 
formulation composition or temperature [24]. To make significant statements about the 
size of a protein, respectively its multimeric forms, the hydrodynamic radius or diameter 
can be considered. Petsev et al. (2000) determined a hydrodynamic diameter using 
CONTIN algorithm for Apoferritin monomers at 11.4 nm, for dimers at 17.1 nm and 
higher aggregate at 30.0 nm after separating the fractions with size exclusion 
chromatography [45]. For HSA, Lin et al. (2000) measured a hydrodynamic radius of 2 to 
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3 nm for the monomeric form and a fraction of aggregates at 30 to 40 nm [46]. In the 
temperature range from 20 to 50°C, respectively 60°C, the z-average of the cytokine 
formulations stayed relatively constant between 14 and 15 nm for pH 3.0 and 3.5 and 
between 16 and 17 nm at pH 4.0 respectively (Figure 17c). When rising the temperature 
further, a slight increase in z-average to 17 nm at pH 3.0 and 22 nm at pH 4.0 at 75°C 
was measured. Increasing the temperature for formulations at pH 4.6 led to a steady 
increase in z-average to 36 nm already at 56°C, reflecting the decreased thermal stability 
of the cytokine at higher pH values. A clear determination of transition temperatures was 
not possible for the studied pH-values. Overall, the DLS data confirmed the decreased 
thermal stability at higher pH values, which was already shown by FTIR. However, DLS 
offered no clear values for transition temperatures and was therefore not considered 
further as tool to characterize the thermal stability.  
 
3.3 Cytokine Adsorption to Vials 
As the hydrophobic cytokine used in low concentrations tends to adsorb on surfaces 
protein adsorption was evaluated prior to performing stability studies. Protein adsorption 
is a complex mechanism, consisting of several steps beginning with the transport of the 
protein towards the surface, followed by binding, a structural rearrangement of the 
adsorbed molecules and finally desorption from the surface [47]. Furthermore, the 
adsorption process is mainly driven by hydrophobic interactions and hydrogen bonding 
[40]. Thereby, numerous factors can impact the kinetics and the degree of adsorption of 
the particular protein on surfaces, e.g. protein concentration, temperature, pH, ionic 
strength and the presence of further excipients [47-49]. The selection of the container 
material can also impact the degree of protein adsorption [12].  
To circumvent the loss of cytokine due to adsorption an excess of HSA can be added to 
the formulation. As the use of HSA goes along with major drawbacks (compare 
Chapter 1) the goal was to replace HSA in the cytokine formulation and find ways to keep 
protein adsorption to a minimum. The goal was not to elucidate the adsorption 
mechanism of the cytokine, but to study the influence of various factors on the degree of 
adsorption and its importance for formulation development. In this initial studies, 1.0 ml 
of the different cytokine formulations at a concentration of 0.25 mg/ml were stored at  
2-8°C in the respective container and the loss of protein content was determined by UV-
spectroscopy. The focus was set on the impact of pH, container type and the addition of 
polysorbate 20 on the extent of adsorption.  
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3.3.1 Influence of pH, Glycine Concentration and Container Type on 
Cytokine Adsorption 
The degree of protein adsorption can be influenced by the formulation pH, as the net 
charge of the protein, as well as the secondary structure depends on pH. Electrostatic 
interactions contribute to the adsorption process and adsorption is favored when surface 
and protein exhibit opposed charge [47]. The pH of the formulations was varied from 3.0 
to 5.5 at a glycine concentration of 10 and 20 mM. As container materials 2 R vials (glass 
type I and I+) and containers made of polypropylene were evaluated.  
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Figure 18: Protein concentration for 0.25 mg/ml cytokine with 10 and 20 mM glycine at pH 3.0 
stored in glass type I and I+ vials for 72 h at 2-8°C. 
 
Figure 18 shows that the decline in protein concentration at pH 3.0 was less distinct at 
20 mM glycine than at 10 mM glycine. In glass type I+ the cytokine concentration 
declined to 97.2% at 20 mM and 90.8% at 10 mM glycine after 72 hours. About 3% more 
protein was lost on glass type I compared to glass type I+ for the same formulations. 
After 24 hours the adsorption process was almost completed. Therefore, the 
concentration after 24 hours was used as comparative value for the further experiments.  
Besides glass, polypropylene was evaluated for protein adsorption. Table 3 summarizes 
the protein recoveries after 24 hours at the different conditions. At 20 mM glycine the 
highest cytokine concentrations of 95.1% and 97.7% remained at pH 3.0 for glass type I 
and I+. Adsorption on polypropylene was unaffected by the pH of the solutions with a 
recovery of approximately 96% for pH 3.0 and 4.5.  
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Table 3: Protein concentration for 0.25 mg/ml cytokine using different formulation compositions 
and containers after 24 hours. 
 
 pH 3.0 pH 4.0 pH 4.5 
10 mM I 88.7 85.7 87.2 
10 mM I+ 91.2 92.9 95.6 
20 mM I 95.1 88.6 88.1 
20 mM I+ 97.7 94.6 92.1 
20 mM PP 96.4 - 96.1 
 
Various factors e.g. pH, ionic strength, container type or the addition of excipients can 
impact the degree of cytokine adsorption. More information about the charge density on 
the glass surface and the protein surface, as well as the degree of electrostatic 
interaction and hydrophobic interactions would be necessary to offer a precise 
explanation. Glass surfaces are typically negatively charged due to the dissociation of 
silanol groups in aqueous media. A positively charged glass surface is only achieved at 
very acidic pH below 2 [50]. In the pH range from 3.0 to 5.5 a slight increase of the 
negative charge on the glass surface can be assumed. The cytokine, with a pI at 9.2 [19] 
should tend to a slightly higher positive charge when the pH is lowered from 5.5 to 3.0. 
The same tendency of an increased positive net charge density at pH 3.0 can be 
assumed for glycine with its pI of 6.02 at 25°C [51]. Thus, a possible explanation for the 
decreased adsorption at higher glycine concentrations could be a competition of glycine 
and the cytokine for the negatively charged glass surface.  
For the development of stable cytokine formulations it is important that a higher glycine 
concentration was more favorable to avoid the loss of protein, best in combination with 
glass type I+. However, the loss of 15% protein after 24 hours especially in glass type I 
vials was unacceptably high. As HSA was to be eliminated from the formulation, the use 
of surfactants to reduce protein adsorption was evaluated next. 
 
3.3.2 Influence of Polysorbate 20 on Cytokine Adsorption 
The addition of surfactants is an effective approach to reduce and inhibit protein 
adsorption on surfaces. By adding polysorbate 20 the adsorption of albumin on silicon 
treated surfaces of different hydrophobicity was reduced by 15 to 90% depending on 
polysorbate 20 concentration and the hydrophobicity of the particular surface [52]. 
Surface active substances may also remove adsorbed protein from surfaces [53,54]. For 
the cytokine the use of polysorbate 20 to minimize protein adsorption was evaluated. 
Less protein was lost within 24 hours when polysorbate 20 was added to a formulation 
Chapter 6 
   
 
144 
with 0.25 mg/ml cytokine in 20mM glycine at pH 3.0 (Figure 19). The protein recovery 
after 24 hours could be improved from 95% without polysorbate 20 to 98% with 0.02% 
polysorbate 20 added to the formulation. 
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Figure 19: Protein concentration for 0.25 mg/ml cytokine in 20 mM glycine with 0.0% to 0.02% 
polysorbate 20 at pH 3.0 in glass type I vials over 24 hours. 
 
Figure 20 compares the impact of polysorbate 20 on the adsorption of the cytokine on 
glass types I and I+ at pH 3.0 and 4.5. The adsorption on glass type I was inhibited to a 
greater extent by increasing the polysorbate 20 concentration compared to glass type I+, 
especially at pH 3.0. However, without polysorbate 20 the initial adsorption was less 
distinct for glass type I+ with 97.9% at pH 4.5 and 98.5% at pH 3.0 compared to glass 
type I with 93.7% at pH 4.5 and 95.2% at pH 3.0. Overall, glass type I+ vials were 
superior to glass type I vials both with and without polysorbate 20 in the formulation.  
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Figure 20: Protein concentration for 0.25 mg/ml cytokine in 20mM glycine (pH 3.0 and 4.5) with 
0.0% to 0.02% polysorbate 20 in glass type I and I+ after 24 hours. 
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The studies showed that cytokine adsorption was dependent on glycine concentration, 
formulation pH and the container type used. Especially at the standard buffer 
concentration of 20 mM glycine a lower pH was beneficial for the cytokine in terms of 
adsorption. This corresponded to the ATR-FTIR spectroscopy results as less protein 
adsorbed on the ATR-crystal at pH 3.0 compared to pH 5.0 (compare 3.2). A buffer 
concentration of 20 mM glycine was favorable compared to 10mM as the decline of 
protein concentration was reduced at 20 mM glycine. Other possibilities to avoid protein 
adsorption were the addition of polysorbate 20 or the utilization of surface treated glass 
type I+. The best results with less than 1% protein loss after 24 hours were achieved by 
adding 0.005% to 0.02% polysorbate 20 to formulations containing 20 mM glycine at 
pH 3.0 and by the use of glass type I+. According to these investigations the use of HSA 
as adsorption preventing excipient could be avoided.  
 
3.4 Short-time Cytokine Stability in Solution 
Preliminary studies indicated that a pH value below 5.5 is necessary to ensure solubility 
and to avoid precipitation of the cytokine (compare 3.1.1). Furthermore, an increase in 
ionic strength by the addition of NaCl or by using higher glycine concentrations led to 
higher turbidity values especially at elevated pH values, reflecting protein aggregation. 
However, in the pH range between 3.0 and 4.5, HP-SEC revealed no significant increase 
in aggregation when 0.05% to 0.5% NaCl was added. As aggregation is emerging over 
time, it was important to evaluate the increase in aggregation during storage. Short-time 
stability studies over one and two weeks were conducted to elucidate the general effects 
of pH, ionic strength and the addition of further excipients on cytokine aggregation 
during storage. During these initial stability studies the focus was set on monitoring 
aggregation with HP-SEC, turbidity measurements and DLS. 
 
3.4.1 Influence of pH on Cytokine Stability 
To study the impact of pH on the cytokine formulations with 0.25 mg/ml cytokine in 
20 mM glycine at pH 3.0, 3.5, 4.0 and 4.5 were stored for one week at 2-8°C, 25°C and 
40°C. Aggregation was determined by HP-SEC and by turbidity measurement. Initial 
aggregation ranged between 3.3% at pH 3.0 and 4.1% at pH 4.5. When stored at 2-8°C 
and 25°C, the increase in aggregation was less than 0.5% for the tested pH range 
between 3.0 and 4.5 (Figure 21a). Storage at 40°C led to more pronounced aggregate 
formation at higher pH values, with 9.1% at pH 4.5 compared to 4.6% at pH 3.0. Data 
from turbidity measurements confirmed that formulations at pH 3.0 and 3.5 were more 
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stable compared to formulations at a higher pH. Turbidity ranged between 1 and 1.5 FNU 
for pH 3.0 and 3.5, and between 1 and 2 FNU for pH 4.0 and 4.5 (Figure 21b).  
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Figure 21: Aggregation determined with HP-SEC (a) and turbidity (b) of 0.25 mg/ml cytokine in 
20 mM glycine after 1 week storage at 2-8°C, 25°C and 40°C. 
 
All solutions were clear with turbidities lower than reference solution I of the European 
Pharmacopoeia. However, the difference between the formulations with respect to larger 
aggregates was less distinctive than the pH-effect on dimer and trimer formation 
analyzed by HP-SEC. Again it became obvious that an increase in soluble aggregates 
detectable by HP-SEC only has a minor impact on turbidity, which is mainly caused by 
medium-sized aggregates [22]. The result that a low pH was beneficial for the stability of 
the cytokine was confirmed with DLS (Figure 22).  
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Figure 22: Size distribution by volume of 0.25 mg/ml cytokine in 20 mM glycine at pH 3.0 (a) and 
pH 4.5 (b) after 1 week storage. 
 
No changes in the size distribution by volume were detected for the samples at pH 3.0 
after one week at 2-8°C and 40°C. At pH 4.5 on the other hand, the size distribution by 
(a) (b) 
(a) (b) 
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volume was affected when the formulations were stored at 25°C and 40°C. After one 
week at 25°C the intensity of the peak at 5 nm decreased followed by a significant 
increase in the intensity at 10 to 30 nm. Storage at 40°C resulted in a disappearance of 
the first peak at 5 nm, while the second peak at 10 to 30 nm augmented, reflecting the 
increased aggregation. So far, the short-time stability study showed that aggregation 
detectable by HP-SEC and turbidity did not significantly increase within one week at  
2-8°C and 25°C when the cytokine was formulated between pH 3.0 and 4.5. However, 
for the formulations at pH 4.5 DLS pointed at a changed size-distribution by volume 
when stored at 25°C. Storage of the samples at 40°C clearly revealed an improved 
stability at lower pH values. To further clarify the role of pH on cytokine stability, the 
impact of pH values above 4.5 was evaluated by HP-SEC in a two-week stability study 
(Figure 23).  
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Figure 23: Aggregation determined by HP-SEC of 0.25 mg/ml cytokine in 20 mM glycine after 
2 weeks storage at 2-8°C, 25°C and 40°C. 
 
No significant increase in aggregation was determined with HP-SEC at pH 3.0 after two 
weeks for all storage temperatures. At pH 4.5 13.2% aggregates were measured by HP-
SEC for the formulations stored at 40°C. For the formulations at pH 3.0 and pH 4.5 the 
total AUC in the HP-SEC chromatograms remained constant for all storage conditions, 
indicating the absence of substantial quantities of larger aggregates. For the cytokine 
formulations at pH 5.3 and 5.6 already at 25°C a substantial increase in aggregation to 
7.8% and 10.2% was obvious. Even higher values of 14.5% and 20% at pH 5.3 and 
pH 5.6 were reached when storing the formulations at 40°C. The AUC in the HP-SEC 
chromatograms were significantly reduced at pH 5.2 and pH 5.6 to 92% and 93% at  
2-8°C, 57% and 70% at 25°C and 33% and 59% at 40°C. The lowered AUC pointed at 
the formation of larger aggregates, which were retained by the guard column. Due to 
increased aggregation already after 2 weeks storage pH values above 4.5 will not 
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included for the development of a liquid formulation. For lyophilized formulations pH 5.0 
could be taken in consideration, as the initial aggregation with 4.0% was not significantly 
higher compared to pH 4.5.  
 
3.4.2 Influence of Ionic Strength on Cytokine Stability 
So far, it could be shown that a formulation pH between 3.0 and 4.5 would be suitable 
for the development of liquid formulations. For this pH range the impact of increasing 
glycine, respectively NaCl concentrations on aggregation was further evaluated in a two 
week stability study at 2-8°C, 25°C and 40°C. This issue needed to be clarified in the 
pre-formulation study to check if NaCl can be employed for isotonicity adjustment of the 
final formulations. HP-SEC revealed that the formation of dimers and lower aggregates 
was independent of the glycine concentration when using 10 to 50 mM glycine between 
pH 3.0 and 4.5 (data not shown). In contrast, the addition of 0.2% to 0.9% NaCl led to a 
boost in aggregates after 2 weeks storage, especially at 40°C (Figure 24). Higher 
aggregate concentrations of about 20% were found by HP-SEC at pH 3.0 as compared to 
about 14% at pH 4.5 for formulations with 0.2% to 0.9% NaCl after 2 weeks at 40°C. 
However, the AUC was declining over storage time, particularly at pH 4.5 and with 
increasing NaCl concentrations, indicating the presence of larger aggregates.  
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Figure 24: Aggregation determined by HP-SEC in 0.25 mg/ml cytokine in 20 mM glycine at 
pH 3.0 (a) and pH 4.5 (b) after 2 weeks storage at 2-8°C, 25°C and 40°C. 
 
The formation of larger aggregates was confirmed by turbiditimetry for samples with 
0.2% NaCl at pH 4.5 and with 0.9% NaCl at pH 3.0 and pH 4.5 when stored for 2 weeks 
at 40°C (Figure 25). Without NaCl the solutions remained clear with turbidities below 3.2 
after 2 weeks at 40°C, independent of the pH. When 0.2% and 0.9% NaCl were added to 
the formulations turbidities of about 17, respectively 24 FNU were measured for at 
(a) (b) 
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pH 4.5, which can be categorized as opalescent according to the European 
Pharmacopoeia.  
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Figure 25: Turbidity of 0.25 mg/ml cytokine in 20 mM glycine at pH 3.0 and 4.5 with 0.0%, 0.2% 
and 0.9% NaCl before storage and after 2 weeks at 40°C. 
 
Summarizing, the increase in ionic strength by adding 0.2 to 0.9% NaCl had a negative 
impact on the storage stability of the cytokine in solution, as aggregation and 
precipitation was fostered. Therefore, NaCl is not suitable to adjust the isotonicity of the 
final formulation.  
 
3.4.3 Influence of Excipients on Cytokine Stability 
Within the pre-formulation studies the impact of the excipients mannitol, trehalose and 
polysorbate 20 on cytokine stability with respect to aggregation was evaluated. In liquid 
formulations mannitol and trehalose can be used as stabilizers and simultaneously to 
adjust the isotonicity of the formulation, without increasing the ionic strength. Generally, 
sugars and sugar alcohols are preferentially excluded from the immediate vicinity of the 
protein surface which leads to a thermodynamically unfavorable state due to the increase 
in entropy. Thereby, the denaturated state of a protein exhibits a larger surface, which is 
more unfavorable resulting in a stabilization of the native state [55-57]. For the planned 
lyophilized formulations of the cytokine, mannitol as single component would not provide 
sufficient stabilization, as it usually crystallizes during lyophilization [58]. Only in the 
amorphous state mannitol is able to adequately stabilize the active protein via molecular 
interactions [59,60]. To provide sufficient stabilization for the protein, trehalose or 
sucrose as amorphous stabilizers can be added. These sugars are capable to stabilize the 
cytokine by acting as water substitute in the dried state and by forming an amorphous 
glass [61,62]. For the cytokine formulation the combination of 4.0% mannitol and 1.0% 
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sucrose or trehalose was used. The physico-chemical studies of the system mannitol-
sucrose and the development of adequate lyophilization cycles were discussed in 
Chapter 5. The adsorption studies revealed that polysorbate 20 was effective in inhibiting 
the loss of cytokine due to adsorption on the container. Furthermore, polysorbates can 
inhibit aggregation which was for example shown by Kreilgaard et al. (1998) for the 
shaking and freezing induced aggregation of recombinant human Factor XIII [63] and by 
Bam et al. (1998) for the shaking induced aggregation of recombinant human Growth 
Hormone [64]. However, for other proteins e.g. Interleukin-1ß polysorbate 80 did not 
influence aggregation [65]. Therefore, the impact of 0.01% polysorbate 20 on the 
aggregation behavior of the cytokine was evaluated. 
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Figure 26: Aggregation determined by HP-SEC (a) and turbidity (b) of 0.25 mg/ml cytokine in 
20 mM glycine with different excipients at pH 3.0, 3.5, 4.0 and 4.5 after 1 week storage at 40°C. 
 
After one week storage at 2-8°C and 25°C HP-SEC revealed that aggregation increased 
less than 0.5% for formulations with 0.25 mg/ml cytokine at pH 3.0 to pH 4.5 
independent of the presence of excipients. A slight stabilizing effect was achieved by the 
addition of mannitol-trehalose and polysorbate 20 when the samples were stored at 40°C 
(Figure 26a). While aggregation increased between 1.3% and 5.0% between pH 3.0 and 
pH 4.5 without excipients, the increase ranged between 0.4% and 3.6% when stabilizers 
were added. No significant differences were observed in the turbidity of the formulations 
with and without excipients, indicating that no larger aggregates were formed under the 
studied conditions (Figure 26b). Here again the formulation pH played the major role for 
the stability of the formulation with respect to aggregation and turbidity. For formulation 
development mannitol can be used to adjust the isotonicity of the formulations.  
(a) (b) 
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3.5 Freeze-Thaw Stability 
During freezing various stress factors, e.g. the formation of ice crystals and the 
corresponding solid liquid interfaces, the increasing concentration of the remaining 
solutes, a pH shift or a phase separation can lead to damage and aggregation of proteins. 
These freezing induced stresses are described in detail in the reviews of Wang (2000) [2] 
and Arakawa et al. (2001) [57]. The freeze-thaw stability is therefore an important issue 
to be evaluated in the pre-formulation studies, also with respect to the planned 
development of lyophilized formulations. The physical stability of the cytokine during 
freezing and thawing was evaluated in terms of aggregation. 2 R vials containing 1.0 ml 
of the formulations were placed on the shelves of the freeze-drier cooled to -50°C within 
2 hours. This freezing procedure was chosen as it will be used for lyophilization of the 
later formulations. After an isothermal phase of 2 hours at -50°C the vials were reheated 
to 20°C and allowed to thaw.  
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Figure 27: Aggregation determined by HP-SEC of 0.25 mg/ml cytokine in 20 mM glycine at pH 3.0 to 
4.5 before and after 1 and 5 freeze-thaw cycles. 
 
Aggregation was determined after one and five freeze-thaw (F/T) cycles for formulations 
with 0.25 mg/ml cytokine with 20 mM glycine at pH 3.0 to 4.5 (Figure 27). A slight 
increase in aggregation by approximately 0.2% after one, respectively 0.5% after five 
freeze-thaw cycles was found in the HP-SEC chromatograms. The AUC of the HP-SEC 
chromatograms was not significantly affected by the freeze-thaw cycles, which pointed at 
the absence of larger aggregates.  
The addition of further excipients (mannitol, trehalose, sucrose and polysorbate 20) and 
combinations of these excipients only had a minor impact on the increase in aggregation 
at pH 3.0 (Figure 28a). After one cycle an average increase in aggregation of 0.2% and 
after five cycles of 0.5% was determined for the formulations at pH 3.0. At pH 4.5 
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aggregation increased by 0.25% after one freeze-thaw cycle (Figure 28b). After five 
cycles the formulations with 4.0% mannitol and 1.0% sucrose respectively 4.0% 
mannitol and 1.0% trehalose and 0.01% polysorbate 20 showed an increase in 
aggregation by 0.2%, compared to an increase between 0.4% to 0.8% for the other 
formulations.  
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Figure 28: Aggregation determined by HP-SEC of 0.25 mg/ml cytokine in 20 mM glycine at pH 3.0 
(a) and pH 4.5 (b) with combinations of mannitol (M), sucrose (S), trehalose (T) and polysorbate 20 
(PS20) before and after 1 and 5 freeze-thaw cycles. 
 
Thus, the cytokine showed an overall good stability against stresses induced by freezing 
and thawing, even without further excipients beside the buffering glycine. Due to this 
good stability the freezing step during lyophilization is not expected to cause major 
physico-chemical alternations of the cytokine.  
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3.6 Long-term Stability of Liquid and Lyophilized Formulations 
The goal of the study was the development of stable, HSA-free formulations of the 
cytokine, as an alternative to the existing HSA-containing lyophilized formulation. Based 
on the results of the preformulation study, which pointed at the structural characteristics 
of the cytokine (compare 3.2), protein adsorption (compare 3.3) and the effect of pH, 
ionic strength and the addition of excipients (compare 3.4) on cytokine stability, the 
most promising conditions were selected. It was shown that the physical stability of the 
cytokine was improved at low pH between 3.0 and 3.5. A glycine concentration of 20 mM 
turned out to be beneficial regarding aggregation and loss of protein due to adsorption. 
FTIR revealed a higher fraction of ß-sheet structure at pH 3.0 and 3.5, but also an 
increased stability against structural changes with increasing temperature. The changed 
secondary structure at pH 3.0 and 3.5 could be regarded as critical, as the activity of the 
cytokine might be changed. However, it was not an irreversible change as the amount of 
ß-sheet was reduced in favor of α-helical structure when the pH was increased. In 
literature an increased thermal stability for the cytokine determined by circular dichroism 
and a protection of its activity at pH 2.9 was described by Boublik et al. (1990) [66]. To 
clarify the question how activity and secondary structure are correlated, in vitro assays 
for antiviral activity, e.g. antiviral yield reduction assays or cytopathic effect bioassays 
[67] would be necessary to quantify the biological activity of the cytokine. The first short-
time stability studies indicated that storage at 2-8°C and 25°C may allow formulating the 
cytokine at pH 4.0 and possibly at pH 4.5. To minimize protein adsorption the addition of 
0.005% to 0.02% polysorbate 20 is reasonable. For the lyophilized formulations glass 
type I+ vials could be used. For the liquid formulation the utilization of pre-filled syringes 
was planned, which were not available in glass type I+ quality. In this case the addition 
of polysorbate 20 could minimize protein adsorption. The addition of salt or the use of 
higher buffer concentrations needs to be avoided, as aggregation and precipitation were 
favored at higher ionic strength. In the further studies, the isotonicity of the solutions 
was therefore adjusted with mannitol in the liquid or with combinations of mannitol with 
sucrose in the lyophilized formulation. The 6 months stability study of the liquid 
formulations was performed in glass prefilled syringes BD Hypak SCF®. All liquid 
formulations contained 0.25 mg/ml cytokine, 20 mM glycine and 4.8% mannitol, whereas 
pH and polysorbate 20 concentrations were varied (Table 4).  
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Table 4: Overview of the liquid formulations tested for stability over 6 months. 
 
pH polysorbate 20 [%] 
3.5 0.02 
4.0 0.0 
4.0 0.005 
4.0 0.02 
4.5 0.02 
 
For an alternative HSA-free lyophilized formulation higher pH values were included. In 
the preliminary studies it could be shown that aggregation increased only marginally 
upon two week storage at 2-8°C for formulations at pH 5.3 and pH 5.6 (compare 3.4.1). 
One drawback of the higher pH values is the augmented adsorption tendency of the 
cytokine (compare 3.3.1). Therefore, glass type I+ vials were used for the lyophilized 
formulations in combination with polysorbate 20. The advantage of higher pH values is 
the possibility to use sucrose as excipient for lyophilization. At pH 3.0 the use of sucrose 
is not feasible due to the acid catalyzed inversion of sucrose to fructose and glucose. The 
inversion process can take place in lyophilized products even at very low moisture levels 
[68]. Therefore, mannitol employed in a concentration of 4.0% was used as bulking 
agent and 1.0% sucrose as lyo- and cryoprotector. The physico-chemical lyophilization 
behavior, as well as an adequate lyophilization cycle for the system was evaluated in 
Chapter 5. Again formulation pH and polysorbate 20 concentrations were varied for the 
lyophilized formulations (Table 5). 
 
Table 5: Overview of the lyophilized formulations tested for stability over 6 months. 
 
pH polysorbate 20 [%] 
4.0 0.0 
4.0 0.005 
4.0 0.02 
4.5 0.02 
5.0 0.02 
 
The stability of the five liquid and five lyophilized formulations was evaluated over 
6 months at 2-8°C, 25°C / 60% RH and 40°C / 75% RH. Stability was monitored in 
terms of aggregation using HP-SEC and the change of the size distribution by volume 
measured with DLS. Chemical modifications were detected by RP-HPLC. 
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3.6.1 Long-term Stability of Liquid Cytokine Formulations 
The formation of dimers and lower aggregates was determined by HP-SEC after 1, 3 and 
6 months storage period at 2-8°C, 25°C and 40°C (Figure 29). After 6 months storage 
the level of dimers and lower aggregates was increased by 0.6% at 2-8°C and by 1.4% 
at 25°C for formulations at pH 3.5. The most significant rise by 1.6% at  
2-8°C and by 5.2% at 25°C was determined at the highest tested pH of 4.5. Aggregation 
stepped up drastically, when the liquid cytokine formulations were stored at 40°C. At 
pH 4.0 more than 40% and at pH 4.5 more than 50% dimers lower aggregates were 
formed, whereas only 11.5% dimers and trimers were detected at pH 3.5. 
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Figure 29: Aggregation determined by HP-SEC of the cytokine in the liquid formulations over 
6 months during storage at 2-8°C (a), 25°C (b) and 40°C (c). 
 
The pH-dependency of the formulation stability was in agreement with the results of the 
FTIR-studies (compare 3.2.1). For the cytokine formulated at pH 3.5 a denaturation 
temperature Tm of 74°C was determined, while pH 4.2 resulted in a Tm of 57°C. FTIR 
had shown that significant structural changes at pH 4.2 already started at a temperature 
(a) (b) 
(c) 
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of 40 to 45°C. Therefore, the storage temperature of 40°C, which is only about 15°C 
below Tm, was already too high to assure the integrity of the cytokine. The addition of 
0.005% and 0.02% polysorbate 20 to the liquid formulation at pH 4.0 had no 
considerable impact on the formation of aggregates. The improved stability at pH 3.5 
compared to the higher pH values was further reflected in the size distribution by volume 
determined with DLS (Figure 30).  
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Figure 30: DLS size distribution by volume of liquid formulations at pH 3.5, 0.02% polysorbate 20 
(a), pH 4.0, 0.0% (b), 0.005% (c), 0.02% polysorbate 20 (d) and pH 4.5 0.02% polysorbate 20 (e) 
after 6 months storage. 
 
For the formulations at pH 3.5 a main peak at 5 nm was present after 6 months at all 
storage conditions. At 40°C a second peak at 10 to 30 nm appeared which reflected the 
significant formation of aggregates seen in HP-SEC. The samples at pH 4.0 exhibited 
comparable changes in the size distribution at all tested levels of polysorbate 20. Already 
before storage a distinct peak at 10 to 20 nm was present without and with 0.005% 
polysorbate 20 and a shoulder at 0.02% polysorbate 20. At 2-8°C the size distribution 
was slightly more stable with 0.02% polysorbate 20, as no distinct peak at 10 to 30 nm 
could be assigned. The decreased thermal stability of formulations at pH 4.5 becomes 
obvious in the drastically changed DLS size distributions. At 25°C and 40°C storage the 
first peak at 5 nm was no longer present and high intensities were measured above 
10 nm. After storage at 40°C a second peak at about 60 nm emerged for the formulation 
at pH 4.5.  
(a) (b) (c) 
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For the formulations stored at 2-8°C and 25°C RP-HPLC was performed to analyze the 
level of chemically modified cytokine. Especially at low pH values chemical modification 
e.g. oxidation or deamidation are more likely to occur [69,70]. Within the RP-
chromatogram a met-oxidized form of the cytokine is eluting prior to the main peak 
followed by several peaks, which can be assigned to oligomerized protein [14]. Before 
storage, the formulations contained an average of 1.6% met-oxidized forms. Figure 31 
shows the amount of met-oxidized cytokine after 3 and 6 months storage at 2-8°C and 
25°C. Met-oxidized cytokine was formed as a function of storage time and temperature. 
At 2-8°C a slight rise in met-oxidized cytokine by 0.2% to 0.6% was determined after 3 
months, which further increased by 1.4% to 2.4% after 6 months compared to the levels 
before storage. Higher values of met-oxidized cytokine were determined for the samples 
stored at 25°C. The data indicated a slight stabilizing effect of polysorbate 20 at pH 4.0, 
as here the lowest levels of met-oxidized cytokine was measured. Furthermore, the level 
of met-oxidized cytokine at pH 3.5 was increased after 6 months storage at 25°C 
compared to the higher pH values. Overall, oxidation of the cytokine should be kept low 
by storage at 2-8°C. As an alternative, the addition of methionine as antioxidant could be 
evaluated. 
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Figure 31: Met-oxidized form of the cytokine determined with RP-HPLC in liquid formulation after 3 
and 6 months at 2-8°C and 25°C.  
 
To evaluate the degree of protein adsorption in the prefilled glass syringes the protein 
content in the formulations was determined with UV-spectroscopy and the AUC in the HP-
SEC chromatograms were considered. After storage at 2-8°C UV spectroscopy revealed a 
residual protein content of 96% for the formulation without polysorbate 20, while 99% 
were found at 0.005% polysorbate 20 and 102% at 0.02% polysorbate 20 at pH 4.0 
(Figure 32a). A protein recovery of 99% at pH 3.0 and 101% at pH 4.5 was determined 
after one month. Especially at 40°C storage temperatures protein contents above 100% 
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were determined. This could be explained by light scattering effects of aggregated 
proteins, also evident by an increased UV-absorption at 350 nm and 550 nm. This trend 
was confirmed by the AUCs of the HP-SEC chromatograms (Figure 32b).  
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Figure 32: Protein content determined by UV-spectroscopy (a) and AUC in the HP-SEC 
chromatograms (b) of the liquid formulations after 1 month storage at 2-8°, 25°C and 40°C.  
 
Summing up, the development of a liquid HSA-free formulation for the cytokine was 
feasible. Most suitable with respect to aggregation and formation of met-oxidized 
cytokine were the formulations at pH 3.5 and pH 4.0, stored at 2-8°C. Storage at 40°C 
facilitated the aggregation process, which was confirmed by HP-SEC and DLS. While 
aggregation was only slightly increased at 25°C, the formation of met-oxidized cytokine 
augmented significantly. To avoid adsorption of the cytokine to the glass syringes the 
addition of at least 0.005% polysorbate 20 was necessary. Furthermore, polysorbate 20 
had a slight stabilizing effect with respect to the DLS size distribution at 2-8°C and the 
formation of met-oxidized cytokine.  
 
3.6.2 Stability of Lyophilized Formulation 
To stabilize the cytokine in lyophilized form pH values of 4.0 to 5.0 were selected. 
Mannitol was used as crystalline bulking agent and sucrose as amorphous stabilizer. 
Thereby, a lyophilization cycle optimized to avoid the formation of mannitol hydrate and 
to ensure mannitol crystallization as far as possible was used (compare Chapter 5). After 
lyophilization mainly δ-mannitol (peak at 9.7° 2-Θ) with a smaller fraction of β-mannitol 
(peaks at 14.6 and 23.5° 2-Θ) was present in all formulations. Figure 33 shows 
exemplarily the XRD patterns of the formulations at pH 4.0 without and with 0.02% 
polysorbate 20. In lyophilized formulation without polysorbate 20 a larger fraction of β-
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mannitol is present compared to the formulations with 0.02% polysorbate 20. 
Polysorbate is known to influence the morphology of mannitol after lyophilization [71].  
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Figure 33: XRD diffraction pattern of lyophilized formulation at pH 4.0 without (a) and with 0.02% 
polysorbate 20 (b) after lyophilization and 6 months storage at 2-8°C, 25°C / 60% RH and 
40°C / 75% RH. 
 
Changes in the physico-chemical properties of the lyophilized products were evaluated as 
they may influence protein stability. However, for formulations with mannitol and HSA it 
could be shown in Chapter 3 that a change in the mannitol modifications and crystallinity 
did not affect the integrity and stability of HSA. Upon storage, slight changes could be 
detected in the XRD-diffraction patterns of the polysorbate 20 free samples (Figure 33a). 
After 6 months storage at 25°C / 60% RH and 40°C / 75% RH peaks of α-mannitol 
appeared at 13.6° 2-Θ and 17.2° 2-Θ. It was further evident that the intensity of the 
δ-mannitol peak at 9.7° 2-Θ decreased during 6 months at 40°C / 75% RH. This could be 
ascribed to the fact that the δ-modification is the least stable modification of mannitol 
[72]. Samples with 0.02% polysorbate 20 were more stable regarding mannitol 
modifications with only a slight decrease in ß-mannitol (Figure 33b).  
After lyophilization all formulations exhibited low residual moisture levels between 0.5% 
and 1.0% (Table 6). This low water contents could be attributed to the high content of 
crystalline mannitol in the formulations. Over 6 months only a slight increase in residual 
moisture up to maximally 1.2% at 2-8°C and 25°C / 60% RH and maximally 1.4% at 
40°C / 75% RH was measured. Water can act as reactant in chemical reactions within 
the lyophilized sample and as plasticizer with the consequence that the molecular 
mobility of the system is altered [73]. Generally, residual moisture levels of about 1% 
are suggested for lyophilized protein formulations [74]. However, Chang et al. (2005) 
showed that water in lyophilized IgG1-sucrose increased the molecular mobility in the 
glassy matrix, while the lowest aggregation rate was measured at intermediate water 
(a) (b) 
40°C 
25°C 
after 
lyo 
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2-8°C 
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contents of 2% to 3% [75]. The constant residual moisture level in the different 
lyophilized cytokine formulations over storage time could be regarded as beneficial. 
 
Table 6: Residual moisture (RM) of lyophilized formulations stored for 6 months at 2-8°C, 
25°C / 60% RH and 40°C / 75% RH (n=3).  
 
 
RM [%] 
after 
lyophilization  
Storage  
conditions 
RM [%] 
after 
1 month 
RM [%] 
after 
3 months 
RM [%] 
after 
6 months 
pH 4.0 
0.0% PS 20 
1.03 2-8°C 
25°C / 60% RH 
40°C / 75% RH 
 
0.90 
1.07 
0.86 
0.98 
0.93 
0.98 
1.24 
0.91 
1.17 
pH 4.0 
0.005% PS 20 
0.67 2-8°C 
25°C / 60% RH 
40°C / 75% RH 
 
0.93 
1.03 
0.96 
1.09 
1.00 
1.00 
1.07 
0.92 
1.40 
pH 4.0 
0.02% PS 20 
0.51 2-8°C 
25°C / 60% RH 
40°C / 75% RH 
 
0.86 
1.03 
1.09 
1.03 
1.00 
1.16 
1.03 
0.94 
1.41 
pH 4.5 
0.02% PS 20 
0.68 2-8°C 
25°C / 60% RH 
40°C / 75% RH 
 
1.10 
1.07 
1.07 
1.05 
1.07 
1.22 
1.06 
1.01 
1.29 
pH 5.0 
0.02% PS 20 
0.57 2-8°C 
25°C / 60% RH 
40°C / 75% RH 
0.88 
1.04 
1.06 
1.14 
1.04 
1.12 
1.22 
0.95 
1.24 
 
The pre-formulation studies pointed at no significant increase in aggregation after a 
single freeze-thawing step (compare 3.5). After the lyophilization process no boosted 
aggregate formation was observed for all formulations (Figure 34). The size distributions 
by volume measured by DLS were equal as prior to lyophilization (data not shown). The 
selected excipients offered sufficient protection for the cytokine against freezing and 
drying induced stress. This showed that the approach of producing a lyophilized cake 
with highly crystalline mannitol in combination with amorphous sucrose as stabilizer in a 
ratio or 4:1 was feasible to stabilize the cytokine.  
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Figure 34: Aggregation determined by HP-SEC of the formulations before and after lyophilization. 
 
The stability of the lyophilized cytokine formulations was further evaluated over 6 months 
at 2-8°C, 25°C / 60% RH and 40°C / 75% RH, with respect to the formation of 
aggregates and a met-oxidized form of the cytokine. After 6 months at 2-8°C the level of 
dimers and lower aggregates increased between 0.3% and 0.7% for all studied 
formulations, independent of formulation pH and the addition of polysorbate 20 (Figure 
35a). Storage at 25°C / 60% RH and 40°C / 75% RH resulted in higher contents of 
dimers and lower aggregates, especially at the presence of 0.02% polysorbate 20 (Figure 
35 b,c). XRD revealed that the formulations at pH 4.0 without polysorbate 20 were 
physico-chemically less stable and underwent morphological changes during storage 
(Figure 33a). Regarding aggregation on the other hand the formulations at pH 4.0 with 
0.0% and 0.005% polysorbate provided an improved stability compared to the 
formulations with 0.02% polysorbate 20 after 6 months storage at 25°C / 60% RH and 
40°C / 75% RH. The improved stabilizing conditions without or with lower polysorbate 20 
concentrations outbalanced a potential detrimental effect of the change in modifications 
during storage (compare Chapter 4). During storage at 40°C / 75% RH the highest 
aggregation values were measured at pH 4.0, when comparing the formulations with 
0.02% polysorbate 20 at the different pH values. For sucrose containing formulations a 
pH of 4.0 is critical due to the risk of the inversion of sucrose at low pH [68]. This was 
confirmed by the slightly brownish color of the reconstituted formulations stored at 40°C, 
which was distinct at pH 4.0. The discoloration induced by the Maillard reaction, occurs 
when sucrose undergoes inversion to fructose and glucose. The use of trehalose instead 
of sucrose would be an alternative approach to improve the stability of the lyophilized 
formulation, by avoiding the inversion of sucrose. The AUC of the HP-SEC remained at a 
constant level for the samples stored at 2-8°C and 25°C / 60% RH indicating that no 
significant loss of protein due to adsorption or precipitation occurred, which could be 
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attributed to the utilization of glass type I+ vials. Storage at 40°C / 75% RH led to a 
decline in the AUC due to the formation of larger aggregates. 
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Figure 35: Aggregation determined by HP-SEC of the cytokine in the lyophilized formulations over 6 
months during storage at 2-8°C (a), 25°C / 60% RH (b) and 40°C / 75% RH (c). 
 
DLS of the formulations confirmed the results from HP-SEC (Figure 36). Here again the 
improved stability of samples without polysorbate 20 at pH 4.0 was evident. The size 
distribution by volume only changed to a moderate degree in polysorbate-free 
formulations when stored at 2-8°C and 25°C / 60% RH. Unlike to HP-SEC, where 
aggregation was comparable for samples at pH 4.0 without and with 0.005% polysorbate 
20, DLS indicated a changed size-distribution by volume for the formulations stored at 
25°C / 60% RH. In the presence of 0.005% polysorbate 20 the first peak was shifted to 
sizes of 20 to 30 nm. In addition a peak between 105 and 120 nm with intensity below 
5% occurred for all samples stored at 40°C / 75% RH (not shown in Figure 36). This 
peak could be attributed to larger protein aggregates, which were not detected by  
HP-SEC but led to a decline of the AUC in the HP-SEC chromatograms. For the samples 
stored at 2-8°C and 25°C / 60% RH this peak was not present.  
(b) 
(c) 
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Figure 36: DLS size distribution by volume of lyophilized formulations storage at pH 4.0, 0.0% 
polysorbate 20 (a), 0.005% polysorbate 20 (b), 0.02% polysorbate 20 (c), pH 4.5 0.02% 
polysorbate 20 (d) and pH 5.0 0.02% polysorbate 20 (e) after 6 months. 
 
The increase in met-oxidized cytokine in the lyophilized formulations was less 
pronounced compared to the liquid formulations (Figure 37). All samples stored at  
2-8°C showed similar levels of approximately 3% met-oxidized cytokine after 6 months 
storage. At 25°C / 60% RH about 1% less met-oxidized cytokine was formed when 
0.02% polysorbate 20 was added to the formulations.  
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Figure 37: Results from RP-HPLC of lyophilized formulation after 3 and 6 months at 2-8°C and 25°C.  
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Thus, the used lyophilization cycle resulted in elegant cakes consisting of crystalline 
mannitol and amorphous sucrose. Low aggregation levels could be preserved upon 
storage at 2-8°C. The addition of 0.02% polysorbate 20 fostered aggregate formation at 
25°C / 60% RH and 40°C / 75% RH, but decreased the formation of met-oxidized 
cytokine at 25°C / 60% RH. However, the mechanism by which polysorbate 20 increased 
aggregate formation in the lyophilized product during storage at 25°C / 60% RH and 
40°C / 75% RH is unclear. The increased formation of aggregates induced by polysorbate 
20 was not observed in the liquid formulation. The optimum stability for the lyophilized 
cytokine formulation could be achieved at pH 4.0 without polysorbate 20 and storage at 
2-8°C. 
 
3.6.3 Comparison of Liquid and Lyophilized Formulation 
In the stability study of the liquid formulation, pH 3.5 and 4.0 turned out to be most 
stable regarding aggregation. The formation of the met-oxidized cytokine was 
independent of the pH but increased with storage time and temperature. Lyophilized 
formulations were stable form pH 4.0 to 5.0, when stored at 2-8°C. Again the formation 
of met-oxidized cytokine was independent of the formulation pH. In order to avoid 
protein adsorption the addition of polysorbate 20 to the liquid formulation was necessary, 
as the pre-filled syringes were manufactured of glass type I. Furthermore, in liquid 
formulation, polysorbate 20 was beneficial with respect to DLS-size distribution by 
volume and the formation of met-oxidized cytokine. The reduced formation of met-
oxidized cytokine in presence of polysorbate 20 was as well seen for the lyophilized 
formulations. However, here polysorbate 20 fostered the formation of aggregates. As 
glass type I+ vials were employed for the lyophilized formulation, polysorbate 20 could 
be omitted with respect to adsorption.  
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4. Conclusions 
The goal of the studies was to develop stable, HSA-free formulations for the cytokine as 
an alternative to the HSA-containing formulation. For formulation development the focus 
was set on the pH range between 3.0 and 5.5 in which an initial solubility of the cytokine 
at a constant aggregation level of about 3% to 4% was given. Above pH 5.5 precipitation 
of the cytokine indicated by an increased turbidity impeded a feasible formulation 
development. Initial characterization of the cytokine at different pH and ionic strength 
conditions revealed an improved stability with respect to aggregation and turbidity at a 
pH below 4.5 and low ionic strength. Furthermore, an improved thermal stability for 
lower pH values could be demonstrated by FTIR. At pH 3.0 and pH 3.5 a steady change 
of the FTIR-spectra with an onset above 25°C was observed. First at pH 3.5 a Tm of 
74°C could be determined. With increasing pH the Tm values were lowered to 57°C at 
pH 4.2 and 49°C at pH 5.5. The improved thermal stability at lower pH values was also 
confirmed by DLS. A concentration of 20 mM glycine was selected as appropriate because 
the tendency of the cytokine to adsorb on glass was reduced compared to lower glycine 
concentration. Protein adsorption was found to be minimal at pH 3.0 using 20 mM glycine 
as buffer. Possible approaches to further reduce the loss of protein by adsorption were 
the use of glass type I+ and the addition of polysorbate 20 to the formulations, where 
more than 97% of the protein content could be recovered after 24 hours at pH 3.0 and 
4.5. First short time stability studies had shown that an increase in ionic strength by 
adding NaCl led to a tremendous increase in aggregates and turbidity already after one 
week especially at 40°C. The addition of mannitol and trehalose on the other hand 
slightly improved the stability, with respect to aggregation. 
For the storage stability study five liquid and five lyophilized formulations were selected, 
which contained 0.25 mg/ml cytokine, 20 mM glycine at different pH-values and 
polysorbate 20 concentrations. The isotonicity was adjusted with mannitol in the liquid 
formulation, due to the increased aggregation in presence of NaCl. For the lyophilized 
formulation sucrose was added as amorphous lyoprotector. Generally, aggregation levels 
and the formation of a met-oxidized form of the cytokine were increasing with higher 
storage temperature. The use of methionine as antioxidant could be an approach to 
reduce oxidation. For the liquid formulation aggregation increased by 0.5% for 
formulations with 0.02% polysorbate 20 independent of the pH. Polysorbate 20 could 
further reduce the loss of protein due to adsorption on the pre-filled glass syringes and 
the formation of met-oxidized cytokine. At pH 4.5 higher aggregation levels and a 
significantly changed DLS size-distribution by volume were obtained when the samples 
were stored at 25°C.  
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For the lyophilized formulations aggregation increased by 0.2% to 0.7% for all studied 
pH-values after 6 months at 2-8°C. Best stability with respect to aggregation was 
achieved for the lyophilized formulations at pH 4.0 with 0.0% and 0.005% polysorbate 
20. The formation of met-oxidized cytokine on the other hand was lower in presence of 
polysorbate 20. For the lyophilized formulations a discoloration of the solutions after 
reconstitution was observed after storage at 40°C / 75% RH for pH 4.0 and pH 4.5 and 
at 25°C / 60% RH also for pH 4.0. The effect can be ascribed to the inversion of sucrose 
to the reducing sugars fructose and glucose, which is accelerated with temperature, 
residual moisture and lower pH. To achieve stable lyophilized formulations also at pH 4.0 
and higher storage temperatures, the use of trehalose instead of sucrose could be a 
possible approach as trehalose shows a higher chemical stability. With lyophilization it 
was possible to use a higher pH of 5.0, which was not possible for the liquid formulations. 
When storing the liquid and lyophilized formulations for 6 months at 2-8°C good results 
could be achieved with all formulations. Within the studied formulations the liquid 
formulations at pH 3.5 and 4.0 with 0.02% polysorbate 20, as well as the lyophilized 
formulations at pH 4.0 with 0 and 0.005% polysorbate 20 offered the best stability at 
higher storage temperatures. Summarizing, it can be concluded that it is possible to 
stabilize the cytokine without the use of HSA as stabilizer at low pH. Aggregation and 
oxidation is critical at higher storage temperatures which required storage at 2-8°C. The 
issue of protein adsorption can be overcome by using polysorbate 20 as excipients, as 
well as by glass type I+ vials.   
Development of Stable, HSA-free Formulations for a Hydrophobic Cytokine 
   
 
167 
5. References 
1. L. S. Lin, M. G. Kunitani, M. S. Hora. Interferon-ß-1b (Betaseron®). A Model for Hydrophobic Therapeutic 
Proteins. Pharm. Biotechnol. 9:275-301 (1996). 
2. W. Wang. Lyophilization and Development of Solid Protein Pharmaceuticals. Int. J. Pharm. 203:1-60 
(2000). 
3. P. McGoff, D. S. Scher. Solution formulation of Proteins/Peptides. 139-158 In E. J. McNally (eds) Protein 
formulation and Delivery; Drugs and the Pharmaceutical Science Volume 99, Marcel Dekker Inc, New York 
pp. 139-158 (2000). 
4. P. J. Dawson. Effect of formulation and freeze-drying on the long-term stability of r-DNA-derived cytokines. 
Dev. Biol. Stand. 74:273-282 (1992). 
5. A. Braun, L. Kwee, M. A. Labow, J. Alsenz. Protein Aggregates Seem to Play a Key Role Among the 
Parameters Influencing the Antigenicity of Interferon Alpha (INF-α) in Normal and Transgenic Mice. Pharm. 
Res. 14:1472-1478 (1997). 
6. E. Hochuli. Interferon immunogenicity: technical evaluation of interferon-α2a. J. Interferon Cytokine Res. 
17 (Suppl. 1): 15-21 (1997). 
7. A. Braun, J. Alsenz. Development and Use of Enzyme-Linked Immunosorbent Assays (ELISA) for the 
Detection of Protein Aggregates in Interferon Alpha (INFα) Formulations. Pharm. Res. 14:1394-1400 
(1997). 
8. J. D. Meyer, J. E. Matsuura, J. A. Ruth, E. Shefter, S. T. Patel, J. Bausch, E. Mc Gonigle, M. C. Manning. 
Selective Precipitation on Interleukin-4 Using Hydrophobic Ion Pairing: A Method For Improved Analysis of 
Proteins Formulated with Large Excesses of Human Serum Albumin. Pharm. Res. 11:1492-1495 (1994). 
9. J. R. Wendorf, C. J. Radke, H. W. Blanch. Reduced Protein Adsorption at Solid Interfaces by Sugar 
Excipients. Biotech. Bioeng. 87:565-573 (2004). 
10. F. Samaritani, A. Del Rio. Human serum albumin (HSA)-free stabilized interferon liquid formulations, WO 
2004096263 A2, PCT Int. Appl. (2004). 
11. M. R. Duncan, J. M. Lee, M. P. Warchol. Influence of surfactants upon protein/peptide adsorption to glass 
and polypropylene. Int. J. Pharm. 120:179-88 (1995). 
12. M. S. Schwarzenbach, P. Reimann, V. Thommen, M. Hegner, M. Mumenthaler, J. Schwob, H. J. Güntherodt. 
Interferon α-2a interactions on Glass Vial Surfaces Measured by Atomic Force Microscopy. PDA J. Pharm. 
Sci. Tech. 59:78-89 (2002). 
13. Clarity and degree of opalescence of liquids; European Pharmacopoeia p. 27-29 (2005). 
14. J. Geigert, B. A. Panschar, S. Fong, H. N. Huston, D. E. Wong, D. Y. Wong, C. Taforo, M. Pemberton. The 
Long-Term Stability of Recombinant (Serine-17) Human Interferon-ß. J. Interferon Res. 8:539-547 (1988).  
15. E. A. Cooper, K. Knutson. Fourier Transform Infrared Spectroscopy Investigations of Protein Structure. in 
Physical Methods to Characterize Pharmaceutical Proteins. edited by J.N. Herron, Plenum Press New York 
101-143 (1995). 
16. S. L. Wang, S. Y. Lin, M. J. Li, Y. S. Wei, T. F. Hsieh. Temperature effect on the structural stability, 
similarity and reversibility of human serum albumin in different states. Biophys. Chem. 114:205-212 
(2005). 
17. S. L. Wang, Y. S. Wei, S. Y. Lin. Subtractive similarity method used to study the infrared spectra of 
proteins in aqueous solution. Vibrat. Spect. 31:313-319 (2003). 
18. B. A. Shirley, M. Choe, M. Tellers, S. Babuka. Solubility of INF-Beta-1b in Sodium Chloride Solutions. PCT 
Int. Appl. WO 02/080976 A2 (2002). 
19. S. Hershenson, J. Thomson. Isoelectric focusing of recombinant interferon-ß. Appl. Theor. Electrophr. 
1:123-124 (1989). 
Chapter 6 
   
 
168 
20. K. L. Shaw, G. B. Grimsley, G. I. Yakovlev, A. A. Makarov, C. N. Pace. The effect of net charge on the 
solubility, activity, and stability of ribonuclease Sa. Protein Sci. 10:1206-1215 (2001). 
21. K. P. C. Vollhardt, N. E. Schore. Organische Chemie. Ed. H. Butenschön. VCH Verlagsgesellschaft mbH, 
Weinheim (1995). 
22. H. C. Mahler, R. Müller, W. Frieß, A. Delille, S. Matheus. Induction of aggregates in a liquid IgG1-antibody 
formulation. Eur. J. Pharm. Biopharm. 59:407-417 (2005). 
23. D. Shaw, P. Dubin. Aggregation of ß-Lactoglobulin. Malvern Application notes. www.malvern.co.uk. (2005). 
24. P. C. Sontum, C. Christiansen. Photon Correlation Spectroscopy applied to characterisation of denaturation 
and thermal stability of human albumin. J. Pharm. Biomed. Anal. 16:295-302 (1997). 
25. J. Demeester, S. S. de Smedt, N. N. Sanders, J. Haustraete. Light Scattering. in Methods for Structural 
Analysis of Protein Pharmaceuticals, edited by W. Jiskoot and D. J. A. Cormmelin, AAPS Press p. 245-277 
(2005). 
26. A. Schön, A. Veláquez-Compoy. Calorimetry in Methods for Structural Analysis of Protein Pharmaceuticals. 
Eds. W. Jiskoot, D. J. A. Crommelin, AAPS Press, Arlington VA, 573-591 (2005). 
27. A. Cooper, M. A. Nutley, A. Wadood. Differential scanning microcalorimetry. Protein-Ligand Interactions: 
Hydrodynamics and Calorimetry, Oxford University Press. 287-318 (2001). 
28. R. L. Remmele, N. S. Nightlinger, S. Srinivasan, W. R. Gombotz. Interleukin-1 Receptor (IL-1R) Liquid 
Formulation Development Using Differential Scanning Calorimetry. Pharm. Res. 15:200-208 (1998). 
29. L. L. Y. Lee, J. C. Lee. Thermal stability of proteins in the presence of poly (ethylene glycols). Biochem. 
26:7813-7819 (1987). 
30. M. van de Weert, J. A. Hering, P. I. Haris. Fourier Transform Infrared spectroscopy. In Methods for 
Structural Analysis of Protein Pharmaceuticals. Eds. W. Jiskoot, D. J. A. Crommelin. AAPS Press Arlington 
131-167 (2005). 
31. D. M. Byler, H. Susi. Examination of the secondary structure of proteins by deconvolved FTIR spectra. 
Biopolym. 25:469-487 (1986). 
32. A. C. Dong, P. Huang; W. S. Caughey. Protein secondary structures in water from second-derivative amide 
I infrared spectra. Biochem. 29:3303-3308 (1990). 
33. A. C. Dong, S. J. Prestrelski, S. D. Allison, J. F. Carpenter. Infrared Spectroscopic studies of lyophilization 
induced protein aggregation. J. Pharm. Sci. 84:415-424 (1995). 
34. F. Meersman, L. Smeller, K. Heremans. Comparative Fourier Transform Infrared Spectroscopy Study of 
Cold-, Pressure-, and Heat-Induced Unfolding and Aggregation of Myoglobin. Biophys. J. 82:2635-2644 
(2002). 
35. K. Murayama, M. Tomida. Head-Induced Secondary Structure and Confomration Change of Bovien Serum 
Albumin investigated by Fourier Transform Infrared Spectroscopy. Biochem. 43:11526-11532 (2004). 
36. K. Goossens, J. Helewyn, F. Meersman, M. De Ley, K. Heremans. Pressure- and temperature- Induced 
unfolding and aggregation of recombinant human interferon-γ: a Fourier transform infrared spectroscopy 
study. Biochem. J. 370:529-535 (2003). 
37. H. Fan, J. Ralston, M. Dibiase, E. Faulkner, C. Russel Middaugh. Solution behavior of INF-ß-1a: An 
Empirical Phase Diagram Based Approach. J. Pharm. Sci. 94:1893-1911 (2005). 
38. Bruker Optics. IR-Spektroskopische Quantifizierung von Strukturänderungen in Proteinlösungen. 
Application Note. 
39. H. H. Bauer, M. Müller, J. Goette, H. P. Merkle, U. P. Fringeli. Interfacial Adsorption and Aggregation 
Associated Changes in Secondary Structure of Human Calcitonin Monitored by ATR-FTIR Spectroscopy. 
Biochem. 33:12276-12282 (1994). 
40. L. Marchal-Heussler. Asorption of Drugs. in Ecyclopeida of Surface and Colloidal Science, Marcel Dekker, 
New York; pp. 294-306 (2002). 
Development of Stable, HSA-free Formulations for a Hydrophobic Cytokine 
   
 
169 
41. S. Matheus, W. Friess, H. C. Mahler. FTIR and n-DSC as analytical tools for high concentration protein 
formulations. Pharm. Res.23:1350-1363 (2006).  
42. A. Dong, B. Kendrick, L. Kreilgaard, J. Matsuura, M. C. Manning, J. F. Carpenter. Spectroscopic Study of 
the Secondary Structure and Thermal Denaturation of Recombinant Human Factor XIII in Aqueous 
Solution. Archives Biochem. Biophys. 347:213-220 (1997). 
43. B. A. Kerwin, M. C. Heller, S. H. Levin, T. W. Randolph. Effects of Tween 80 and Sucrose on Acute Short-
Term Stability and Long-Term Storage at -20°C of a Recombinant Hemoglobin. J. Pharm. Sci. 87:1062-
1068 (1998). 
44. Malvern Application note: Characterization of protein melting point, www.malvern.co.uk.  
45. D. M. Petsev, B. R. Thomas, S. T. Yau, P. G. Vekilov. Interaction and Aggregation of Apoferritin Molecules 
in Solution: Effect of Added Electrolytes. Biophys. J. 78:2060-2069 (2000). 
46. J. J. Lin, J. D. Meyer, J. F. Carpenter, M. C. Manning. Stability of Human Serum Albumin During 
Bioprocessing: Denaturation and Aggregation During Processing of Albumin Paste. Pharm. Res. 17:391-
396 (2000). 
47. W. Norde. Adsorption of Proteins at Solid-Liquid Interfaces. Cells Mat. 5:97-112 (1995). 
48. F. Y. Oliva, L. B. Avalle, O. R. Cámara, C. P. De Pauli. Adsorption of human serum albumin (HSA) onto 
colloidal TiO2 particles, Part I. J. Coll. Interf. Sci. 261:299-311 (2003). 
49. J. R. Wendorf, C. J. Radke, H. W. Blanch. Reduced Protein Adsorption at Solid Interfaces by Sugar 
Excipients. Biotech. Bioeng. 87:565-573 (2004). 
50. S. Sjöberg. Silica in aqueous Environments. J. Non-crystall. Sol. 196:51-57 (1995). 
51. M. Hiraki. Isoelectric point of glycine and α-alanine. J. Biochem. 15:345-357 (1932). 
52. M. Zhang, M. Ferrari. Reduction of Albumin Adsorption onto Silicon Surfaces by Tween 20. Biotech. Bioeng. 
56:618-625 (1997). 
53. W. Norde, F. MackRitchie, G. Nowicka, J. Lyklema. Protein adsorption at solid-liquid interfaces: reversibility 
and conformation aspects. J. Coll. Interf. Sci. 112:447-456 (1986). 
54. M. C. Kaplan, A. Jégou, B. Chaufer, M. Rabiller-Baudry, M. C. Michalsky. Adsorption of lysozyme on 
membrane material and cleaning with non-ionic surfactant characterized through contact angle 
measurements. Desal. 146:149-154 (2002).  
55. T. Arakawa, S. N. Timasheff. Preferential Interactions of Proteins with Salts in Concentrated Solutions. 
Biochem. 21:6545-6552 (1982). 
56. T. Arakawa, S. N. Timasheff. Mechanism of Protein Salting In and Salting Out by Divalent Cation Salts: 
Balance between Hydration and Salt Binding. Biochem. 23:5912-5923 (1984). 
57. T. Arakawa, S. J. Prestrelski, W. C. Kenney, J. F. Carpenter. Factors affecting short-term and long-term 
stability of proteins. Adv. Drug Del. Rev. 46:307-326 (2001). 
58. A. Kim, M. Akers and S. Nail. The Physical State of Mannitol after Freeze-Drying: Effect of Mannitol 
Concentration, Freezing Rate and a Noncrystallizing Cosolute. J. Pharm. Sci. 87:931-935 (1998). 
59. K. Izutsu, S. Yoshioka, T. Terao. Effect of Mannitol Crystallinity on the Stabilization of Enzymes during 
Freeze-Drying. Chem. Pharm. Bull. 42:5-8 (1994). 
60. H. R. Costantino, J. D. Andya, P. A. Nguyen, N. Dasovich, T. D. Sweeney, S. J. Shire, C. C. Hsu, Y. F. Maa. 
Effect of Mannitol Crystallization on the Stability and Aerosol Performance of a Spray-Dried Pharmaceutical 
Protein, Recombinant Humanized Anti-IgE Monoclonal Antibody. J. Pharm. Sci. 87:1406-1411 (1998). 
61. J. H. Crowe, J. F. Carpenter. An infrared spectroscopic study of the interactions of carbohydrates with dried 
protein. Biochem. 28:3916-3922 (1989). 
62. F. Franks, R. H. M. Hatley, S. F. Mathias. Materials science and the production of shelf-stable biologicals. 
Bio. Pharm. 4:38-55 (1991). 
Chapter 6 
   
 
170 
63. L. Kreilgaard, L. S. Jones, T. W. Randolph, S. Frokjoer, J. M. Flink, M. C. Manning, J. F. Carpenter. Effect of 
Tween 20 on Freeze-Thawing- and Agitation-Induced Aggregation of Recombinant Human Factor XIII. J. 
Pharm. Sci. 87:1597-1603 (1998). 
64. N. B. Bam, J. L. Cleland, J. Yang, M. C. Manning, J. F. Carpenter, R. F. Kelley, T. W. Randolph. Tween 
Protects Recombinant Human Growth Hormone against Agitation-Induced Damage via Hydrophobic 
Interactions. J. Pharm. Sci. 87:1554-1559 (1998). 
65. L. C. Gu, E. A. Erdos, H. S. Chiang, T. Calderwood, K. Tsai, G. C. Visor, J. Duffy, W. C. Hsu, L. C. Foster. 
Stability of Interleukin 1.beta. (IL-1.beta.) in aqueous solution: analytical methods, kinetics, products, and 
solution formulation implications. Pharm. Res. 8:485-490 (1991). 
66. M. Boublik, J. A. Moschera, C. Wei, H-F. Kung. Conformation and Activity of Recombinant Human Fibroblas 
Interferon-ß. J. Interferon Res. 10:213-213 (1990). 
67. S. E. Grossberg, J. L. Taylor, R. E. Seibenlist, P. Jameson. Biological and immunological assays of human 
interferons. in Manual of Clinical Immunology, Editors: N. R. Rose, H. Friedman, J. L. Fahey, Am. Soc. of 
Microbiol. 295-299 (1985). 
68. E. Y. Shalaev, Q. Lun, M. Shalaeva, G. Zografi. Acid-Catalyzed Inversion of Sucrose in the Amorphous 
State at Very Low Levels of Residual Water. Pharm. Res. 17:366-370 (2000). 
69. M. C. Manning, K. Patel, R. T. Borchardt. Stability of Protein Pharmaceuticals. Pharm. Res. 6:903-918 
(1989). 
70. W. Wang. Instability, stabilization and formulation of liquid protein pharmaceuticals. Int. J. Pharm. 
185:125-188 (1999). 
71. R. Haikala, R. Eerola, V. P. Tanninen, J. Yliruusi. Polymorphic changes of mannitol durino freeze-drying: 
effect of surface active agents. PDA J. Pharm. Sci. Tech. 51:96-101 (1997). 
72. L. Yu. Nucleation of One Polymorph by Another. J. Am. Chem. Soc. 125:6380-6381 (2003). 
73. E. Y. Shalaev, G. Zografi. How Does Residual Moisture Affect the Solid-State Degradation of Drugs in the 
Amorphous State. J. Pharm. Sci. 85:1137-1141 (1996). 
74. M. J. Pikal. Freeze-drying of Proteins. Part I: process design. Biopharm. 3:18-27 (1990). 
75. L. Chang, D. Shepherd, J. Sun, X. Tang, M. J. Pikal. Effect of Sorbitol and Residual Moisture on the Stabiliy 
of Lyophilized Antibodies: Implications for the Mechanism of Protein Stabilization in the Solid State. J. 
Pharm. Sci. 94:1445-1455 (2005). 
 
 
 
171 
Chapter 7: Summary of the Thesis 
 
1. General Introduction 
The goal of the thesis was to study the impact of formulation conditions on the stability 
of a hydrophobic cytokine. Chapter 1 provides a general introduction into the formulation 
of hydrophobic proteins. Poor solubility and the tendency of hydrophobic proteins to 
adsorb on surfaces are the major challenges. To circumvent these problems Human 
Serum Albumin (HSA) is frequently used as excipient, however, its use is related to the 
risk of blood born pathogens and enhanced immunogenicity. Possible approaches for the 
development of HSA-free formulations for hydrophobic proteins are discussed. In its 
function as cryo- and lyoprotector HSA can be replaced by sugars, sugar alcohols or 
amino acids. By adjusting the formulation pH and ionic strength protein solubility can be 
optimized and adsorption reduced. Protein adsorption is most effectively addressed by 
the addition of surfactants and can be solved by the use of container materials which are 
less prone to adsorption e.g. glass type I+. 
 
2. Characterization of Cytokine Solubility and Particle Formation in 
Presence of Human Serum Albumin  
Based on commercially available formulations a hydrophobic recombinant human 
cytokine lyophilized with HSA and mannitol was used for the studies. In Chapter 2 the 
HSA-cytokine formulation was characterized with respect to turbidity, particle formation 
and protein-protein interactions. The impact of NaCl, the HSA-stabilizers Na-octanoate 
and Na-N-acetyltryptophanate, as well as formulation pH on the HSA-cytokine 
formulation was elucidated. When lowering the pH, a significant increase in turbidity with 
maximum values close to the isoelectric point of HSA around pH 5.0 was observed which 
was partially irreversible mainly due to the cytokine. The precipitated fraction was 
characterized by Dynamic Light Scattering, Atomic Force Microscopy, disc centrifugation 
and light obscuration. The main particle classes ranged between 4 to 10 nm, 20 to 50 nm 
and 500 to 1000 nm. A shift from smaller to larger particles was found when the pH was 
lowered from 7.4 to 5.0. By the addition of NaCl to the formulation the turbidity increase 
at pH 5.0 could be prevented. Fluorescence spectroscopy revealed weaker interactions 
between HSA and the cytokine at pH 4.5 in the presence of NaCl. Furthermore, studies 
with HSA placebo formulation demonstrated a direct stabilizing effect of NaCl on HSA, 
with respect to the turbidity increase at pH 5.0. At concentrations applied for the 
stabilization of HSA, Na-octanoate and Na-N-acetyltryptophanate only played a minor 
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role for the prevention of the turbidity increase at pH 5.0. Thus, it could be shown in 
Chapter 2 that NaCl was essential for the overall stability of the HSA-cytokine 
formulation.  
 
3. Characterization of the Lyophilization Behavior of Mannitol-Human 
Serum Albumin-NaCl Formulations 
As NaCl can impact the freezing and lyophilization behavior, the impact of NaCl on the 
behavior of mannitol-HSA placebo mixtures based on the cytokine-HSA formulations was 
studied. The freezing process of mannitol–HSA-NaCl formulations was subject of 
Chapter 3. Two different HSA-qualities, unstabilized-HSA and stabilized-HSA containing 
NaCl, Na-octanoate and Na-N-acetyltryptophanate were used. Differential Scanning 
Calorimetry and Low Temperature X-ray Diffraction showed that both HSA-types and 
NaCl could delay and inhibit the crystallization of mannitol. This effect has to be taken in 
consideration, as it is possible that mannitol crystallizes in an uncontrolled way upon 
storage. Due to the presence of the stabilizers, formulations with stabilized-HSA differed 
in their freezing behavior as compared to those containing unstabilized-HSA. In the 
particular concentration used for the stabilization of HSA, NaCl had the most distinct 
impact on the low temperature behavior of mannitol. Already small quantities of NaCl 
shifted Tg’ and Tc of mannitol formulations to lower temperatures. The study 
demonstrated that the freezing step had a significant effect on the physico-chemical 
properties of the formulations which can affect the subsequent drying process and the 
lyophilized products.  
The effect of NaCl on the overall lyophilization processes, as well as the resulting 
lyophilized products of mannitol-HSA-NaCl formulations was described in Chapter 4. 
Increasing NaCl-concentrations led to products with a lower degree of crystallinity and 
less compact cake structures. In the presence of NaCl the drying time was shorter due to 
the changed cake structure. Differential Scanning Calorimetry, X-ray Powder Diffraction 
and Scanning Electron Microscopy showed that NaCl-concentration and applied freezing-
protocol governed the morphology of the formulations after lyophilization. Increasing 
NaCl concentration led to partially amorphous products. However, upon storage the 
amorphous state could not be preserved, with the consequence that mannitol and NaCl 
crystallized. The data indicated that products without NaCl were more stable in their 
modifications. However, the stability of HSA upon storage in the lyophilized products, 
monitored by a turbidity scan from pH 3.0 to 7.0 and size exclusion chromatography was 
improved by the addition of NaCl. This could be referred to the direct stabilizing effect of 
NaCl on HSA. For the studied systems the benefit of NaCl on protein stability outbalanced 
the observed potential drawbacks. Consequently, Chapter 3 and 4 showed the 
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importance of the physico-chemical characterization of the formulations used for 
lyophilization, when NaCl is part of the formulation. The lowering of Tg’ and the inhibition 
of mannitol crystallization are the most distinct effects of NaCl.  
 
4. Development of a Human Serum Albumin-free formulation for the 
Cytokine 
One goal of the thesis was to develop a HSA-free formulation for the cytokine. In 
Chapter 5 the system mannitol–sucrose was evaluated as possible excipient combination 
for the cytokine during lyophilization. The optimum ratio of mannitol to sucrose and 
appropriate lyophilization cycles were evaluated with the objective to achieve a product 
consisting of highly crystalline mannitol in combination with amorphous sucrose. Special 
focus was set on the formation of the metastable mannitol hydrate, as it can cause 
stability problems due to the release of hydrate water. NaCl lowered the Tg’ of mannitol-
sucrose formulations, as it acts as plasticizer for the amorphous phase which needs to be 
considered to avoid collapse. Mannitol crystallization during freezing was inhibited by 
sucrose and NaCl. This results in partially crystalline systems which come along with the 
disadvantage of potential crystallization upon storage that can be detrimental for the 
stability of the active protein. In addition, an increased content of mannitol hydrate was 
found after lyophilization with annealing, which was applied to maximize mannitol 
crystallization. Low Temperature X-ray Diffraction experiments with 8.0% mannitol and 
2.0% sucrose showed that mannitol hydrate was preferably formed at lower annealing 
temperatures, which was confirmed by Powder X-ray Diffraction after lyophilization. 
Thus, if annealing during lyophilization is necessary, a sufficiently high temperature 
needs to be selected. Adequate crystallization of mannitol was achieved in formulations 
with 4.0% mannitol and 1.0% sucrose in processes without annealing. Therefore, this 
system was selected for a HSA-free lyophilized formulation of the cytokine.  
The development of stable, HSA-free formulations for the cytokine was outlined in 
Chapter 6. Pre-formulation studies revealed that sufficient cytokine solubility was given 
in the pH-range from 3.0 to 5.5. Above pH 5.5 a turbidity increase caused by the 
precipitation of the cytokine was observed. Below pH 4.5 at a low ionic strength the best 
stability of the cytokine with respect to aggregation and turbidity was achieved. As buffer 
system 20 mM glycine was selected, since lower glycine concentrations favored protein 
adsorption to the container and higher glycine concentrations led to an increased 
aggregation tendency. Protein adsorption could be minimized by the utilization of glass 
type I+ and the addition of polysorbate 20 to the formulations. The thermal stability of 
the cytokine, monitored by the denaturation temperature determined with Fourier 
Transform Infrared Spectroscopy, decreased at higher pH values.  
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The stability of five liquid formulations at pH 3.5 to 4.5 with 4.8% mannitol and five 
lyophilized formulations at pH 4.0 to 5.0 with 4% mannitol and 1% sucrose was 
evaluated over 6 months at 2-8°C, 25°C / 60% RH and 40°C / 75% RH. For both, liquid 
and lyophilized formulations the formation of met-oxidized cytokine was independent of 
the pH but increased with storage time and temperature. In the liquid formulations the 
level of met-oxidized cytokine was slightly higher compared to the lyophilized 
formulation. The liquid formulation at pH 3.5 and 4.0 and the lyophilized formulations 
between pH 4.0 and 5.0 turned out to be most stable regarding aggregation, when 
stored at 2-8°C. To avoid protein adsorption the addition of polysorbate 20 to the liquid 
formulation was necessary, as the pre-filled syringes were manufactured of glass type I. 
In the liquid formulation polysorbate 20 further had a slight protective effect with respect 
to the formation of larger protein aggregate populations detectable by Dynamic Light 
Scattering and the formation of met-oxidized cytokine. However, in the freeze-dried 
formulation polysorbate 20 fostered the formation of aggregates. As glass type I+ vials 
were employed for lyophilization adsorption was minimal and one could omit 
polysorbate 20. Overall, it was possible to stabilize the cytokine without the use of HSA 
at low pH.  
Thus, the studies provided an extensive characterization of the hydrophobic cytokine, its 
stabilization with HSA and the pH dependent instability of HSA-containing systems. As an 
alternative a stable HSA-free formulation for the cytokine could be presented. Especially 
for the lyophilized formulations it could be shown that subtle changes of excipients e.g. in 
the NaCl content can have a detrimental impact.  
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